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1 Introduction 
 
1.1 Definition and epidemiology of colorectal cancer (CRC) 
Colorectal cancer (CRC) is a malignant epithelial tumor that originates in the colon or 
rectum (Bosman 2010). Worldwide, CRC is one of the most common cancer types with 
more than 1.3 million new cases in the year 2012 (Martel et al. 2012). In men, CRC is 
the fourth most frequent cancer after lung, prostate and stomach cancer. In women, 
CRC is the third most common cancer after cancers of the breast and uterine cervix 
(Bosman 2010). Several risk factors are known to be associated with the incidence of 
CRC. The incidence of CRC increases with age and more than 90% of CRC patients 
are aged 50 or older. Hereditary risk factors, such as familial adenomatous polyposis 
(FAP) and hereditary nonpolyposis colorectal cancer (HNPCC), account for 5 to 10% 
of CRCs. The geographic distribution of CRC varies largely and higher incidence rates 
of CRC occur in industrialized, high-resource countries, whereas developing countries 
account for lower rates. Interestingly, incidence rates among immigrants and their 
descendants converge to those of their adopted countries, indicating that diet, such as 
high-caloric food, obesity, meat and alcohol consumption, and lifestyle, are also 
important risk factors (Haggar and Boushey 2009; Bosman 2010). The survival rate of 
CRC is highly dependent upon the stage of disease at diagnosis. The earlier the stage 
at diagnosis, the higher is the chance of survival (Haggar and Boushey 2009). Regular 
screening is an option for the detection of early-stage adenocarcinomas and for the 
detection and removal of adenomatous polyps, the precursor lesions of CRC. 
Screening tests for the detection of CRC are e.g. fecal occult blood tests and 
colonoscopy (Shinya and Wolff 1979; Levin et al. 2008). Invasion of cancer cells 
through the muscularis mucosae into the submucosa is the defining feature of CRC. 
More than 90% of CRCs are adenocarcinomas developing from a non-malignant polyp 
(Bosman 2010). 
 
1.2 Development of CRC 
The development of CRC is a multistep process in which genetic alterations, involving 
the mutational activation of oncogenes coupled with the mutational inactivation of 
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tumor suppressor genes, accumulate (Fearon and Vogelstein 1990; Cho and 
Vogelstein 1992). The transition from normal colorectal epithelium to adenomas and 
furthermore their malignant transformation to adenocarcinomas requires years and 
possibly decades (Bedi et al. 1995; Gryfe et al. 1997). Fearon and Vogelstein (1990) 
developed a model to explain the genetic basis of colorectal tumorigenesis which 
includes several central features. First, colorectal tumors arise as a result of the 
mutational activation of oncogenes coupled with the mutational inactivation of tumor 
suppressor genes. Second, mutations in at least four to five genes are required to form 
a malignant tumor. Third, the total accumulation of genetic alterations, rather than their 
chronological order, is responsible for determining the biological properties of the 
tumor (Fearon and Vogelstein 1990). In correlation with the development of new 
methodical approaches, such as genome-wide sequencing, novel insights into the 
development of CRC could be gained. A recent study addressing the question how 
many “driver” gene mutations are required for a normal cell to become a cancer cell, 
proved, by combining conventional epidemiologic studies with genome-wide 
sequencing data, that only three sequential mutations are required for the development 
of CRC (Tomasetti et al. 2015).  
 
1.2.1 Accumulation of genetic alterations in oncogenes and tumor suppressor 
genes 
The tumor suppressor gene Adenomatous polyposis coli (APC) is mutated in more 
than 70% of sporadic cancers. Germline mutations in APC result in familial 
adenomatous polyposis (FAP) or in one of its variants (Kheirelseid et al. 2013). FAP is 
an autosomal dominant syndrome and accounts for approx. 0.5% of all CRCs (Haggar 
and Boushey 2009; Fearon 2011). The protein encoded by the APC gene is a member 
of the Wnt signaling pathway (Takayama et al. 2006) and has multiple functional 
domains that mediate oligomerization and binding to a variety of intracellular proteins, 
such as β-catenin, the glycogen synthase kinase (GSK)-3β and axin. One main tumor-
promoting effect of the mutation in APC results in overactivation of the Wnt signaling 
pathway with subsequent expression of genes that promote cell growth (Kheirelseid et 
al. 2013). The majority of the mutations lead to a premature stop codon and thus to a 
truncated protein (Chung 2000; Takayama et al. 2006; Fearon 2011; Human Gene 
Mutation Database (HGMD® Professional 2016.1)). Powell et al. (1992) were able to 
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prove that mutations in APC occur as a very early event during colorectal 
tumorigenesis, and showed that the frequency of these mutations does not change 
between adenomas and carcinomas (Powell et al. 1992).  
The Kirstein rat sarcoma (K-RAS) is among H-RAS (Harvey rat sarcoma viral 
oncogene homolog) and N-RAS (neuroblastoma RAS viral oncogene homolog) a 
member of the RAS family of genes (Forrester et al. 1987; Fearon 2011). RAS proteins 
function downstream of the receptor tyrosine kinase (RTK) epidermal growth factor 
receptor (EGFR) (Fearon 2011). K-RAS is mutated in approx. 50% of CRCs (Forrester 
et al. 1987; Fearon 2011). Alterations in this gene occur as activating point mutations 
mostly in codon 12 and 13 (Bos 1989; Fearon 2011; HGMD® Professional 2016.1), 
leading to continuous activation of downstream signaling pathways (Malumbres and 
Barbacid 2003). The percentage of mutations of intermediate-stage and late-stage 
adenomas is similar (Vogelstein et al. 1988), but in only 20% of small adenomas with 
APC mutations (Powell et al. 1992; Tsao and Shibata 1994). This leads to the 
suggestion that alterations of K-RAS follow APC mutations. Interestingly, mutations of 
K-RAS seem not to be necessary for the conversion of adenomas to malignant 
adenocarcinomas (Kheirelseid et al. 2013). Activated RAS regulates multiple cellular 
functions, such as cell proliferation, differentiation and survival (Shaukat et al. 2012).  
The loss of chromosome 18q occurs in almost 50% of late adenomas and in more than 
70% of CRCs (Vogelstein et al. 1988). The gene Deleted in colorectal cancer (DCC) is 
localized in the region 18q21. DCC is expressed in normal colonic mucosa, but its 
expression is reduced or even absent in the majority of CRCs (Fearon and Vogelstein 
1990), leading to the idea of DCC being a tumor suppressor gene (Kheirelseid et al. 
2013). Elimination of DCC is not believed to be a key genetic alteration in tumor 
formation, but one of a variety of changes that can promote growth of existing tumors 
(Kheirelseid et al. 2013). This hypothesis is supported by the observation of 
Krimpenfort et al. (2012). They showed, by using a mouse model of mammary 
carcinoma based on somatic inactivation of the Tumor-protein-53 (P53), that the loss 
of DCC is irrelevant for primary tumor development, but in addition to inactivation of 
P53 it promotes the formation of metastases (Krimpenfort et al. 2012). Importantly, this 
finding is contradictory to the model of Fearon and Vogelstein (1990), in which the DCC 
loss occurs before P53 inactivation. Interestingly, other researchers even scrutinize 
the role of DCC during CRC development e.g. because of the absence of a cancer 
phenotype of DCC-deficient mice. They rather point to the tumor suppressor genes 
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SMAD4/2 as the candidate genes on 18q, because inactivation of SMAD4 has been 
shown to associate with the progression of cancer (Takayama et al. 2006). SMAD4/2 
encode proteins that are members of the TGF-β signaling pathway (Fearon 2011). 
Inactivating mutations in SMAD4 were found in approx. 10 to 15% of CRCs, whereas 
mutations that inactivate SMAD2 occur in approx. 5% of CRCs (Fearon 2011). 
Furthermore, SMAD4 was shown to be one of the eight most frequent mutated genes 
in CRC among e.g. APC, P53 and K-RAS (Muzny et al. 2012). These controversial 
data indicate that further research is needed. 
The Tumor-protein-53 (P53) is a transcription factor with tumor suppressor activity. 
P53 recognizes DNA damage and controls cell cycle progression and cell survival and 
thus is called “guardian of the genome” (Kheirelseid et al. 2013). It is known to be 
mutated in 50% of primary human tumors (Somasundaram 2000; Kheirelseid et al. 
2013). The vast majority of mutations in P53 are missense mutations (Fearon 2011; 
HGMD® Professional 2016.1). Mutations and the loss of heterozygosity in the P53 
gene were detected at a low frequency in adenomas and at a high frequency in 
carcinomas, suggesting that alterations in P53 mediate the conversion from adenoma 
to carcinoma (Vogelstein et al. 1988; Ohue et al. 1994; Fearon 2011). Furthermore, 
two or more of the described alterations (mutations in K-RAS, APC, DCC and P53) 
were found in more than 90% of CRCs, while only 7% of early adenomas had more 
than one of the four genetic alterations. The percentage of mutations gradually 
increases as the adenomas progress to intermediate and late stages. In addition, all 
late-stage adenomas contained all four genetic alterations. These facts support the 
idea that the alterations of the four genes were not sufficient for the progression to 
malignancy (Fearon and Vogelstein 1990). 
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Fig. 1: Model for the multistep development of colorectal cancer. 
Colorectal tumorigenesis proceeds through a series of genetic alterations involving oncogenes                
(K-RAS) and tumor suppressor genes (APC, DCC / SMAD4/2, P53). The loss or mutation of APC occurs 
at a relatively early stage of tumorigenesis and may be responsible for the hyperproliferative epithelium. 
Mutation of the K-RAS gene occurs in one cell of a pre-existing small adenoma and produces a larger 
and more dysplastic tumor through clonal expansion. Deletion of the APC gene occurs at a very early 
stage in tumorigenesis and deletions of DCC / SMAD4/2 and P53 usually appear at a later stage. Recent 
studies scrutinize the role of DCC during CRC development and rather SMAD4/2 is currently a candidate 
gene. However, the order of these alterations differs, and accumulation of these alterations, rather than 
their order with respect to each other, is important. The signaling pathways, in which the proteins 
encoded by the mutated genes are involved in, are indicated in red (modified after Fearon and 
Vogelstein 1990; Fearon 2011). 
 
1.2.2 Overexpression of the insulin-like growth factor 1 receptor (IGF1R) 
It is well known that the insulin-like growth factor 1 receptor (IGF1R) is frequently 
overexpressed in a variety of human malignancies, such as breast (Jones et al. 2007), 
endometrial (Zhang et al. 2010) and colorectal cancer (Hakam et al. 1999; Reinmuth 
et al. 2002; Wu et al. 2014). The IGF1R is a transmembrane tyrosine kinase receptor 
and is composed of two covalently linked polypeptide chains (Sachdev and Yee 2007). 
Each chain consists of an extracellular α-subunit that contains ligand binding sites, and 
two transmembrane β-subunits that contain tyrosine kinase domains (Zhang et al. 
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IGF-2, to the extracellular ligand binding site of the IGF1R leads to a conformational 
change that subsequently results in the transphosphorylation of one β-subunit by the 
other one. Adaptor proteins, such as the insulin receptor substrate-1 (IRS-1), IRS-2 or 
SHC, are recruited and phosphorylated by the IGF1R and thereby mediate 
downstream signaling, including the phosphatidylinositol 3-kinase (PI3K) and the 
mitogen-activated protein kinase (MAPK) pathways (Sachdev and Yee 2007; 
Ekyalongo et al. 2013).  
 
Fig. 2: The IGF1R signaling pathway. 
Binding of the ligands IGF-1 or IGF-2 to the extracellular domain of the IGF1R leads to the activation of 
the tyrosine kinase domain of the IGF1R. The activation of the IGF1R subsequently results in the 
phosphorylation and thereby activation of the downstream signaling pathways, such as the PI3K 
(PI3K/AKT/mTOR) and MAPK (RAS/RAF/MEK/ERK) pathway, mediated through IRS, which promote 
cell proliferation, cell survival and even invasion (modified after Janku et al. 2010; Pillai and Ramalingam 
2013). 
 
Several studies analyzed the expression of the IGF1R in human colorectal carcinoma 
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The majority of colorectal carcinomas reveal a strong overexpression of the IGF1R 
(Weber et al. 2002). Furthermore, IGF1R expression was found to progressively 
increase during the transition from normal to adenomatous to carcinomatous colonic 
mucosa, with the highest IGF1R expression in metastatic tumors (Hakam et al. 1999). 
Additionally, a correlation between IGF1R expression and the lymph node status was 
observed in 120 rectal tumor biopsies (unpublished data of the working group). 
Reinmuth et al. (2002) transfected the human colon cancer cell line KM12L4 with a 
truncated dominant-negative form of IGF1R      (IGF1R dom-neg.) and demonstrated 
decreased expression of VEGF, a marker for angiogenesis. In addition, decreased 
tumor growth associated with decreased tumor cell proliferation, VEGF expression and 
increased tumor cell apoptosis was shown after injection of IGF1R dom-neg.-
transfected cells in nude mice (Reinmuth et al. 2002). All these in vitro and in vivo 
studies support the hypothesis of an important role of the IGF1R in the pathogenesis 
of colorectal cancer. In other cancer entities, such as breast cancer, an oncogenic 
function of IGF1R could already be proven. Carboni et al. (2005) showed that 
transgenic mice that express a constitutively active IGF1R developed mammary 
adenocarcinomas (Carboni et al. 2005). Furthermore, it was shown that transgenic 
mice that overexpress wild type IGF1R under control of the mouse mammary tumor 
virus (MMTV) promoter developed mammary tumors. In addition, it could be proven 
that the overexpression of IGF1R is sufficient for mammary tumor formation in vivo 
(Jones et al. 2007). In contrast, comparable studies using transgenic mice that 
overexpress IGF1R in the intestine are not available to date. Therefore, it is of high 
interest to establish a mouse model with intestinal overexpression of the IGF1R, and 
also an intestine-specific Igf1r knockout mouse line in order to study the function of the 
IGF1R / Igf1r in intestinal tumor formation and progression in vivo. 
 
1.3 Treatment of CRC 
The current standard therapy of CRC is the complete excision of the affected tissue, 
including the associated lymphatic system (Kuhry et al. 2008). Furthermore, a 
combined radiochemotherapy (RCT) is recommended for advanced stages. 
Chemotherapy can be administered as a monotherapy or as a combination of different 
chemotherapeutics like 5-fluoruracil (5-FU) and Oxaliplatin. RCT can be applied in a 
neoadjuvant or adjuvant manner (McCarthy et al. 1996; Petersen et al. 1996; 
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Gustavsson et al. 2015). On purpose to prevent harm to healthy cells and to reduce 
side effects, targeted therapy is recently developed to specifically block cancer cells 
from growing and spreading (Tabernero et al. 2004; Hagan et al. 2013). Cancer cells 
often fail to regulate main cellular functions, such as proliferation and the induction of 
apoptosis, due to overexpression of receptors like receptor tyrosine kinases (RTKs) 
(Yano et al. 2003; Spano 2005a). RTKs are transmembrane receptors that regulate 
key cellular processes, such as proliferation and differentiation, cell survival and 
metabolism, cell migration and cell cycle control. All 58 known human RTKs have a 
similar molecular architecture with a ligand-binding region in the extracellular domain, 
a single transmembrane helix, and an intracellular tyrosine kinase domain (Lemmon 
and Schlessinger 2010). Dysregulation of the RTKs insulin-like growth factor 1 receptor 
(IGF1R) or epidermal growth factor receptor (EGFR) by overexpression was shown to 
be associated with an aggressive tumor phenotype, tumor progression and poor 
outcome in several malignancies, including ovarian-, prostate-, gastric-, bladder- and 
colorectal cancer (Hewish et al. 2009; Lurje and Lenz 2009). Several approaches have 
demonstrated the therapeutic efficacy of the interference with IGF1R or EGFR 
mediated signaling (Höpfner et al. 2006). These approaches include approved 
monoclonal antibodies, such as cetuximab or panitumumab (directed against the 
EGFR), which compete with the binding of activating ligands to the extracellular domain 
of the EGFR, and highly selective small molecule kinase inhibitors, such as erlotinib 
and gefitinib (directed against the EGFR), which competitively inhibit the binding of 
ATP to the tyrosine kinase domain of EGFR and thereby inhibit the 
autophosphorylation of EGFR (Christensen et al. 2001; Grünwald and Hidalgo 2003; 
Höpfner et al. 2006; Hewish et al. 2009). De novo resistance to cetuximab and erlotinib 
could be observed in the human metastatic CRC cell line DiFi and in lung cancer 
patients, respectively (Lin and Bivona 2012; Montagut et al. 2012; Tang et al. 2013; 
Suda et al. 2014). Suda et al. (2014) observed increased phosphorylation of the IGF1R 
in lung adenocarcinoma cells after the cells had acquired resistance to erlotinib, and 
suggested the IGF1R as an important molecular target to prevent or overcome 
acquired resistance to erlotinib in lung cancers (Suda et al. 2014). In 2009, Kaulfuß et 
al. (2009) showed that inhibition of the IGF1R transduction cascade elevates the 
antiproliferative and proapoptotic effects of EGFR inhibition in CRC cells (Kaulfuß et 
al. 2009). These results indicated that the combination therapy targeting both, the 
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EGFR and the IGF1R, could also be a promising therapeutic strategy in clinical 
applications.  
1.4 Aims of the present study 
In the present study the role of the receptor tyrosine kinase IGF1R during the 
development of the intestine and during the development and treatment of CRC is 
investigated.  
Recent in vitro studies have shown that the simultaneous inhibition of the IGF1R and 
EGFR with or without the additional application of combined 5-FU-based RCT leads to 
a remarkably reduction of the cell survival fraction in CRC cells (Kaulfuß et al. 2009; 
Seemann 2013). The analysis if similar effects of the simultaneous RTK inhibition in 
addition to RCT can also be observed in vivo is one of the main subjects. The second 
focus is the basic research of the function of the IGF1R during the development of the 
intestine and during colonic tumor formation and progression.  
 
 Establishment of the double transgenic Villin-TRE-IGF1R mouse line as a 
model for the inducible overexpression of human IGF1R  
o Establishment of the transgenic Villin-rtTA2-M2 mouse line 
o Establishment of the transgenic TRE-IGF1R mouse line 
o Breeding of the Villin-rtTA2-M2 mouse line with the TRE-IGF1R mouse 
line to establish the Villin-TRE-IGF1R mouse line 
 
 Analysis of the role of the IGF1R during the development, maintenance and 
regulation of the intestine 
o Administration of doxycycline to Villin-TRE-IGF1R mice to induce the 
IGF1R overexpression  
o Staining of tissue sections of the small intestine and colon for goblet, 
enteroendocrine, Paneth and proliferating cells 





1 Introduction  10 
 Analysis if IGF1R overexpression per se induces intestinal tumor formation 
o Continuous administration of doxycycline to Villin-TRE-IGF1R mice for 
1.5 years to induce IGF1R overexpression  
o Regular colonoscopy to screen for colonic tumor formation 
 
 Analysis if the IGF1R plays a role during intestinal tumor progression 
o Administration of doxycycline to Villin-TRE-IGF1R mice to induce IGF1R 
overexpression  
o Treatment of the IGF1R-overexpressing and control Villin-TRE-IGF1R 
mice with the genotoxic agent azoxymethane (AOM) or the combination 
of AOM and the inflammatory agent dextran sulfate sodium (DSS) to 
induce colonic tumor formation and inflammation 
o Regular colonoscopy to screen for colonic tumor formation 
o Macroscopic and histopathological analyses of developed intestinal 
tumors 
o Immunohistochemical and immunofluorescence staining of intestinal 
tumor sections for IGF1R 
o Analysis of IGF1R expression as well as of the downstream PI3K and 
MAPK signaling pathways in developed intestinal tumors by western blot 
analysis 
 
 Establishment of the double transgenic Villin-CreERT-Igf1r mouse line as a 
model for the inducible knockout of Igf1r 
o Establishment of the transgenic Villin-CreERT2 mouse line 
o Establishment of the transgenic Igf1r(lox) mouse line 
o Breeding of the Villin-CreERT2 mouse line with the Igf1r(lox) mouse line to 
establish the Villin-CreERT-Igf1r mouse line 
 
 Analysis of the role of the Igf1r during the development, maintenance and 
regulation of the intestine 
o Intraperitoneal injection of Villin-CreERT-Igf1r mice with tamoxifen on 
five consecutive days to induce the knockout of Igf1r 
o Staining of tissue sections of the small intestine and colon for goblet, 
enteroendocrine, Paneth and proliferating cells 
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 Analysis if the Igf1r plays a role during intestinal tumor formation and 
progression 
o Injection of Villin-CreERT-Igf1r mice with tamoxifen to induce the 
knockout of Igf1r 
o Treatment of Villin-CreERT-Igf1r mice with the genotoxic agent 
azoxymethane (AOM) or the combination of AOM and the inflammatory 
agent dextran sulfate sodium (DSS) to induce colonic tumor formation 
and inflammation 
o Regular colonoscopy to screen for colonic tumor formation 
o Macroscopic and histopathological analyses of developed intestinal 
tumors 
o Immunohistochemical and immunofluorescence staining of tumor 
sections for Igf1r 
o Analysis of Igf1r expression as well as of the downstream PI3K and 
MAPK signaling pathways in developed intestinal tumors by western blot 
analysis 
 
 Analysis of the effect of simultaneous inhibition of the IGF1R and EGFR in 
addition to combined 5-FU-based RCT on tumor progression in vivo 
o Subcutaneous implantation of the colorectal and rectal cancer cells DLD-
1, CaCo-2 and SW837 into immune-deficient nude mice 
o Treatment of nude mice after tumor formation with RTK inhibitors and 
RCT 
o Macroscopic analysis of developed tumors 
o Analysis of IGF1R and EGFR expression as well as of the downstream 
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2 Materials and Methods 
 
2.1 Chemicals and reagents 
Chemicals Manufacturer 
AEW541 Novartis, Nürnberg, Germany 
Agarose Carl Roth GmbH, Karlsruhe, Germany 
Ampuwa Fresenius AG, Bad Homburg, Germany 
Azoxymethane (AOM) Sigma-Aldrich, Deisenhofen, Germany 
Buffer (Mango Taq PCR) (5x) Bioline, Luckenwalde, Germany 
Cell culture media PAN, Aidenbach, Germany; Life 
Technologies, Darmstadt, Germany 
Citric acid monohydrate AppliChem GmbH, Darmstadt, Germany 
Dextran sulfate sodium (DSS) salt MP Biomedicals, Illkirch, France 
Dimethyl sulfoxide (DMSO) Carl Roth GmbH, Karlsruhe, Germany 
Dithiotreitol (DTT) Bioline, Luckenwalde, Germany 
DNA Stain G Serva GmbH, Heidelberg, Germany 
dNTPs (100 mM) Life Technologies, Darmstadt, Germany 
Doxycycline Hyclate AppliChem GmbH, Darmstadt, Germany 
DPBS PAN, Aidenbach, Germany 
Erlotinib LC Laboratories, Woburn, USA 
Ethanol Walter CMP GmbH & Co. KG, Kiel, 
Germany 
Ethylendiaminetetraacetic acid (EDTA) ICN Biomedicals, Aurora, USA 
5-fluouracil Sigma-Aldrich, Deisenhofen, Germany 
Formaldehyde (37%) Carl Roth GmbH, Karlsruhe, Germany 
Glycergel Mounting Medium Dako, Carpinteria, USA 
Glycine Carl Roth GmbH, Karlsruhe, Germany 
Hemalum solution Carl Roth GmbH, Karlsruhe, Germany 
Igepal CA-630 (NP-40) Sigma-Aldrich, Deisenhofen, Germany 
Isoflurane Abbvie, Wiesbaden, Germany 
Isopropanol Carl Roth GmbH, Karlsruhe, Germany 
Low fat dry milk Carl Roth GmbH, Karlsruhe, Germany 
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Magnesium chloride (MgCl2) Bioline, Luckenwalde, Germany 
Methanol Carl Roth GmbH, Karlsruhe, Germany 
NuPAGETM LDS Sample buffer (4x) Life Technologies, Darmstadt, Germany 
NuPAGETM MES Running buffer (20x) Life Technologies, Darmstadt, Germany 
NuPAGETM See Blue Plus 2 Life Technologies, Darmstadt, Germany 
Penicillin / Streptomycin PAN, Aidenbach, Germany 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Deisenhofen, Germany 
Potassium chloride Carl Roth GmbH, Karlsruhe, Germany 
Roti®Nanoquant Carl Roth GmbH, Karlsruhe, Germany 
Sodium chloride AppliChem GmbH, Darmstadt, Germany 
Sodium chloride, liquid Braun, Melsungen, Germany 
Sodium deoxycholate Fluka, Deisenhofen, Germany 
Sodium dihydrogen phosphate 
monohydrate 
Fluka, Deisenhofen, Germany 
Sodiumdodecylsulfate (SDS) Serva GmbH, Heidelberg, Germany 
Sodium phosphatase dibasic dihydrate Sigma-Aldrich, Deisenhofen, Germany 
Sunflower seed oil from Helianthus 
annuus 
Sigma-Aldrich, Deisenhofen, Germany 
Tamoxifen Sigma-Aldrich, Deisenhofen, Germany 
Temgesic® RB Pharmaceuticals Limited, Berkshire, 
UK 
Tris AppliChem GmbH, Darmstadt, Germany 
Tri- Sodium Citrate Dihydrate Carl Roth GmbH, Karlsruhe, Germany 
Triton X-100 Fluka, Deisenhofen, Germany 
Trypan blue Sarstedt, Nürnbrecht, Germany 
Tween 20 Carl Roth GmbH, Karlsruhe, Germany 
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2.2 Biochemicals and enzymes 
Biochemical Manufacturer 
Albumin fraction V (BSA) Carl Roth GmbH, Karlsruhe, Germany 
Complete Mini Protease Inhibitor 
Cocktail Tablets 
Roche, Mannheim, Germany 
Direct PCR Tail Peqlab, Erlangen, Germany 
ExtrAvidin®-Peroxidase Sigma-Aldrich, Deisenhofen, Germany 
Fetal bovine serum  PAN, Aidenbach, Germany 
MangoTaq-DNA-Polymerase Bioline, Luckenwalde, Germany 
MatrigelTM BD Bioscience, San Jose, USA 
MycoZAPTM Spray Lonza, Cologne, Germany 
Phosphatase Inhibitor Mix II, solution Serva GmbH, Heidelberg, Germany 
Platinum® SYBR® Green qPCRSuperMix-
UDG with Rox 
Life Technologie, Darmstadt, Germany 
Proteinase K Carl Roth GmbH, Karlsruhe, Germany 
Trypsin / EDTA solution PAN, Aidenbach, Germany 
 
 
2.3 Usage ware 
Usage ware Manufacturer 
5 ml, 10 ml Pipettes Sarstedt, Nürnbrecht, Germany 
13 ml Tubes Sarstedt, Nürnbrecht, Germany 
15 ml, 50 ml Cellstar® Tubes Greiner-bio-one, Frickenhausen, 
Germany 
384-well plates, white ABgene, Hamburg, Germany 
384-well plates, black 4titude® Ltd., Berlin, Germany  
6-well cell culture plates Greiner-bio-one, Frickenhausen, 
Germany 
96-well cell culture plates Thermo Scientific, Langenselbold, 
Germany 
BD Discardit™ II (20 ml syringe) 
 
BD, Heidelberg, Germany 
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BD Eclipse™ Needle (0.8 x 40 mm; 21 G 
x 1 ½ TW) 
BD, Heidelberg, Germany 
Blotting Paper GB 002, 003, 004 Schleicher & Schnüll, Dassel, Germany 
Cell culture flasks Sarstedt, Nürnbrecht, Germany 
Combitips plus, 10 ml Eppendorf, Hamburg, Germany 
Coverglass 22x22 mm, 24x40 mm, 
24x60 mm 
Menzel Gläser, Braunschweig, Germany 
Cryo.S™ cups with screw cap Greiner-bio-one, Frickenhausen, 
Germany 
Disposable insulin needle (0.45 x 12 mm; 
26 G x ½”) 
Braun, Tuttlingen, Germany 
Flat-bottomed NuclonTM surface 96-well 
cell culture plates 
Nunc A/S, Danmark 
Microcentrifuge Tubes Sarstedt, Nürnbrecht, Germany 
Neubauer improved counting chamber Hartenstein, Würzburg, Germany 
NuPAGETM 4-12% Bis-Tris Gels Life Technologies, Darmstadt, Germany 
Pasteur pipettes Brand, Wertheim, Germany 
Petri dishes Sarstedt, Nürnbrecht, Germany 
Pipet tips Sarstedt, Nürnbrecht, Germany 
PVDF transfer membrane GE Healthcare, Munich, Germany 
Quarz-Cuvette Hellma, Mühlheim, Germany 
Scissors (HSB-390-10 / HSB-006-10) Hammacher, Solingen, Germany 
Serological pipettes (5 ml, 10 ml) Sarstedt, Nürnbrecht, Germany 
Sterile Single-use filter Minisart Sartorius, Göttingen, Germany 
Syringe disposable filters, 0.45 µm / 
20 µm 
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2.4 Technical equipment 
Technical equipment Manufacturer 
Accu-jet® (Pipet-boy) Brand, Wertheim, Germany 
Balance Sartorius, Göttingen, Germany 
Bioruptor® Sonication System Diagenode, Denville, USA 
Centrifuges Thermo Scientific, Langenselbold, 
Germany; Sigma-Aldrich, Deisenhofen, 
Germany 
Circular rotor Sprout, Vernon Hills, USA 
CO2 Incubator MCO-20AIC Sanyo, Munich, Germany 
Colonoscopy device Karl Storz GmbH & Co. KG, Tuttlingen, 
Germany 
Confocal Laser Scanning Microscope 
IX81 
Olympus, Hamburg, Germany 
C1000 Thermal Cycler Bio-Rad Laboratories, Hercules, USA 
Electro-blotter Biometra, Göttingen, Germany 
Electrophoresis power supply PS-304 Life technologies, Darmstadt, Germany 
FluorChem® Q Alpha Innotech, Logan, USA 
Fluorescence microscope BX60 Olympus, Hamburg, Germany 
Irradiation device 225A Gulmaymedical, Camberley, UK 
HT7900 Fast Real-Time PCR System Applied Biosystems GmbH, Darmstadt, 
Germany 
Nanodrop 2000c Thermo Scientific, Langenselbold, 
Germany 
pH-Meter 766 Knick, Berlin, Germany 
SynergyMx Bio Tek, Bad Friedrichshall, Germany 
Tissue Lyser LT Qiagen, Hilden, Germany 
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2.5 Sterilization of solutions and equipment 
Solutions and laboratory equipment were autoclaved at 121°C and 105 Pa for 
60 minutes or sterilized at 220°C overnight. 
 
2.6 Ready-to-use Reaction systems 
Reaction system Manufacturer 
Dako REALTM EnVisionTM Detection 
System 
Dako, Hamburg, Germany 
Direct PCR tail reagent Peqlab, Erlangen, Germany 
ECL Prime GE Healthcare, Munich, Germany 
Myco Alert® Mycoplasma Detection Kit Lonza, Cologne, Germany 
PeqGold Total RNA Kit Peqlab, Erlangen, Germany 
PhosSTOP Phosphatase Inhibitor Roche, Mannheim, Germany 
 
 
2.7 Buffers and Solutions 
Solutions for routine applications were prepared according to Mamiatis et al. (1985). 
Required chemicals were dissolved in ddH2O and autoclaved or filtered under sterile 
conditions when necessary. 
Solutions Composition 
AP Buffer 100 mM NaCl 
50 mM MgCl2 
100 mM Tris / HCl, pH 9.5 
AP staining solution 45 µl NBT (75 mg / ml in DMF) 
35 µl BCIP (50 mg / ml in DMF) 
in 10 ml AP Buffer 
Blocking Buffer (IHC I) 1x DPBS 
10% FBS 
Blocking Buffer (IHC II) 1x DPBS 
5% BSA 
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Blocking Buffer (IHC III) 1x DPBS 
5% FBS 
10% BSA 
Blocking Buffer (Western Blot) 1x TBS-Tween 20 
5% low-fat dry milk 
Citrate Buffer (IHC I and III) 10 mM Citric acid monohydrate, pH 6 
Formalin, buffered (4%) 1.66 g Sodium dihydrogen phosphate 
Monohydrate 
9.79 g di-Sodiumhydrogen phosphate 
Dihydrate 
100 ml Formaldehyde (37%) 
Lysis Buffer for proteins (modified RIPA) 150 mM NaCl 
1 mM EDTA 
50 mM Tris-HCl, pH 7.4 
1% Igepal CA-630 (NP-40) 
0.25% Sodium deoxycholate 
1% PMSF 
1 tablet / 10 ml Complete Mini protease 
inhibitor 
100 µl / 10 ml Phosphatase-Inhibitor-
Mix II, solution 
SE Buffer 75 mM NaCl 
1 mM EDTA 
pH 8 
Sodium Citrate Buffer (IHC II) 10 mM Tri- Sodium Citrate Dihydrate, 
pH 6 
0.05% Tween 20 
10x TBS 1.37 M NaCl 
100 mM Tris / HCl, pH 7.6 
1x TBS-Tween (TBS-T) 1x TBS 
0.1% Tween 20 
Transfer Buffer IIa (Western Blot) 25 mM Tris, pH 8.3 
150 mM Glycine 
20% Methanol 
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20x Turbo Buffer 0.2 M NaOH 
adjusted to pH 8 using solid H3BO3 
Washing Buffer (Western Blot) 1x TBS-Tween 20 
2.5% low-fat dry milk 
 
 
2.8 Culture media for eukaryotic cell cultures 
Media used for the cultivation of eukaryotic cell lines was purchased from PAN, 
Aidenbach, Germany and Life Technologies, Darmstadt, Germany. Before use, special 
processed fetal bovine serum (FBS) (PAN, Aidenbach, Germany) and antibiotics 
(PAN, Aidenbach, Germany) were added. Following media were used for eukaryotic 
cell culturing: 
  






Medium for DLD-1 and SW837 cells: 
 
 
MEM (Life Technologies, Darmstadt, 
Germany) 
100 µg / ml Streptomycin 
100 U / ml Penicillin 
20% fetal bovine serum (FBS) 
 
RPMI 1640 (PAN, Aidenbach, Germany) 
100 µg / ml Streptomycin 
100 U / ml Penicillin 
10% fetal bovine serum (FBS) 
 
 
2.9 Biological material 
 




Colorectal adenocarcinoma cells, adherent (ATCC®; Rockville, 
USA), aneuploid (Ghadimi et al. 2000), p53 wild type (ATCC®; 
Rockville, USA), intermediate RCT sensitive (Spitzner et al. 2010) 
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DLD-1 cells 
 
Colorectal adenocarcinoma cells, adherent (ATCC®; Rockville, 
USA), pseudodiploid (Ghadimi et al. 2000), p53 deficient (ATCC®; 
Rockville, USA) 
 
SW837 cells Adenocarcinoma cells of the rectum, adherent (ATCC®; Rockville, 
USA), aneuploid (Ghadimi et al. 2000), p53 deficient (ATCC®; 
Rockville, USA), weakly sensitive to RCT (Spitzner et al. 2010) 
 
2.9.2 Mouse strains 
All experiments were conducted according to the European and German protection of 
animals act. The number of sacrificed animals and the stress and pain the mice were 
suffering was kept to the minimum. Euthanasia of mice was performed by                    
CO2-asphyxation. Mice were kept at a 12 hours light / dark cycle at 22°C and 55 ± 5% 
relative humidity. Animal food was purchased from ssniff (Soest, Germany). 
 
2.9.2.1 RjOrl:NMRI-Foxn1nu/Foxn1nu 
The mouse line RjOrl:NMRI-Foxn1nu/Foxn1nu carries an autosomal recessive mutation 
in the Foxn1 (forkhead box N1) gene on chromosome 11. This mutation causes a 
thymic aplasia which results in an immunodeficiency. The mice lack T cells, B cells 
remain. The mutation also leads to a keratinization defect of the hair follicule and the 
epidermis. For this reason, mice appear nude. The RjOrl:NMRI-Foxn1nu/Foxn1nu mice 
were purchased from Janvier Labs (Le Genest-Saint-Isle, France). 
 
2.9.2.2 Villin-rtTA2-M2 
The mouse line Villin-rtTA2-M2 is a transgenic mouse line expressing the reverse 
tetracycline transactivator rtTA2-M2 under the control of the 12.4 kb murine villin 
promoter. By administration of doxycycline, the Villin-rtTA2-M2 system drives 
transgene expression in a dosage-dependent manner (Roth et al., 2008). The Villin-
rtTA2-M2 mouse line was a kind gift of Ron Smits (Department of Gastroenterology 
and Hepatology, Erasmus MC, Rotterdam, The Netherlands). 
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2.9.2.3 TRE-IGF1R 
The TRE-IGF1R mouse line is a transgenic mouse line expressing the full-length 
human IGF1R cDNA under the control of the doxycycline inducible pTRE2 promoter 
(Jones et al. 2007). The TRE-IGF1R mouse line was kindly provided by Dr. Moorehead 




The Villin-TRE-IGF1R mouse line is a double transgenic mouse line expressing the 
reverse tetracycline transactivator rtTA2-M2 under the villin promoter (see chapter 
2.9.2.2) as well as the human IGF1R cDNA under the control of the doxycycline 
inducible pTRE2 promoter (see chapter 2.9.2.3). Villin is broadly expressed in every 
cell of the intestinal epithelium on both the vertical axis (crypt to villus tip) and the 
horizontal axis (duodenum through colon) of the intestine (Madison 2002). The 
transactivator protein rtTA2-M2 is able to bind the pTRE2 promoter of the TRE-IGF1R 
mouse line when the antibiotic doxycycline is present (Jones et al. 2007). Thus, the 
overexpression of human IGF1R in the intestine can be induced by the administration 
of doxycycline.  
 
2.9.2.5 Villin-CreERT2 
The Villin-CreERT2 mouse line is a transgenic mouse line expressing the tamoxifen-
dependent cre recombinase under the control of a 9 kb regulatory region of the murine 
villin promoter (vil-Cre-ERT2) (El Marjou et al. 2004). The vil-Cre-ERT2 construct is 
based on a fusion of the cre recombinase with a mutated ligand-binding domain of the 
human estrogen receptor, which results in a tamoxifen-dependent cre recombinase 
(Feil et al. 1996; El Marjou et al. 2004). The Villin-CreERT2 mouse line was kindly 
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2.9.2.6 B6;129-Igf1rtm2Arge/J 
The B6;129-Igf1rtm2Arge/J mouse line is also known as Igf1r(lox) mouse line and is called 
Igf1r(lox) mouse line in the further study. The Igf1r(lox) mouse line is a cre-responder 
mouse line carrying loxP-modified alleles of the gene encoding the Igf1r. The floxed 
segment of the reporter loci is exon 3 of the Igf1r. A third loxP site is localized next to 
the 3‘end of the neomycin selection cassette (Dietrich et al. 2000). Igf1r(lox) mice were 
purchased from The Jackson Laboratory (Sulzfeld, Germany). 
 
2.9.2.7 Villin-CreERT-Igf1r 
The Villin-CreERT-Igf1r mouse line is a model for the inducible knockout of the Igf1r 
specifically in epithelial cells of the murine intestine. This mouse model is generated 
by crossing the Villin-CreERT2 mouse line (see chapter 2.9.2.5) with the mouse line 
Igf1r(lox) (see chapter 2.9.2.6). Administration of tamoxifen to the Villin-CreERT-Igf1r 
mouse line leads to the deletion of exon 3 of the Igf1r gene specifically in the intestine 
of the mouse at a desired time point. 
 
2.9.3 Synthetic DNA-oligonucleotides 
Synthetic DNA-oligonucleotides for the generation of PCR products were purchased 
from Eurofins MWG Operon (Ebersberg, Germany).  
Mouse-specific primers for genotyping: 
Primer name Sequence 
Villin-rtTA2-For 2 5‘-CAA GAC TTT CTG CGG AAC AAC-3‘ 
Villin-rtTA2-Rev 3 5‘-GTG TCT CTC TTT CCT CTT TTG-3‘ 
IGF-IR-F2 5‘-CAT CCA CGC TGT TTT GAC CTC C-3‘ 
IGF-IR-R3 5‘-GAT CAC CGT GCA GTT CTC CAG G-3‘ 
Villin-2kbseqS 5‘- CAA GCC TGG CTC GAC GGC C-3‘ 
Villin-Cre198 5‘-CGC GAA CAT CTT CAG GTT CT-3‘ 
IGF-IR-Floxed-Fw 5‘-CTT CCC AGC TTG CTA CTC TAG G-3‘ 
IGF-IR-Floxed-Re 5‘-CAG GCT TGC AAT GAG ACA TGG G-3‘ 
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Mouse-specific primers for the confirmation of the Igf1r knockout: 
Primer name Sequence 
P1 5‘-CTT CCC AGC TTG CTA CTC TAG G-3‘ 
P2 5‘-CAG GCT TGC AAT GAG ACA TGG G-3‘ 





2.9.4.1 Primary antibodies 
Primary antibody Manufacturer 
α-AKT, monoclonal antibody, rabbit Cell Signaling Technology Inc., Danvers, 
USA 
α-Chr. A, polyclonal antibody, rabbit Santa Cruz Biotechnology, Heidelberg, 
Germany 
α-HSC-70, monoclonal antibody, mouse Santa Cruz Biotechnology, Heidelberg, 
Germany 
α-IGF1R, polyclonal antibody, goat R&D Systems, Minneapolis, USA 
α-IGF1Rα, polyclonal antibody, rabbit Santa Cruz Biotechnology, Heidelberg, 
Germany 
α-IGF1Rβ, monoclonal antibody, mouse Merck Millipore, Darmstadt, Germany 
α-IGF1Rβ, polyclonal antibody, rabbit Santa Cruz Biotechnology, Heidelberg, 
Germany 
α-Ki 67, monoclonal antibody, mouse BD, Heidelberg, Germany 
α-Lysozyme, monoclonal antibody, rabbit Abcam, Cambridge, UK 
α-Mucin 2, polyclonal antibody, rabbit Santa Cruz Biotechnology, Heidelberg, 
Germany 
α-p44/42 MAPK (ERK1/2), polyclonal 
antibody, rabbit 
 
Cell Signaling Technology Inc., Danvers, 
USA 
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α-Phospho-AKT (Ser473), monoclonal 
antibody, rabbit 
Cell Signaling Technology Inc., Danvers, 
USA 
α-Phospho-AKT (Thr308), monoclonal 
antibody, rabbit 
Cell Signaling Technology Inc., Danvers, 
USA 
α-Phospho-IGF1R, polyclonal antibody, 
rabbit 
Abcam, Cambridge, UK 
α-Phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204), monoclonal antibody, 
rabbit 
Cell Signaling Technology Inc., Danvers, 
USA 
α-Tubulin, monoclonal antibody, mouse Sigma-Aldrich, Deisenhofen, Germany 
α-Villin, monoclonal antibody, rabbit Abcam, Cambridge, UK 
 
 
2.9.4.2 Secondary antibodies 
Secondary antibody Manufacturer 
α-goat IgG, Cy3-conjugated Sigma-Aldrich, Deisenhofen, Germany 
α-mouse IgG, Cy3-conjugated (C2181) Sigma-Aldrich, Deisenhofen, Germany 
α-mouse IgG, FITC-Phalloidin-
conjugated 
Sigma-Aldrich, Deisenhofen, Germany 
α-mouse IgG (H+L), HRP-conjugated, 
rabbit 
Dianova Jackson ImmunoResearch, 
Hamburg, Germany 
α-rabbit IgG, biotinylated species-
specific whole antibody 
GE Healthcare, Braunschweig, 
Germany 
α-rabbit IgG, Cy3-conjugated (C2306) Sigma-Aldrich, Deisenhofen, Germany 
α-rabbit IgG, FITC-Phalloidin-
conjugated 
Sigma-Aldrich, Deisenhofen, Germany 
α-rabbit IgG (H+L), HRP-conjugated, 
goat 
Dianova Jackson ImmunoResearch, 
Hamburg, Germany 
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2.10 Databases 
Application Database 
Analysis of DNA- and protein 
sequences 
BLAST-program (Altschul et al., 1990) 
(http://ncbi.nlm.nih.gov) 
Analysis of statistical significance GraphPad Prism, 
(http://graphpad.com/quickcalcs/ttest1.cfm) 
Bioinformatics Ensembl v32 (http://www.ensembl.org) 
Nation Center for Biotechnology 
Information (http://ncbi.nlm.nih.goc) 
Collection of published human 
inherited disease mutations 
Human Gene Mutation Database (HGMD® 
Professional 2016.1) 




2.11 Isolation and purification of nucleic acids 
 
2.11.1 Isolation of genomic DNA from the small intestine and colon  
For the confirmation of the Igf1r knockout in the small intestine and colon of                 
Villin-CreERT-Igf1r mice, genomic DNA was isolated. Therefore, small intestinal and 
colonic tissue was solved in 2.5 ml SE buffer by vortexing. Afterwards, 
125 µl proteinase K as well as 250 µl 10% SDS were added. Tubes were swung and 
incubated at 56°C overnight. The next day, 750 µl 6M NaCl were added and the 
suspension was vortexed for 15 seconds. The suspension was centrifuged at 
5200 rpm at 25°C for 15 minutes and the supernatant was added to 2.5 vol. 
100% EtOH. The accumulated DNA was purified with 70% EtOH and centrifuged at 
1400 rpm for 5 minutes. Afterwards, the extracted DNA was dried and resuspended in 
ddH2O. 
 
2.11.2 Precipitation of genomic DNA for genotyping by quantitative real time PCR 
For the preparation of the genomic DNA that was extracted from tail biopsies (see 
chapter 2.13.1) for genotyping by quantitative real time PCR, the DNA, which was 
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before lysed using 200 µl PCR direct (Peqlab, Erlangen, Germany) and                               
1 µl proteinase K (Carl Roth GmbH, Karlsruhe, Germany) was precipitated. Therefore, 
144.2 µl isopropanol and 26 µl 2 M NaCl were added to each DNA sample. The 
suspension was inverted and incubated at -20°C overnight. The next day, the DNA 
was precipitated by centrifugation at 13.000 rpm at 4°C for 30 minutes. The samples 
were washed with 70% EtOH and centrifuged at 13.000 rpm at 4°C for 5 minutes. 
Afterwards, the EtOH evaporated at 50°C and the DNA pellet was dissolved in 10 mM 
Tris-HCl, pH 8.0 by using the thermomixer at 50°C for 10 minutes. The DNA was stored 
at -20°C. 
 
2.12 Gel electrophoresis 
 
2.12.1 Agarose gel electrophoresis of DNA 
Gel electrophoresis is a technique for the separation of nucleic acid molecules. 
Depending on the fragment size, agarose gels with a concentration of 0.5 to 2% (w / v) 
were prepared. The agarose was dissolved by boiling it in 30 ml 1x Turbo buffer. DNA 
Stain G was used to stain the DNA and added according to the manufacturer’s 
instructions. The gel was poured into the gel chamber. After the agarose gel was 
completely solidified, electrophoresis was performed at 150 mA and 150 V. 
 
2.12.2 Length standard 
For the determination of the DNA fragment length, the 1 Kb Plus DNA Ladder was 
used. 
 
2.13 Polymerase Chain Reaction (PCR) 
(Saiki et al. 1985) 
The polymerase chain reaction is an in vitro method for the amplification of specific 
DNA fragments. This method uses high temperatures to denature double strand 
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template DNA (denaturation), so that short oligonucleotides (primers) are able to bind 
to the DNA (annealing). Once bound to the single stranded DNA, these 
oligonucleotides are elongated by a polymerase (elongation). The multiple repetition 
of these three steps of denaturation, annealing and elongation results in an exponential 
increase of specific DNA fragments. The success of the DNA amplification can be 
checked by agarose gel electrophoresis (see chapter 2.12). 
 
2.13.1 Mango Taq-PCR for genotyping 
For the genotyping of newborn pubs, DNA was extracted from tail biopsies. Therefore, 
tails were incubated with 200 µl PCR direct (Peqlab, Erlangen, Germany) and 1 µl 
proteinase K (Carl Roth GmbH, Karlsruhe, Germany) at 55°C overnight. The reaction 
was terminated by heating the solution at 85°C for 45 min. 
Afterwards, a Mango Taq-PCR was performed using the genotyping primers specific 
for each mouse line (see chapter 2.9.2).  
The following PCR reaction mixture was prepared: 
1 µl DNA 
 0.75 µl MgCl2 (50 mM) 
0.7 µl Mango Taq DNA polymerase (1 U / µl) 
5 µl 5x buffer 
2.5 µl dNTP’s (2 mM) 
0.5 µl Primer 1 (10 pmol / µl, sequence-specific) 
0.5 µl Primer 2 (10 pmol / µl, sequence-specific) 
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Following conditions were used: 
Cycle step Temperature Times Cycles 
Initial denaturation 95°C 5 min 1 
Denaturation 95°C 30 sec  
Annealing 62°C 1 min 30 
Elongation 72°C 1 min  
Final elongation 72°C 10 min 1 
Pause 12°C ∞  
    
After completion of the run, Stop mix was added to 1 µl of the reaction mixture and 
loaded on a 1% agarose gel.  
 
2.13.2 Quantitative real time PCR for genotyping 
The quantitative real time PCR is a PCR method that relies on the convential PCR 
principle, but additionally enables the quantification of the amount of the synthesized 
PCR product in real time after each cycle. The increase of the PCR product is 
quantified using a fluorescent dye that binds unspecifically double strand DNA. In the 
present study, the PCR Mastermix Platinum® SYBR® Green qPCRSuperMix-UDG with 
Rox (Life technologies, Darmstadt, Germany) was used. This dye binds the minor 
groove of double strand DNA and then fluoresce 1000 x stronger than its unbound 
state. SYBR® Green is excited by a wavelength of 480 nm and shows an emission 
spectrum with a maximum at 520 nm. The Rox reference dye serves for normalization 
of non-PCR-related fluctuations in fluorescence. The fluorescent intensity was 
quantified using the ABI Prism 7900T Sequence Detection System. During the 
exponential phase of the PCR reaction, in which the conditions are optimal, which 
means optimal polymerase activity and a sufficient amount of reaction materials 
(primers, MgCl2), the threshold value is determined. The threshold value defines the 
PCR cycle with the optimal conditions and is further used for the calculation of the 
quantification (Ct value). The generated data was analyzed using the Sequence 
Detection System software (SDS Version 2.1, PE Applied Biosystems).  
In the present study, quantitative real time PCR was performed to be able to distinguish 
between the heterozygous and homozygous state of the Villin-rtTA2-M2 mice (see 
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chapter 2.9.2.2) during genotyping. Therefore, the DNA of the mice, which were 
positive for the Villin-rtTA2-M2 transgene after Mango-Taq-PCR (see chapter 2.13.1) 
was purified overnight (see chapter 2.11.2). Afterwards, quantitative real time PCR was 
performed. The reaction consisted of the following components: 
2.5 µl purified DNA 
2.5 µl Primer (fw + rev 100 pmol / µl) 
5.0 µl SYBR® Green 
 
The following programme on the ABI Prism 7900T Sequence Detection System was 
used: 
Cycle step Temperature Times Cycles 
 50°C 2 min  
Taq activation 95°C 3 min  
Denaturation 94°C 15 sec  
Annealing 60°C 30 sec 40  









2°C / min 
 
 
After completion of the measurement, data was transferred to MS Excel (Microsoft). 
The relative expression was determined by the ΔΔ-Ct-method using the following 
formulas: 
 ΔCt = Ct (gene of interest) – Ct (housekeeping gene) 
 ΔΔCt = ΔCt (control) – ΔCt (sample of interest) 
 Relative expression = 2ΔΔCt 
For normalization, the mRNA expression of the two housekeeping genes Hprt 
(hypoxanthine-guanine phosphoribosyltransferase) and Tbp (TATA box binding 
protein) was used.  
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2.14 Protein chemical techniques 
 
2.14.1 Isolation of total protein from tumors derived in xenograft mice and from 
colonic tumors induced by AOM / DSS, respectively 
For the isolation of total protein from tumors derived in xenograft mice and from colonic 
tumors induced in Villin-TRE-IGF1R and Villin-CreERT-Igf1r mice by AOM / DSS, 
respectively, the tumors were excised from the mice, transferred into a screw cap cup 
and quick-frozen in liquid nitrogen. A small piece of the quick-frozen sample was 
administered to approx. 50 µl modified RIPA buffer and lysed using the Tissue Lyser 
LT (Qiagen, Hilden, Germany) at an oscillation of 50 / s for 5 min. Afterwards, the 
samples were sonicated for 5 cycles á 20 sec and centrifuged at 13.000 rpm at 4°C for 
10 min. The supernatant was transferred into a new reaction tube and stored at -20°C. 
 
2.14.2 Isolation of total protein from intestinal tissue 
For the isolation of total protein from intestinal tissue, the small intestine and colon 
were excised from the mice and cut longitudinally. The epithelial cells of the small 
intestine and colon were scraped using a 22 x 22 mm coverglass, transferred into a 
screw cap cup and quick-frozen in liquid nitrogen. A small piece of the quick-frozen 
sample was administered to approx. 50 µl modified RIPA buffer and lysed using the 
Tissue Lyser LT (Qiagen, Hilden, Germany) at an oscillation of 50 / s for 5 min. 
Afterwards, the samples were sonicated for 5 cycles á 20 sec and centrifuged at 
13.000 rpm at 4°C for 10 min. The supernatant was transferred into a new reaction 
tube and stored at -20°C.  
 
2.14.3 Determination of protein concentration 
(Bradford 1976) 
Protein concentration was determined using the Roti®Nanoquant reagent (Carl Roth 
GmbH, Karlsruhe, Germany) according to the method of Bradford. The principle of this 
method is based on the change of the absorption after binding of the Coomassie 
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Brilliant Blue dye to cationic and hydrophobic side chains of proteins. Upon binding, 
the absorption maximum increases from 495 nm to 595 nm, which is proportional to 
the concentration of the proteins. For measurement, proteins from cell cultures were 
diluted 1:100, while proteins from tissue samples were diluted 1:200, and triplicates of 
50 µl of each solution were appended into a 96-well plate. 200 µl 1x Roti®Nanoquant 
was added to each sample and incubated for 5 min at RT. The measurement was 
performed using the Synergy Mx plate reader (BioTek, Friedrichshall, Germany). For 
western blot analysis, 5 µg to 25 µg protein was used. 
 
2.14.4 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
For the separation of proteins, the NuPAGE® Pre-Cast Gel System (Life Technologies, 
Darmstadt, Germany) was used. This is a polyacrylamide gel system for high 
performance gel electrophoresis and is based on SDS-PAGE gel chemistry 
(Laemmli 1970). The system consists of NuPAGE® Bis-Tris pre-cast gels and 
specifically optimized buffers with a pH of 7.0. This neutral pH increases the stability 
of proteins and gels, providing increased confidence in electrophoresis. 
Five to 25 µg protein was mixed with 0.4 vol NuPAGE® LDS Sample Buffer (4x) (Life 
Technologies, Darmstadt, Germany) and 10% of the reducing agent DTT. The proteins 
were denatured at 70°C for 10 minutes, centrifuged and loaded onto the NuPAGE™ 
4-12% Bis-Tris gel (Life Technologies, Darmstadt, Germany). Gel electrophoresis was 
performed at 160 V for approx. 30 min to 2 hours depending on the molecular weight 
of the target proteins using 1x MES buffer (Life technologies, Darmstadt, Germany). 
For the determination of the size of the proteins, the NuPAGE™ See Blue Plus2 (Life 
Technologies, Darmstadt, Germany) was used. 
 
2.14.5 Transfer of proteins from Polyacrylamide gels to PVDF membranes 
(Gershoni and Palade 1982, 1983) 
To detect proteins by western blot analysis, separated proteins were transferred on a 
PVDF membrane by semi-dry blotting. Therefore, a PVDF membrane (GE Healthcare, 
Freiburg, Germany) was activated in 100% methanol for 5–10 sec and equilibrated in 
transfer buffer IIa for approx. 10 min together with six Whatman filter papers 
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(Schleicher & Schull, Dassel, Germany). For blotting, three Whatman filter papers, the 
activated and equilibrated PVDF membrane, the polyacrylamide gel and again three 
Whatman filter papers were placed on the anode. The electro-blotter (Biometra, 
Göttingen, Germany) was closed placing the cathode on top. The transfer was 
performed at 25 V and 220 mA for approx. 30 min to 1 hour depending on the molecular 
weight of the proteins. 
 
2.14.6 Incubation of protein-bound membranes with antibodies 
To block unspecific binding sites, the membrane was incubated in 1x TBS-T with           
5% low-fat dry milk (blocking buffer) for 1 hour. The membrane was washed with           
1x TBS-T and incubated with the primary antibody specific against the protein of 
interest in TBS-T at 4°C overnight. Subsequently, the membrane was washed twice 
with 1x TBS-T with 2.5% low-fat dry milk (washing buffer) and incubated with the 
appropriate horseradish peroxidase conjugated secondary antibody diluted in blocking 
buffer for 2 hours at RT. After incubation, the membrane was washed three times for 
15 min with washing buffer and 5 min with TBS-T. For the detection of 
chemiluminescent signals, the ECL Prime Kit (GE Healthcare, Freiburg, Germany) was 
used. The solution was appended on the membrane, incubated and the signal was 
digitally developed using the western blot detection system FlourChem® Q Alpha with 
the appropriate AlphaView software (Innotech, Logan, USA). Following antibodies and 
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Primary antibody Dilution of primary 
antibody 
Dilution of secondary 
antibody 
α-AKT 1:2000 1:20000 
α-HSC-70 1:20000 1:40000 
α-IGF1Rα 1:1000 1:10000 
α-IGF1Rβ 1:2000 1:20000 
α-p44/42 MAPK (ERK1/2) 1:2000 1:20000 
α-Phospho-AKT (Ser473) 1:2000 1:20000 
α-Phospho-AKT (Thr308) 1:2000 1:20000 




α-Tubulin 1:10000 1:20000 
α-Villin 1:1000 1:10000 
 
 
2.15 Cell biological methods 
 
2.15.1 Cell culture of eukaryotic cells 
The adherent growing human colorectal cancer cell lines CaCo-2, DLD-1 and the rectal 
cancer cell line SW837 were used for the xenograft experiments (see chapter 2.17.10). 
DLD-1 and SW837 cells were cultured in commercially purchased RPMI 1640 medium 
(PAN, Aidenbach, Germany), the CaCo-2 cells were grown in MEM medium (Life 
Technologies, Darmstadt, Germany). The cells were cultured at 37°C in a humified 
atmosphere with 5% CO2. Depending on the proliferation rate, cells were splitted one 
to two times per week. For splitting, the cells were incubated with a minimal amount of 
Trypsin / EDTA (PAN, Aidenbach, Germany) at 37°C until cells detached from the 
bottom of the culture flask, which was controlled using the AE2000 inverted microscope 
(Ted Pella, Inc., Redding, USA). After cells have detached, the proteolytic activity of 
Trypsin / EDTA was terminated by the addition of growth medium. Then, cells were 
diluted in fresh growth medium. For the xenograft experiments, a distinct number of 
cells was used. Therefore, cells were counted with a Neubauer improved counting 
chamber (Hartenstein, Würzburg, Germany).  
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2.15.2 Cryo-preservation and revitalization of eukaryotic cells 
For the cryo-preservation, cells were grown to a confluence higher than 80%, washed 
with DPBS (PAN, Aidenbach, Germany) and trypsinized. After detachment, cells were 
centrifuged at 500 g for 5 min to remove remaining Trypsin / EDTA and resuspended 
in an appropriate amount of culture medium containing 10% DMSO. Subsequently, the 
cells were slowly cooled to -80°C (1°C / min) in a freezer using the Mr. Frosty system 
(Thermo Scientific, Langenselbold, Germany). Frozen cells were transferred to liquid 
nitrogen for long term storage. 
For the revitalization of eukaryotic cells, frozen cells were quickly thawed within a water 
bath at 37°C, centrifuged at 200 g for 5 min and the supernatant was discarded. The 
cells were gently resuspended in fresh culture medium, transferred into a culture flask 
and incubated at 37°C in a humified atmosphere with 5% CO2. 
 
2.15.3 Test for Mycoplasma contamination 
The test for mycoplasma contamination was routinely performed using the MycoAlert® 
Mycoplasma Detection Kit (Lonza, Cologne, Germany) according to the 
manufacturer’s instructions. Importantly, only half of the recommended amounts of the 
reagent and substrate were used.  
Mycoplasma are small prokaryotes that compete with the cultured cells for the nutrients 
in the growth media and therefore change cellular functions, such as proliferation and 
gene expression. The MycoAlert® Mycoplasma Detection Kit is based on the 
measurement of the activity of mycoplasma-specific enzymes before and after 
application of specific substrates.  
Weakly contaminated cells were treated with Mycokill AB (Lonza, Cologne, Germany) 
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2.16 Immunostainings 
 
2.16.1 Immunohistochemistry on paraffin-embedded tissue sections 
Immunohistochemistry was performed on paraffin-embedded murine tissue sections 
(2 to 4 µm) of the small intestine and colon. For the different staining experiments 
different protocols were used. At first, tissue sections were depariffinized in xylene for 
15 to 20 min and rehydrated through graded ethanol series at RT. For antigen retrieval, 
tissue sections were boiled in citrate buffer or sodium citrate buffer, respectively, for 
15 to 20 min. Afterwards, the endogenous peroxidase was blocked using 1% or            
3% H2O2, respectively, for 15 to 45 min at RT. For the blocking of unspecific binding 
sites, the small intestinal and colonic tissue sections were blocked with either 10% FBS 
in DPBS, 5% BSA in DPBS or 5% FBS and 10% BSA in DPBS for 20 min to 1 hour, 
depending on the protocol. Subsequently, tissue sections were incubated with the 
primary antibody at 4°C overnight. The next day, the sections were washed and 
incubated with the secondary antibody depending on the protocol. The staining was 
developed using DAB Chromogen (Dako, Hamburg, Germany), counterstained using 
hemalum solution (Carl Roth GmbH, Karlsruhe, Germany) and covered with Glycergel 




















1 : 200 α-rabbit biotinylated 
antibody 
1 : 1000 
IGF1R 1 : 100 α-goat biotin 
conjugated antibody 
1 : 1000 
Ki 67 1 : 50 α-rabbit / mouse HRP 
conjugated antibody 
1 : 1 in TBS 
Lysozyme 1 : 200 α-rabbit biotinylated 
antibody 
1 : 1000 
Mucin 2 1 : 200 α-rabbit biotinylated 
antibody 
1 : 1000 
 
 
2.16.2 Alkaline phosphatase (AP) staining of enterocytes 
The small intestinal and colonic tissue sections (2 to 4 µm) were depariffinized in xylene 
for 10 min and rehydrated through graded ethanol series at RT. Then, 200 µl AP buffer 
was added and incubated for 5 to 10 min at RT. The AP buffer was removed and 
approx. 120 µl AP staining solution was added and incubated for approx. 25 min at RT 
until sufficient staining was visible. The sections were washed, counterstained with 
hemalum solution (Carl Roth GmbH, Karlsruhe, Germany) and covered using 
Glycergel Mounting Medium (Dako, Carpinteria, USA). 
 
2.16.3 Immunofluorescence double staining on paraffin-embedded tissue 
sections 
Immunofluorescence double staining was performed on paraffin-embedded murine 
tissue sections (2 to 4 µm) of the small intestine and colon. At first, tissue sections were 
depariffinized in xylene for 20 min and rehydrated through graded ethanol series at 
RT. For antigen retrieval, tissue sections were boiled in 10 mM citrate buffer for 
3 x 5 min. For the blocking of unspecific binding sites, the small intestinal and colonic 
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tissue sections were blocked with 10% FBS in DPBS for 1 hour. Subsequently, tissue 
sections were incubated with the primary antibodies at 4°C overnight. The next day, 
sections were incubated with the Cy3-conjugated and FITC-Phalloidin-conjugated 
secondary antibodies diluted in DPBS for 2 hous at RT. Afterwards, sections were 
washed 3 x 10 min in DPBS and 1 x 10 min in ddH2O. Tissue sections were covered 
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2.17 In vivo studies 
 
2.17.1 Induction of the IGF1R overexpression in epithelial cells of the intestine 
of Villin-TRE-IGF1R mice by doxycycline administration 
For the induction of the overexpression of human IGF1R in epithelial cells of the 
intestine, 4 week old Villin-TRE-IGF1R mice were administered to 0.2 mg / ml and 
2 mg / ml doxycycline hyclate (AppliChem GmbH, Darmstadt, Germany), respectively, 
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over the drinking water. Common household sweetener “Das gesunde PLUS” (dm-
drogerie markt GmbH + Co. KG, Karlsruhe, Germany) was additionally added to the 
drinking water (1 tablet per 150 ml drinking water). Mice in the control group received 
only drinking water with sweetener. Villin-TRE-IGF1R mice received doxycycline over 
the drinking water until they were sacrificed. 
 
2.17.2 Induction of the Igf1r knockout in epithelial cells of the intestine of        
Villin-CreERT-Igf1r mice by tamoxifen injection 
For the induction of the Igf1r knockout in epithelial cells of the intestine, 4 week old 
Villin-CreERT-Igf1r mice were intraperitoneally injected with 1 mg tamoxifen (Sigma-
Aldrich, Deisenhofen, Germany) per day on five consecutive days. Therefore, 200 mg 
tamoxifen was dissolved in 800 µl EtOH and 19.2 ml sunflower seed oil from Helianthus 
annuus (Sigma-Aldrich, Deisenhofen, Germany). 
 
2.17.3 Induction of colonic tumor formation by AOM or AOM / DSS 
For the induction of tumor formation in the colon of Villin-TRE-IGF1R or                        
Villin-CreERT-Igf1r mice, respectively, the mutagenic agent azoxymethane (AOM) 
(Neufert et al. 2007) or the combination of azoxymethane and the inflammatory agent 
dextran sulfate sodium (DSS) (Neufert et al. 2007; Thaker et al. 2012) were used. 
 
2.17.3.1 AOM treatment 
To induce tumor formation in the colon of Villin-TRE-IGF1R and Villin-CreERT-Igf1r 
mice by AOM, mice were injected intraperitoneally with 10 mg / ml AOM in NaCl once 
per week on four consecutive weeks.  
 
2.17.3.2 AOM / DSS treatment 
For the induction of colonic tumor formation and inflammation in Villin-TRE-IGF1R and 
Villin-CreERT-Igf1r mice by AOM / DSS, mice were once intraperitoneally injected with 
10 mg / ml AOM to induce colonic tumor formation followed by two cycles of 2% DSS 
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over the drinking water to induce intestinal inflammation. Common household 
sweetener “Das gesunde PLUS” (dm-drogerie markt GmbH + Co. KG, Karlsruhe, 
Germany) was additionally added to the drinking water (1 tablet per 150 ml drinking 
water). The first DSS cycle started one week after the AOM injection and lasted four 
days. The second cycle started one week after the end of cycle one and lasted three 
days. Between the DSS cycles and for 21 days after completion of the second DSS 
cycle, mice were fed with cereal mush to prevent dehydration of the mice. DSS 
administration often led to rapid loss of weight, diarrhea or bloody feces. To minimize 
the pain, mice were subcutaneously injected with 0.1 mg / kg body weight of the 
analgesic Buprenorphin (Temgesic®, RB Pharmaceuticals Limited, Berkshire, UK) 
diluted in NaCl. 
 
2.17.4 Colonoscopy 
Colonoscopy was performed to check for tumor formation in the colon of                       
Villin-TRE-IGF1R and Villin-CreERT-Igf1r mice. In cooperation with Dr. Ramona 
Schulz (Department of Molecular Oncology, University Medical Center Göttingen, 
Germany) the colonoscopy device (Karl Storz GmbH & Co. KG, Tuttlingen, Germany) 
was used according to the manufacturer’s instructions. To minimize the stress during 
the process of colonoscopy, a special, very thin endoscope was used. The mice were 
anesthetized using the inhalant isoflurane (Abbvie, Wiesbaden, Germany). To estimate 
tumor size, grading of tumors was done related to Becker et al. (2007). The scores 1 
to 5 indicate the tumor size relative to the circumference of the colon. Is the tumor just 
detectable, it has a score of 1. If the tumor surrounds 12.5% of the circumference of 
the colon, it has a score of 2. A score of 3 is at 25%, a score of 4 at 50% tumor size 
relative to the circumference of the colon. If the tumor comprises more than 50% of the 
circumference of the colon, it has a score of 5. 
 
2.17.5 Macroscopic analysis of the tumors 
For macroscopic analysis of the developed tumors induced by AOM or AOM / DSS 
treatment, the Villin-TRE-IGF1R and Villin-CreERT-Igf1r mice were sacrificed and the 
small intestine and colon were excised from the animals. The intestinal tissue was cut 
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longitudinally and the number of colonic tumors was counted. Furthermore, the part of 
the colon, where the tumors have developed, was determined. Therefore, the colon 
was divided into three parts: distal, middle and proximal part from the anus to the 
stomach (Fig. 3). Afterwards, the length and width of all tumors was measured using a 
caliper. Subsequently, the intestinal samples were fixed in formalin and paraffin-
embedded for histopathological analysis. 
 
Fig. 3: Preparation of the murine colon for analysis. 
The colon was excised from the sacrificed mice and cut longitudinally. For the determination of the tumor 
location in the colon, the colon was divided into three parts: distal, middle and proximal part from the 
anus to the stomach. The number of tumors per part was counted. 
 
2.17.6 Histopathological analysis of tumors 
For the histopathological analysis of the colonic tumors after AOM or AOM / DSS 
administration, the fixed colon samples were paraffin-embedded and hematoxylin and 
eosin staining was prepared in the Institute of Pathology, University Medical Center 
Göttingen, Germany. Importantly, the colonic tissue samples with tumors induced by 
AOM / DSS were cut stepwise as follows: the first section was taken and the following 
ten sections were discarded. This process was repeated until three tissue sections 
were prepared. This process was done to increase the probability to detect as many 
tumors as possible along the axis from distal to proximal for histopathological analysis. 
Afterwards, the tumor stage and tumor size were determined together with Dr. med. 
Felix Bremmer (Institute of Pathology, University Medical Center Göttingen, Germany) 
using the Axio Scope.A1 microscope and the appropriate ZEN lite 2012 software 
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2.17.7 Histopathological analysis of liver tissue and lymph nodes in regional 
colonic fat tissue 
In order to screen for metastatic cells in the liver tissue and lymph nodes in regional 
colonic fat tissue, liver tissue and lymph nodes in the regional colonic fat tissue were 
excised from the mice, fixed in 4% formalin and paraffin-embedded. Ten sections were 
each cut and stained with hematoxylin and eosin. Afterwards, Dr. med. Felix Bremmer 
(Institute of Pathology, University Medical Center Göttingen, Germany) screened the 
ten sections of the livers and lymph nodes for metastases, respectively. 
 
2.17.8 Quantification of goblet cells, Paneth cells, enteroendocrine cells and 
proliferating cells 
For the quantification of goblet cells, Paneth cells, enteroendocrine cells and 
proliferating cells, Villin-TRE-IGF1R mice were administered to doxycycline to induce 
the IGF1R overexpression (see chapter 2.17.1) and Villin-CreERT-Igf1r mice were 
intraperitoneally injected with tamoxifen to induce the knockout of the Igf1r                    
(see chapter 2.17.2), respectively. Four weeks, three months and 1.5 years after the 
induction of the IGF1R overexpression and the Igf1r knockout, respectively, mice were 
sacrificed, the small intestinal and colonic tissue were dissected from the mice, cut 
longitudinally, rolled and fixed in 4% formalin. The fixed tissue samples were paraffin-
embedded and cut in the Institute of Pathology, University Medical Center Göttingen, 
Germany. Ten sections (2 to 4µm) were each cut. Immunohistochemistry was 
performed (see chapter 2.16.1). For the quantification of the different cell types, stained 
cells of 50 crypts and 50 villi, respectively, per mouse were manually counted using 
the AlphaView software (Innotech, Logan, USA).  
 
2.17.9 Determination of the villi length and crypt depth of Villin-TRE-IGF1R mice 
For the determination of the villi length and crypt depth, Villin-TRE-IGF1R mice were 
continuously treated with 0 mg / ml or 2 mg / ml doxycycline for three months to induce 
the IGF1R overexpression (see chapter 2.17.1). Subsequently, the animals were 
sacrificed, the small intestinal and colonic tissues were excised from the mice and 
divided into small pieces without cutting them longitudinally. Thus, the villi and crypts 
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were kept in their “natural” appearance without squeezing. The tissue samples were 
fixed in 4% formalin, paraffin-embedded and cut. Hematoxylin and eosin staining was 
performed on 10 tissue sections (Institute of Pathology, University Medical Center 
Göttingen, Germany). Afterwards, the length of 50 villi and the depth of 50 crypts of 
each mouse were measured using the cellSens Dimension software appropriate to the 
microscope BX60 (Olympus, Hamburg, Germany). 
 
2.17.10 Xenograft experiments 
For the xenograft experiments, a distinct number of DLD-1, CaCo-2 and SW837 cells, 
respectively (see chapter 2.15.1) in the logarithmic phase of growth were added to 
0.5 mg / ml matrigel (BD Bioscience, San Jose, USA) and subcutaneously injected into 
each flank of 6 to 8 week old female immune-deficient RjOrl:NMRI-Foxn1nu/Foxn1nu 
mice (see chapter 2.9.2.1). Tumor volume was determined regularly using a caliper 
and calculated using the formula “V = width2 x length x 0.5”. When the tumors reached 
a volume of approx. 300 mm3, mice were randomized into either a treatment group of 
AEW541 (40 mg / kg; dissolved in 25 mM L(+)-Tartaric acid (Sigma-Aldrich, 
Deisenhofen, Germany)), erlotinib (100 mg / kg; dissolved in 0.2% (w / v) 
Carboxymethylcellulose with 0.1% Tween 80), the combination of AEW541 and 
erlotinib or a control group. Mice were treated with combined 5-FU-based RCT 
(50 mg / kg, dissolved in PBS followed by 1.8 Gy irradiation per day (Department of 
Radiotherapy and Radio Oncology, University Medical Center Göttingen, Germany) in 
addition to inhibitor treatment. Mice in the control group received combined RCT like 
the treatment groups in combination with the same amount of the solvent. Combined 
5-FU-based RCT was applied on five consecutive days. In addition, inhibitors were 
administered on eight consecutive days. Since the mice did not tolerate the treatment, 
the treatment scheme was changed in cooperation with Dr. rer. nat. Melanie Spitzner 
(Department of General, Visceral and Pediatric Surgery, University Medical Center 
Göttingen, Germany). Thus, mice were administered to combined 5-FU-based RCT on 
the first three days of treatment as well as on the days ten and eleven. Inhibitors were 
applied in two cycles. The first cycle started on day one of treatment and lasted for four 
days, whereas the second cycle started on day seven and lasted for five days. Tumor 
volume was measured daily using a caliper. When the tumors reached a volume of 
approx. 1500 mm3, the tumors were dissected from the mice, weighed and measured. 
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Here, tumor volume was calculated using the formula 
“V = width x length x height x π / 6”.  
 
2.18 Statistical analysis 
To test for statistical significance, the unpaired student’s t test was performed. The 
program GraphPad Prism was used to calculate the P value. The P value indicates the 
probability that the results are not different. A P value smaller than * p < 0.05 means 
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3 Results 
 
3.1 Establishment of a mouse line used to induce overexpression of 
the IGF1R in the intestine 
To study the role of the IGF1R during the development of the intestine and during 
intestinal tumor formation and progression, respectively, a mouse model for the 
inducible overexpression of the IGF1R was established, called thereafter                    
Villin-TRE-IGF1R. The Villin-TRE-IGF1R mouse line is a double transgenic mouse line 
and was generated by the breeding of the Villin-rtTA2-M2 mouse line (chapter 2.9.2.2) 
with the TRE-IGF1R mouse line (chapter 2.9.2.3). 
 
3.1.1 Genotyping of the Villin-rtTA2-M2 mouse line 
The Villin-rtTA2-M2 mouse line is a transgenic mouse line that expresses the 
doxycycline-dependent reverse tetracycline transactivator rtTA2-M2 under the 
intestine specific villin promoter (Roth et al. 2009). 
To check the newborn pubs for the presence of the Villin-rtTA2-M2 transgene, DNA of 
the tail was isolated and analyzed by PCR. Therefore, transgene-specific primers were 
used (Roth et al. 2009). In Fig. 4a the result of a genotyping PCR is shown.   T/+ is a 
positive control meaning that the transgene is present. H2O was used as a negative 
control. Mice #236 and #237 are negative for Villin-rtTA2-M2. However, mice #238 to 
#246 show a band for T/+, which means that those mice are carriers of the Villin-rtTA2-
M2 transgene. To be able to distinguish between the heterozygous and homozygous 
state for Villin-rtTA2-M2, the expression of the transgene was analyzed by quantitative 
real time PCR. Therefore, the DNA of the mice, which were positive for Villin-rtTA2-M2 
(#238 to #246) was purified overnight and quantitative real time PCR was performed. 
The relative expression of the transgene of the heterozygous mice was half the relative 
expression of homozygous mice (Fig. 4b).  
For further breedings only the homozygous mice for Villin-rtTA2-M2 (T/T) were used, 
so that genotyping was not necessary for each breeding experiment. Nevertheless, 
genotyping PCRs were performed on a regular basis to check for the correct genotype.  
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Fig. 4: Genotyping of the Villin-rtTA2-M2 mouse line. 
For genotyping, tail DNA was extracted and used in the PCR together with transgene-specific primers. 
(a) Mice #238 to #246 carried the Villin-rtTA2-M2 transgene. (b) For the discrimination between mice 
heterozygous or homozygous for the transgene, the expression of the Villin-rtTA2-M2 transgene was 
analyzed by quantitative real time PCR. Mice #239 and #243 were homozygous for the transgene, 
whereas mice #238, #240 to #242 and #244 to #246 were heterozygous for the Villin-rtTA2-M2 
transgene. M=1 Kb Plus DNA Ladder, T/+=positive control of a heterozygous Villin-rtTA2-M2 mouse, 
T/T=positive control of a homozygous Villin-rtTA2-M2 mouse, H2O=negative control without DNA. 
 
3.1.2 Genotyping of the TRE-IGF1R mouse line 
The TRE-IGF1R mouse line is a transgenic mouse line expressing the human IGF1R 
under the control of the doxycycline-inducible pTRE2 promoter (Jones et al. 2007). To 
analyze the genotype of the pubs, PCR amplification of tail DNA was performed using 
specific primers for the TRE-IGF1R transgene. The product length is 450 bp. Mice 
#340 and #342 to #344 showed a band for the TRE-IGF1R transgene. Only mouse 
#341 was a wild type mouse (Fig. 5). This mouse line was kept as a heterozygous 
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Fig. 5: Genotyping of the TRE-IGF1R mouse line. 
Tail DNA was extracted and used as template in the PCR. Agarose gel electrophoresis was performed. 
The transgene-specific PCR-product has a size of 450 bp. Mice #340 and #342 to #344 showed a band 
of 450 bp and were therefore carriers of the TRE-IGF1R transgene. M=1 Kb Plus DNA Ladder, 
T/+=positive control of a heterozygous TRE-IGF1R mouse, H2O=negative control without DNA. 
 
3.1.3 Genotyping of the Villin-TRE-IGF1R mouse line  
For the generation of the double transgenic Villin-TRE-IGF1R mouse line, the 
transgenic Villin-rtTA2-M2 mouse line was crossed with the transgenic TRE-IGF1R 
mouse line. For the genotyping of the pubs, tail DNA was amplified by one PCR with 
specific primers for the Villin-rtTA2-M2 transgene (Fig. 6a) and by another PCR with 
specific primers for the TRE-IGF1R transgene (Fig. 6b). The Villin-rtTA2-M2 mouse 
line was kept as a homozygous mouse line, while the TRE-IGF1R mouse line was kept 
as a heterozygous mouse line. Therefore, the offspring could either be heterozygous 
for Villin-rtTA2-M2 and heterozygous for TRE-IGF1R (T/+; T/+) or heterozygous for 
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Fig. 6: Genotyping of the Villin-TRE-IGF1R mouse line used for the induction of the IGF1R 
overexpression. 
For the genotyping of the newborn pubs of the Villin-TRE-IGF1R mouse line, DNA extracted from tail 
biopsies was amplified by PCR. Here, two PCR experiments were performed. (a) PCR using specific 
primers for the Villin-rtTA2-M2 transgene. (b) PCR with specific primers for the TRE-IGF1R transgene. 
All pubs were carriers of the Villin-rtTA2-M2 transgene, while only mice #204, #206 to #207, #210 and 
#212 to #215 carried the TRE-IGF1R transgene. M=1 Kb Plus DNA Ladder, T/+=positive control of either 
a heterozygous Villin-rtTA2-M2 mouse or a heterozygous TRE-IGF1R mouse, H2O=negative control 
without DNA. 
 
3.2 Induction of IGF1R overexpression in Villin-TRE-IGF1R mice 
To study the effect of IGF1R overexpression during the development of the intestine 
and during intestinal tumor formation and progression, the Villin-TRE-IGF1R mouse 
line was used. As described in chapter 3.1.3, Villin-TRE-IGF1R mice could either be 
heterozygous for Villin-rtTA2-M2 and heterozygous for TRE-IGF1R (T/+; T/+; double 
transgenic) or heterozygous for Villin-rtTA2-M2 and wild type for TRE-IGF1R 
(T/+; +/+). Importantly, the overexpression of IGF1R can only be induced in the double 














































































3 Results  48 
express the reverse tetracycline transactivator rtTA2-M2 under the intestine-specific 
villin promoter, and the human IGF1R under the doxycycline inducible pTRE2 
promoter. In the presence of doxycycline, the reverse tetracycline transactivator is able 
to bind to the pTRE2 promoter and therefore induces the overexpression of human 
IGF1R in the intestine. 
For the following experiments, double transgenic Villin-TRE-IGF1R mice were 
administered to 0.2 mg / ml or 2 mg / ml doxycycline over the drinking water to induce 
IGF1R overexpression. This group of mice was named thereafter IGF1R-oe (for 
IGF1R-overexpressing mice). As control, double transgenic Villin-TRE-IGF1R mice 
were administered to H2O instead of doxycycline (0 mg / ml doxycycline), and, in 
addition, Villin-TRE-IGF1R mice, which only carried the Villin-rtTA2-M2 transgene but 
not the TRE-IGF1R transgene, were administered to 0.2 mg / ml or 2 mg / ml 
doxycycline over the drinking water. These two latter groups of mice were summarized 
as control group. The drinking water was exchanged twice a week. For the 
experiments, doxycycline was continuously administered until the mice were sacrificed 
(Fig. 7). 
 
Fig. 7: Treatment scheme for the induction of IGF1R overexpression in the intestine of              
Villin-TRE-IGF1R mice. 
To develop IGF1R overexpressing mice (IGF1R-oe), Villin-TRE-IGF1R mice that carried both, the Villin-
rtTA2-M2 and the TRE-IGF1R transgene (T/+ T/+), were continuously administered to doxycycline over 
the drinking water. As control mice, double transgenic Villin-TRE-IGF1R mice (T/+ T/+), which were 
administered to H2O, and Villin-TRE-IGF1R mice, which carried only the Villin-rtTA2-M2 transgene 
(T/+ +/+), but which were continuously administered to doxycycline over the drinking water, were used. 
The drinking water was exchanged twice a week. The red arrows mark time points when the mice were 
sacrificed for subsequent experiments. 
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3.3 Confirmation of villin expression in epithelial cells of the intestine 
of Villin-TRE-IGF1R mice via immunohistochemistry 
Villin is known to be broadly expressed in every cell of the intestinal epithelium on both 
the vertical axis (crypt to villus tip) and the horizontal axis (duodenum through colon) 
of the intestine (Madison 2002). To confirm the expression of villin in epithelial cells of 
the small intestine (SI) and colon of Villin-TRE-IGF1R mice, intestinal tissue sections 
were stained with an antibody specific for villin. In Fig. 8 representative pictures of the 
staining are shown. Villin was highly expressed in epithelial cells of the villi of the small 
intestine. A gradient from strong villin expression in the villi to weak villin expression in 
the crypts of the small intestine was visible. In colonic epithelial cells, villin was highly 
expressed at the top of the crypts, whereas the expression of villin at the bottom of the 
crypts was weak.  
 
Fig. 8: Villin is expressed in epithelial cells of the murine intestine. 
For the confirmation of villin expression in epithelial cells of the murine intestine, tissue sections of the 
small intestine (SI) (n=5) and colon (n=5) were stained for villin (brown). Cell nuclei were stained with 
hemalum solution (blue). Expression was visible in epithelial cells of the intestine. A gradient of villin 
expression could be observed from strong expression in the villi to weak expression in the crypts of the 
small intestine as well as strong expression at the top of the crypts to weak expression at the bottom of 
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3.4 Confirmation of IGF1R overexpression in epithelial cells of the 
intestine via immunohistochemistry 
The overexpression of human IGF1R in IGF1R-oe mice was confirmed by 
immunohistochemistry. Therefore, Villin-TRE-IGF1R mice were continuously treated 
with 0 mg / ml, 0.2 mg / ml and 2 mg / ml doxycycline over the drinking water for four 
weeks. The mice were sacrificed, the small intestine and colon were excised from the 
animals, fixed in formalin and paraffin-embedded. Afterwards, tissue sections were 
stained with a specific antibody for human IGF1R. IGF1R-oe mice revealed strong 
expression of human IGF1R in epithelial cells of the small intestine (Fig. 9a) and colon 
(Fig. 9b) compared to control mice, which showed no staining for human IGF1R. 
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Fig. 9: The IGF1R is overexpressed in epithelial cells of the villi and crypts in the small intestine 
and in epithelial cells of the crypts of the colon of IGF1R-oe Villin-TRE-IGF1R mice. 
For the confirmation of the overexpression of IGF1R, Villin-TRE-IGF1R mice were continuously treated 
with doxycycline or H2O for four weeks. The mice were sacrificed and tissue sections of the small 
intestine (n=5) and colon (n=5) were stained with an antibody specific for human IGF1R (brown). Cell 
nuclei were stained with hemalum solution (blue). IGF1R-oe mice highly expressed human IGF1R in 
the small intestine and colon in comparison to control mice. 
 
3.5 Confirmation of IGF1R overexpression in the intestine and 
analysis of its downstream PI3K and MAPK signaling pathways 
For the confirmation of the overexpression of IGF1R in epithelial cells of the mouse 
intestine, western blot analysis was performed (Fig. 10). Therefore, Villin-TRE-IGF1R 
mice were continuously treated with 0 mg / ml, 0.2 mg / ml or 2 mg / ml doxycycline for 
four weeks. After sacrificing the mice, the small intestine and colon were excised from 
the animals, cut longitudinally and proteins of epithelial cells were extracted separately. 
Western blot analysis revealed strong expression of IGF1Rα and IGF1Rβ in epithelial 
cells of the small intestine and colon of IGF1R-oe mice compared to control mice. 
Interestingly, in IGF1R-oe mice, the expression level of IGF1Rα and IGF1Rβ was 
extremely elevated in epithelial cells of the small intestine compared to the colon. 
Furthermore, the expression level of IGF1R depended on the doxycycline 
concentration. Thus, the expression of IGF1Rα and IGF1Rβ was highly increased in 
IGF1R-oe mice treated with 2 mg / ml doxycycline compared to IGF1R-oe mice treated 
with only 0.2 mg / ml doxycycline or control mice. To analyze if overexpression of the 
IGF1R results in the activation of its downstream PI3K and MAPK signaling pathways, 
western blot analysis was performed with specific antibodies for the phosphorylated 
forms of AKT (pAKT) and ERK (pERK). Notably, IGF1R-oe mice showed strong 
activation of AKT, whereas control mice revealed only a low AKT phosphorylation level. 
Of note, one control mouse also displayed AKT phosphorylation in the colon. The 
activation level of AKT depended on the doxycycline concentration with an increase of 
activated AKT in IGF1R-oe mice treated with 2 mg / ml doxycycline. This fact is of high 
interest when comparing the expression level of IGF1Rα and IGF1Rβ with the 
activation level of AKT. As already described, cells of the small intestine revealed an 
extremely high expression level of IGF1Rα and IGF1Rβ compared to cells of the colon, 
while in contrast the activation level of the downstream AKT was higher in cells of the 
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colon compared to the small intestine. Strong ERK activation was visible in the small 
intestine of the IGF1R-oe mice administered to 0.2 mg / ml doxycycline, whereas the 
two IGF1R-oe mice administered to 2 mg / ml doxycycline showed lower or even no 
activation of ERK in the small intestine. In the colon, a high phosphorylation level of 
ERK was visible in one control mouse, whereas IGF1R-oe mice showed lower ERK 
activation. 
Taken together, western blot analyses demonstrated that the human IGF1R was 
overexpressed in the small intestine and colon of IGF1R-oe mice. Additionally, the 
downstream PI3K signaling pathway was activated in IGF1R-oe mice, whereas IGF1R 
overexpression seemed to have no influence on the activation of the downstream 
MAPK signaling pathway. 
 
Fig. 10: Confirmation of IGF1R overexpression and the induction of downstream signaling 
pathways in IGF1R-oe mice. 
Proteins were extracted from epithelial cells of the small intestine (SI) and colon of Villin-TRE-IGF1R 
mice administered to 0 mg / ml doxycycline (n=2), 0.2 mg / ml doxycycline (n=1) and 2 mg / ml 
doxycycline (n=2), respectively. Western blot analysis was performed. IGF1R-oe mice highly expressed 
IGF1Rα and IGF1Rβ in a doxycycline concentration-dependent manner. The phosphorylation level of 
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(pERK) was visible in the small intestine of the IGF1R-oe mouse administered to 0.2 mg / ml doxycycline 
as well as in the colon of one control mouse. 
 
3.6 Identification of the intestinal cell type overexpressing the IGF1R 
The overexpression of the IGF1R in the small intestine and colon of IGF1R-oe          
Villin-TRE-IGF1R mice could be verified by both immunohistochemistry (chapter 3.4) 
and western blot analysis (chapter 3.5). Immunofluorescence staining also revealed 
intense overexpression of IGF1R in cells of the small intestine (representative picture 
shown in Fig. 11). The expression pattern of IGF1R was evenly distributed over the 
villi, but, importantly, not all cells of the small intestine displayed IGF1R 
overexpression. This observation was in contrast to findings published by                          
El Marjou et al. (2004) who generated a transgenic mouse line expressing a tamoxifen-
dependent cre recombinase under the villin promoter. The authors proved that the 
villin-guided cre recombinase is homogenously expressed in epithelial cells all along 
the crypt-villus axis. Furthermore, they showed that also the undifferentiated progenitor 
cells in the intestine express the villin-guided cre recombinase, and observed stronger 
expression in the differentiated cells compared to the cells in the crypts, which was 
similar to the expression gradient of endogenous villin (El Marjou et al. 2004). In 
addition, Madison (2002) proved that villin is broadly expressed in every cell of the 
intestinal epithelium (Madison 2002). This led to the assumption that, despite the villin-
guided IGF1R overexpression, only a special intestinal cell type overexpresses the 
IGF1R upon doxycycline treatment. For this reason, it was of high interest to identify 
the cell type in the small intestine and colon overexpressing the IGF1R.  
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Fig. 11: Overexpression of the IGF1R in cells of the small intestine of IGF1R-oe mice. 
Villin-TRE-IGF1R mice (n=10) were administered continuously to 2 mg / ml doxycycline for four weeks 
to induce IGF1R overexpression. The mice were sacrificed and tissue samples were fixed and paraffin-
embedded. Immunofluorescence staining was performed using an antibody specific for the human 
IGF1R (red). DAPI visualized cell nuclei (blue). Intense expression of IGF1R was visible in the villi, but 
not all cells revealed IGF1R expression. 
 
Therefore, IGF1R-oe mice were continuously treated with 2 mg / ml doxycycline for 
four weeks to induce IGF1R overexpression. The mice were sacrificed, the small 
intestine and colon were excised from the animals, fixed and paraffin-embedded. 
Afterwards, double stainings with an antibody specific for a distinct intestinal cell type 
together with an antibody specific for human IGF1R were performed on the tissue 
sections. In this context, mucin 2 was used as a marker for goblet cells, 
Chromogranin A (CHGA) as a marker for enteroendocrine cells and lysozyme was 
used to stain Paneth cells. In Fig. 12 representative pictures of the double stainings of 
mucin 2, CHGA and lysozyme, respectively, together with IGF1R in the small intestine 
and colon of IGF1R-oe mice are shown. All three double stainings revealed both, 
expression of the distinct cell type and intense IGF1R overexpression. A gradient of 
IGF1R overexpression from high expression in the villi of the small intestine and at the 
top of the crypts of the colon to low expression in the crypts of the small intestine and 
at the bottom of the crypts of the colon was visible. Interestingly, a concordant 
100 x
DAPI    IGF1R
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expression of IGF1R together with mucin 2, IGF1R together with CHGA or IGF1R 
together with lysozyme, respectively, could not be observed in the small intestine and 
colon, showing that neither goblet cells nor enteroendocrine cells nor Paneth cells 
overexpressed the IGF1R. 
 
Fig. 12: Identification of the intestinal cell type overexpressing the IGF1R upon doxycycline 
treatment. 
For the identification of the cell type overexpressing the IGF1R, epithelial cells of the small intestine and 
colon were doublestained for mucin 2 as a marker for goblet cells (red), CHGA as a marker for 
enteroendocrine cells (red) and lysozyme as a marker for Paneth cells (red), respectively, together with 
human IGF1R (green). The expression of all three cell types as well as intense IGF1R overexpression 
was visible. A concordant expression pattern of IGF1R together with mucin 2, IGF1R together with 
CHGA and IGF1R together with lysozyme, respectively, in the small intestine and colon could not be 
observed, showing that neither goblet cells nor enteroendocrine cells nor Paneth cells overexpressed 
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3.7 IGF1R overexpression does not induce intestinal tumor formation 
per se 
Jones et al. (2007) demonstrated that IGF1R overexpression is sufficient to induce 
mammary tumor formation in vivo by using a transgenic mouse model containing the 
human IGF1R under the doxycycline-inducible MMTV (mouse mammary tumor virus) 
promoter. To investigate if IGF1R overexpression per se also induces intestinal tumor 
formation, overexpression of IGF1R was induced in Villin-TRE-IGF1R mice. Therefore, 
the mice were continuously treated with 0 mg / ml, 0.2 mg / ml or 2 mg / ml doxycycline 
for 1.5 years. As described in chapter 3.2, IGF1R overexpression can only be induced 
in double transgenic mice that receive doxycycline (IGF1R-oe mice). Mice which were 
administered to 0 mg / ml doxycycline, and mice which carried only the Villin-rtTA2-M2 
transgene but were administered to doxycycline, were used as controls. To check for 
intestinal tumor formation, colonoscopies were regularly performed (Fig. 13). 
 
Fig. 13: Treatment scheme for the long-term experiment to analyze if IGF1R overexpression 
induces intestinal tumor formation. 
Villin-TRE-IGF1R mice were continuously administered to 0 mg / ml (n=4), 0.2 mg / ml (n=7) or 2 mg / ml 
doxycycline (n=10) for 78 weeks to induce IGF1R overexpression. To check for tumor formation, 
colonoscopy was regularly performed. After 78 weeks, the mice were sacrificed and the small intestine 
and colon were excised from the mice, fixed and paraffin-embedded for immunohistochemical 
examination. 
 
As can be seen in Fig. 14, colonoscopy one year and 1.5 years after the start of 
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Fig. 14: Colonoscopy of IGF1R-oe and control Villin-TRE-IGF1R mice. 
To examine if tumors have formed in the colon of Villin-TRE-IGF1R mice upon doxycycline treatment, 
colonoscopy was regularly performed. Therefore, the mice were anesthetized using isoflurane and the 
endoscope was rectally penetrated. Tumor development could not be observed in IGF1R-oe (n=6) or 
control mice (n=15) 1 year and 1.5 years after the start of doxycycline administration, respectively. 
 
To prove that the IGF1R was still overexpressed in the colon and small intestine of 
IGF1R-oe mice that were continuously treated with doxycycline after 1.5 years, 
immunohistochemical staining was performed on intestinal tissue sections. In Fig. 15 
representative pictures of the stainings are shown. One and a half year after the start 
of doxycycline administration, IGF1R overexpression was still detectable in the small 
intestine and colon of the IGF1R-oe mice. Control mice showed no IGF1R 
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Fig. 15: IGF1R overexpression in epithelial cells of the small intestine and colon of IGF1R-oe and 
control Villin-TRE-IGF1R mice after 1.5 years. 
For the confirmation that IGF1R was still overexpressed in cells of the small intestine (SI) and colon of 
IGF1R-oe mice after 1.5 years, immunohistochemical staining was performed using an antibody specific 
for the human IGF1R (brown). Cell nuclei were stained with hemalum solution (blue).                            
IGF1R-oe (n=6: n=3 (0.2 mg / ml doxycycline) + n=3 (2 mg / ml doxycycline)) mice showed intense 
expression of human IGF1R, while IGF1R expression could not be observed in the small intestine and 
colon of control mice (n=15). 
 
3.8 Analyses of the morphology of the small intestinal and colonic 
villi and crypts of Villin-TRE-IGF1R mice 
To analyze if IGF1R overexpression altered the morphology of the intestine, 
hematoxylin and eosin stainings of small intestinal and colonic tissue sections were 
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IGF1R-oe and control mice with five mice per group were continuously treated with 
0 mg / ml, 0.2 mg / ml or 2 mg / ml doxycycline to induce the overexpression of the 
IGF1R. The mice were sacrificed after four weeks, three months and 1.5 years, 
respectively. Together with Dr. med. Felix Bremmer (Institute of Pathology, University 
Medical Center Göttingen, Germany) the morphology of the villi and crypts was 
examined. In Fig. 16 representative pictures of the villi and crypts of the small intestine 
and colon after the three time points are shown. A difference in the morphology of the 
small intestinal and colonic villi and crypts between IGF1R-oe and control animals was 
not visible. Furthermore, a time-dependent difference in the morphology was also not 
observed. 
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Fig. 16: Hematoxylin and eosin stainings of the small intestine and colon of IGF1R-oe and control 
Villin-TRE-IGF1R mice after four weeks, three months and 1.5 years of IGF1R overexpression. 
IGF1R-oe (n=5) and control (n=5) Villin-TRE-IGF1R mice were continuously administered to 0 mg / ml, 
0.2 mg / ml or 2 mg / ml doxycycline to induce IGF1R overexpression. After four weeks, three months 
and 1.5 years, mice were sacrificed, the small intestine and colon were dissected from the mice, fixed, 
paraffin-embedded and cut. Hematoxylin and eosin stainings were performed on the sections in the 
Institute of Pathology (University Medical Center Göttingen, Germany). Together with Dr. med. Felix 
Bremmer (Institute of Pathology, University Medical Center Göttingen, Germany) the morphology of both 
the villi and crypts were analyzed. (a) A difference in the morphology of the small intestine and (b) colon 
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Also a difference in the morphology of the villi and crypts of the small intestine and 
colon could not be observed, further analysis with regard to the villus length and crypt 
depth was performed. Therefore, ten IGF1R-oe and control mice each were 
continuously treated with 0 mg / ml, 0.2 mg / ml or 2 mg / ml doxycycline for three 
months. Subsequently, the animals were sacrificed, the small intestinal and colonic 
tissues were excised from the mice and divided into small pieces without cutting them 
longitudinally. Thus, the villi and crypts were kept in their “natural” appearance without 
squeezing, and the length of the villi and the depth of the crypts could be measured. 
For measurement, the samples were fixed and paraffin-embedded, hematoxylin and 
eosin stainings were performed and the length of 50 villi and the depth of 50 crypts of 
each mouse were measured using the cellSens Dimension software appropriate to the 
microscope BX60 (Olympus, Hamburg, Germany). In Fig. 17a a representative image 
of how the measurement was performed is shown.  
In the small intestine, IGF1R-oe mice showed a significantly extended depth of the 
crypts (Fig. 17b), whereas the length of the villi revealed no alterations compared to 
the control mice (Fig. 17c). In the colon, IGF1R overexpression did not result in a 
difference in crypt depth between IGF1R-oe and control animals (Fig. 17d). 
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Fig. 17: IGF1R overexpression significantly altered the crypt depth in the small intestine of 
IGF1R-oe mice compared to control mice. 
(a) For the analysis of the villus length and the crypt depth, hematoxylin and eosin stainings were 
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Villin-TRE-IGF1R mice, respectively. Pictures were taken and the villus length and the depth of the 
crypts were determined using the cellSens Dimension software (Olympus, Hamburg, Germany). 
(b) IGF1R-oe mice revealed a significant increase in the average crypt depth of the small intestine 
compared to control mice. (c, d) The average villi length of the small intestine as well as the average 
crypt depth of the colon was not altered after IGF1R overexpression. * P <0.05 (student’s t test). 
 
3.9 Quantification of the different intestinal cell types of                    
Villin-TRE-IGF1R mice after four weeks, three months and 1.5 years 
of doxycycline treatment 
To analyze the maintenance and regeneration of the intestine, the number of the 
different intestinal cell types was quantified. Therefore, IGF1R-oe and control             
Villin-TRE-IGF1R mice with five mice per group were continuously treated with 
0 mg / ml, 0.2 mg / ml or 2 mg / ml doxycycline for four weeks, three months and 
1.5 years to induce IGF1R overexpression. The mice were sacrificed, intestinal tissues 
were fixed and paraffin-embedded and tissue sections were stained for the different 
cell types. In Fig. 18 representative pictures of the stainings for Villin-TRE-IGF1R mice 
are shown. Hereby, mucin 2 was used as a marker for goblet cells, Chromogranin A 
(CHGA) as a marker for enteroendocrine cells, lysozyme was used to stain Paneth 
cells and Ki 67 staining was used to detect proliferating cells. For the quantification of 
the number of the different cell types, pictures of the stainings were taken using the 
microscope BX60 (Olympus, Hamburg, Germany). Importantly, the stained cells of 
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Fig. 18: Stainings of goblet cells (mucin 2), enteroendocrine cells (CHGA), Paneth cells 
(lysozyme) and proliferating cells (Ki 67) for the quantification of the different cell types in the 
small intestine and colon of Villin-TRE-IGF1R mice. 
To analyze if IGF1R overexpression has any influence on the maintenance and regeneration of the 
intestine, the number of the different intestinal cell types was quantified and compared to control mice. 
Therefore, immunohistochemical stainings were performed on tissue sections of the small intestine (SI) 
and colon of IGF1R-oe (n=5) and control (n=5) Villin-TRE-IGF1R mice using antibodies specific for the 
different cell types (brown) as indicated. Cell nuclei were stained with hemalum solution (blue).  
 
3.9.1 IGF1R overexpression results in a significant reduction of goblet cells 
For the quantification of goblet cells in the small intestine and colon, mucin 2-positive 
cells of 50 villi and 50 crypts per mouse were counted. In IGF1R-oe mice, the number 
of goblet cells was significantly reduced in the crypts and villi of the small intestine as 
well as in the crypts of the colon compared to control mice. However, the number of 
goblet cells of the IGF1R-oe mice decreased after three months, but showed no 
change after 1.5 years. Interestingly, a significant decrease of goblet cells with time in 
the crypts of the small intestine and colon was observed in control mice, whereas a 
significant increase from four weeks to 1.5 years was observed in the villi of control 
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Fig. 19: IGF1R overexpression resulted in a significant reduction of goblet cells. 
Cells of the small intestine (a, b) and colon (c) were stained for mucin 2, a marker for goblet cells. The 
number of goblet cells per crypt and villus with 50 crypts and villi per mouse was counted. The number 
of goblet cells per crypt and villus of the small intestine and per crypt of the colon significantly decreased 
in IGF1R-oe mice (n=5) compared to control mice (n=5). ** P < 0.01, *** P < 0.0001 (student’s t test). 
 
3.9.2 The number of enteroendocrine cells increases with time after IGF1R 
overexpression 
To quantify the number of enteroendocrine cells, chromogranin A-positive cells of 
50 villi of the small intestine and of 50 crypts of the colon per mouse were counted. 
Enteroendocrine cells are known to be not localized in the crypts of the small intestine 
(Medema and Vermeulen, 2011). In the small intestine and colon, the number of 
enteroendocrine cells increased significantly with time. After three months, IGF1R-oe 
mice showed a significantly higher number of chromogranin A-positive cells in the small 
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mice. In the colon, the IGF1R-oe mice revealed a significantly higher number of 
enteroendocrine cells than control mice after four weeks, but after three months and 
1.5 years no difference in the number of chromogranin A-positive cells was visible 
(Fig. 20). 
 
Fig. 20: The number of enteroendocrine cells increased with time after IGF1R overexpression. 
For the quantification of enteroendocrine cells, cells of the small intestine (a) and colon (b) were stained 
for chromogranin A (CHGA) as a marker for enteroendocrine cells. The number of enteroendocrine cells 
per villus or crypt, respectively, significantly increased over time in IGF1R-oe (n=5) and control mice 
(n=5). * P <0.05, ** P < 0.01, *** P < 0.0001 (student’s t test). 
 
3.9.3 The number of Paneth cells decreases over time in IGF1R-oe and control 
mice 
Paneth cells are localized in the crypts of the small intestine, but are not detected in 
the colon (Medema and Vermeulen, 2011). Paneth cells are characterized by the 
expression of lysozyme, and lysozyme-positive cells per crypt were counted. The 
number of Paneth cells decreased significantly over time in IGF1R-oe and control mice. 
After four weeks and three months of doxycycline treatment, the number of lysozyme-
positve cells was significantly lower in IGF1R-oe mice compared to control mice. 
Interestingly, the number of Paneth cells was significantly increased in IGF1R-oe mice 
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Fig. 21: The number of Paneth cells decreased over time in IGF1R-oe and control mice. 
Tissue sections of the small intestine were stained for lysozyme, a marker for Paneth cells.   Lysozyme-
positive cells per villus of 50 villi per mouse were manually counted. The number of Paneth cells 
significantly decreased over time in IGF1R-oe (n=5) and control mice (n=5). *** P < 0.0001 (student’s t 
test). 
 
3.9.4 The number of proliferating cells is decreased in the colon of IGF1R-oe 
mice 
Ki 67 is a marker for proliferating cells. The process of proliferation is known to occur 
at the bottom of the crypts. At the top of the crypts, proliferation halts and cells 
differentiate into goblet cells, Paneth cells or enteroendocrine cells or into enterocytes 
(Medema and Vermeulen 2011). 
In the small intestine, the number of proliferating cells significantly increased after three 
months, but significantly decreased after 1.5 years in both IGF1R-oe and control mice. 
In the small intestine, the number of Ki 67-positive cells was significantly higher in 
IGF1R-oe animals compared to control mice four weeks after the start of doxycycline 
treatment. After three months and 1.5 years, no difference in the number of proliferating 
cells between IGF1R-oe and control mice was visible. In the crypts of the colon, the 
number of proliferating cells slightly decreased over time in IGF1R-oe and control mice. 
Comparison of the number of Ki 67-positive cells between IGF1R-oe and control mice 





















t c o n tr o l
IG F 1 R -o e
***






s m a ll in te s tin e
3 Results  69 
 
Fig. 22: The number of proliferating cells was decreased in the colon of IGF1R-oe mice. 
Sections of the small intestine (a) and colon (b) of IGF1R-oe (n=5) and control mice (n=5) were stained 
for Ki 67 as a marker for proliferating cells. The Ki 67-positve cells per crypt were manually counted. In 
the small intestine, the number of Ki 67-positive cells increased in IGF1R-oe mice compared to control 
mice after four weeks of doxycycline administration, but decreased after three months and 1.5 years of 
doxycycline administration. The number of proliferating cells per crypt in the colon of IGF1R-oe mice 
was significantly decreased compared to control mice after four weeks, three months and 1.5 years. 
* P <0.05, *** P < 0.0001 (student’s t test). 
 
3.9.5 IGF1R overexpression does not alter the presence of enterocytes 
Enterocytes are absorptive cells in the intestinal epithelium. Enterocytes originate from 
the intestinal stem cells in the crypts and differentiate and migrate from the crypt to the 
villus tip in the small intestine and from the bottom of the crypt to the top of the crypt in 
the colon, respectively (Overeem et al. 2016). To analyze if IGF1R overexpression 
altered the presence of enterocytes in the intestine, five tissue sections of the small 
intestine and colon of IGF1R-oe and control Villin-TRE-IGF1R mice each were stained 
for enterocytes by alkaline phosphatase staining. In Fig. 23 representative pictures of 
the stainings are shown. A difference in the presence of enterocytes in the intestinal 
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Fig. 23: The presence of enterocytes in the small intestine and colon of Villin-TRE-IGF1R mice. 
IGF1R-oe (n=5) and control mice (n=5) were each treated with doxycycline to induce the overexpression 
of IGF1R. The mice were sacrificed and tissue sections of the small intestine and colon were stained for 
enterocytes by alkaline phosphatase (brown). Cell nuclei were stained with hemalum solution (blue). A 
difference in the presence of enterocytes between IGF1R-oe and control Villin-TRE-IGF1R mice could 
not be observed. 
 
3.10 The IGF1R overexpression in the intestine promotes intestinal 
tumor formation and progression (AOM model) 
As already shown, IGF1R overexpression did not induce intestinal tumor formation per 
se (chapter 3.7). To analyze if IGF1R overexpression plays a role during intestinal 
tumor progression, intestinal tumor formation was induced in Villin-TRE-IGF1R mice 
using the mutagenic agent azoxymethane (AOM). AOM is known to initiate cancer by 
alkylation of DNA and thereby facilitation of base mispairings (Neufert et al. 2007). 
Therefore, IGF1R-oe and control Villin-TRE-IGF1R mice were administered to 
doxycycline. In the following experiments mice that carried only the Villin-rtTA2-M2 
transgene (T/+ +/+) treated with doxycycline were used as control. In addition, IGF1R-
oe and control mice were only administered to 2 mg / ml doxycycline. Furthermore, all 
mice were intraperitoneally injected with four weekly repeated injections of 
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Fig. 24: Treatment scheme for the analysis if IGF1R overexpression has any influence on colonic 
tumor progression (AOM model). 
IGF1R-oe (T/+ T/+) (n=11) and control (T/+ +/+) (n=11) Villin-TRE-IGF1R mice were administered to 
2 mg / ml doxycycline to induce IGF1R overexpression and injected four times with azoxymethane 
(AOM) to induce colonic tumor formation. To check if tumors have developed, colonoscopy was regularly 
performed. Thirty-five weeks after the first AOM injection, the mice were sacrificed and the tumors were 
counted and measured. 
 
To screen for intestinal tumor formation, regular colonoscopies were performed. For 
the estimation of the tumor size, tumors were scored relating to Becker et al. (2007). 
 
Fig. 25: Colonoscopy of IGF1R-oe and control Villin-TRE-IGF1R mice treated with AOM to induce 
colonic tumor formation. 
To examine if tumors have formed in the colon of Villin-TRE-IGF1R mice, colonoscopy was regularly 
performed. IGF1R-oe (n=11) and control mice (n=11) developed tumors in the colon. Stars mark the 
formed tumors. The numbers indicate the score of the tumor (after Becker et al. 2007). 
 
Thirty-five weeks after the first AOM injection, the mice were sacrificed, the colon 
length of the mice that have developed tumors was measured using a caliper (Fig. 27) 
and the developed tumors were macroscopically counted and measured. Therefore, 
the colon was divided into three parts (distal, middle and proximal part of the colon 








2 mg / ml doxycycline
regular colonoscopies
5 6 7 8








3 Results  72 
 
Fig. 26: Example of the macroscopic analysis of tumors developed in an IGF1R-oe                       
Villin-TRE-IGF1R mouse. 
The colon was determined into three parts: distal, middle and proximal part from the anus to the 
stomach. The number of tumors per colonic part was counted and the tumors were measured using a 
caliper. Stars indicate tumors. 
 
Shortening of the colon is a typical sign of acute intestinal inflammation (Ito et al. 2006). 
For this reason, the average colon length of IGF1R-oe and control mice that have 
developed tumors was compared (Fig. 27). There was no significant difference in the 
average colon length. 
 
Fig. 27: Average colon length of IGF1R-oe and control Villin-TRE-IGF1R mice after tumor 
induction by AOM. 
No significant difference in the average colon length between IGF1R-oe (n=11) and control mice (n=11) 
was observed (student’s t test). 
 
In Fig. 28a a comparison of the total number of IGF1R-oe and control mice with or 
without tumor formation after the four AOM injections is shown. Interestingly, only three 
out of eleven (27.3%) control mice developed tumors, whereas six out of eleven 
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and control mice were splitted regarding their sex (Fig. 28b, c). While half (50%) of the 
female control mice showed tumor formation, not one male control mouse out of five 
(0%) developed a tumor (Fig. 28b). In IGF1R-oe mice, six out of ten (60%) female mice 
formed a tumor, whereas the only male IGF1R-oe mouse did not develop a tumor (0%) 
(Fig. 28c). These results indicated that female mice could be more sensitive to AOM 
treatment than male mice. In Fig. 28d the average number of tumors of IGF1R-oe and 
control mice is shown. In Fig. 28e the localization and in Fig. 28f the size of the tumors 
was compared between IGF1R-oe and control mice. Here, only those mice which 
developed a tumor were included for analyses. Control mice developed on average 
1.67 tumors, whereas IGF1R-oe even developed on average 2.5 tumors. Regarding 
the localization of developed tumors, IGF1R-oe mice showed twice the number of distal 
tumors than control mice. The development of tumors in the middle part of the colon 
differed only weakly between IGF1R-oe and control mice. Neither IGF1R-oe nor 
control mice formed tumors in the proximal part of the colon. Regarding the size of the 
tumors, IGF1R-oe mice revealed a higher number of tumors larger than 2 mm in size 
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Fig. 28: Macroscopic analyses of the tumors developed in the colon of Villin-TRE-IGF1R mice 
after induction of tumor formation by AOM. 
IGF1R-oe (n=11) and control (n=11) mice were treated according to the treatment scheme (Fig. 24). 
Mice were sacrificed and the tumors were macroscopically analyzed. Therefore, the number of the 
tumors was counted, the size of the tumors was measured and the localization was determined. 
(a) IGF1R-oe mice developed a higher number of tumors compared to control mice. (b, c) Male mice 
did not form any tumors, only female mice revealed tumor development. (d) Analyzing only those mice 
which developed tumors, IGF1R-oe mice (n=6) developed on average more tumors compared to control 
mice (n=3). (e) IGF1R-oe mice showed a higher number of tumors in the distal and middle part of the 
colon compared to control mice. Neither control nor IGF1R-oe mice formed tumors in the proximal part 
of the colon. (f) Regarding the tumor size, IGF1R-oe mice formed a higher number of tumors bigger 
than 2 mm compared to control mice. (student’s t test). 
 
For histopathological analyses of the tumors the colonic tissues were fixed, paraffin-
embedded and hematoxylin and eosin stainings were prepared. In Fig. 29a a 
representative picture of the hematoxylin and eosin staining is shown. Together with 
Dr. med. Felix Bremmer (Institute of Pathology, University Medical Center Göttingen, 
Germany) the stage and size of the tumors were determined. To check for invasion 
and metastasis of tumor cells, hematoxylin and eosin stainings of the liver and lymph 
nodes in regional colonic fat tissue were also histopathologically analyzed. Regarding 
the stage of the tumors, IGF1R-oe mice revealed twice the number of low grade 
intraepithelial neoplasias per mouse than control mice. In fact, control mice showed a 
higher number of high grade neoplasias per mouse than IGF1R-oe mice. But, 
interestingly, one IGF1R-oe mouse even developed an intramucosal as well as an 
invasive adenocarcinoma (Fig. 29b). The determination of the average tumor size per 
mouse showed an increase of the tumor size of about 22.5% in IGF1R-oe mice 
(average tumor size: 2771.52 µm2) compared to control mice (average tumor 
size: 2148.26 µm2) (Fig. 29c). 
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Fig. 29: Histopathological analyses of the colonic tumors developed in IGF1R-oe and control 
Villin-TRE-IGF1R mice after AOM treatment. 
IGF1R-oe (n=11) and control mice (n=11) were administered to doxycycline to induce IGF1R 
overexpression and injected with AOM to induce intestinal tumor formation. Sections of paraffin-
embedded tissue samples of IGF1R-oe (n=6) and control mice (n=3) with tumors were stained with 
hematoxylin and eosin and the tumors were histopathologically analyzed together with Dr. med. Felix 
Bremmer (Institute of Pathology, University Medical Center Göttingen, Germany). (a) Hematoxylin and 
eosin stainings of an invasive tumor developed in the colon of an IGF1R-oe Villin-TRE-IGF1R mouse. 
The white arrows mark the zone of invasion. The black arrow indicates the muscularis mucosae. 
(b) IGF1R-oe mice developed a higher number of low grade intraepithelial neoplasias, but a lower 
number of high grade intraepithelial neoplasias compared to control mice. Even one IGF1R-oe mouse 
formed an intramucosal as well as an invasive carcinoma. (c) The average tumor size per mouse was 
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In addition, lymph nodes in the regional colonic fat tissue and liver tissue were excised 
from the mice to analyze both the lymph node status and to check for metastatic cells 
in the liver. It is known that colonic tumor cells predominantly metastasize to these 
organs (Hess et al. 2006). The tissue samples were fixed, paraffin-embedded, approx. 
10 sections per mouse were cut and hematoxylin and eosin stainings were prepared. 
The tissue sections were then examined for the lymph node status and screened for 
metastatic cells in the liver. However, metastases in the lymph nodes and livers could 
not be detected, neither in tissue sections from IGF1R-oe mice nor in lymph nodes and 
livers from control mice. 
 
3.11 IGF1R overexpression promotes intestinal tumor formation and 
progression (AOM / DSS model) 
Another model for the analysis of intestinal tumor formation and progression is the 
azoxymethane / dextran sulfate sodium (AOM / DSS) model. Dextran sulfate sodium 
(DSS) is an agent that has direct toxic effects on the colonic epithelium and thus 
creates a chronic inflammatory state. To induce tumor development, mice are treated 
with a combination of the genotoxic agent AOM and the inflammatory agent DSS 
(Thaker et al. 2012). For the combinational treatment of mice with AOM / DSS several 
different protocols exist (Neufert et al. 2007; Thaker et al. 2012). For the experiment of 
the present study, Villin-TRE-IGF1R mice were once intraperitoneally injected with 
10 mg / ml AOM and were afterwards administered to two cycles of 2% DSS over the 
drinking water. In addition, control (T/+ +/+) and IGF1R-oe (T/+ T/+) mice were treated 
with 2 mg / ml doxycycline (Fig. 30). 
 
Fig. 30: Treatment scheme for the induction of colonic tumors in Villin-TRE-IGF1R mice. 
IGF1R-oe (n=20) and control (n=22) Villin-TRE-IGF1R mice were administered to 2 mg / ml doxycycline 
to induce IGF1R overexpression. Furthermore, mice were once injected with AOM to induce colonic 
tumor formation and administered to two cycles of 2% DSS over the drinking water to induce intestinal 
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mice. To screen for tumor development, colonoscopy was performed regularly. The mice were sacrificed 
and the formed tumors were counted and measured. 
 
To screen for intestinal tumor development, colonoscopy was performed regularly. 
 
Fig. 31: Colonoscopy of Villin-TRE-IGF1R mice treated with AOM / DSS to induce colonic tumor 
formation and inflammation. 
To examine if tumors have formed in the colon of IGF1R-oe (n=20) and control (n=22)                              
Villin-TRE-IGF1R mice, colonoscopy was regularly performed. IGF1R-oe and control mice developed 
tumors in the colon. Stars mark the developed tumors. The numbers indicate the score of the tumor 
(after Becker et al. 2007). 
 
Twelve weeks after the AOM injection, many tumors revealed a score of 4 to 5 (after 
Becker et al., 2007) and the Villin-TRE-IGF1R mice had to be sacrificed. The colon 
length of mice that have developed tumors was measured using a caliper (Fig. 32). 
IGF1R-oe mice revealed a significant reduction in the average colon length compared 
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Fig. 32: Average colon length of IGF1R-oe and control Villin-TRE-IGF1R mice after colonic tumor 
induction by AOM / DSS. 
The average colon length was significantly reduced in IGF1R-oe mice (n=17) compared to control mice 
(n=20). * P <0.05 (student’s t test). 
 
Furthermore, the developed tumors were counted and measured macroscopically. 
Twenty out of 22 (91%) control mice developed colonic tumors, whereas 17 out of 20 
(85%) IGF1R-oe mice formed a tumor (Fig. 33a). Regarding their sex, eight female 
(80%) and twelve male (100%) control mice revealed tumor formation (Fig. 33b). In 
IGF1R-oe mice, seven female (78%) and ten male (91%) mice formed a tumor 
(Fig. 33c). These results showed that the sex of the mice did not significantly influence 
tumor development induced by AOM / DSS. In Fig. 33d the average number of tumors 
of IGF1R-oe and control mice that developed tumors is shown. On average, control 
mice developed 3.3 tumors, whereas IGF1R-oe even developed on average 
4.3 tumors. In Fig. 33e and Fig. 33f tumor localization and tumor size are shown. 
Control mice displayed tumor development predominantly in the distal part of the colon, 
only a small number of tumors developed in the middle part of the colon. However, 
IGF1R-oe mice formed tumors only in the distal part of the colon (Fig. 33e). Regarding 
the size of the tumors, IGF1R-oe mice presented 50% more tumors smaller than 2 mm 
than control mice. The number of tumors bigger than 2 mm did not differ between 
IGF1R-oe and control mice (Fig. 33f). 
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Fig. 33: Macroscopic analyses of the colonic tumors induced in Villin-TRE-IGF1R mice by 
AOM / DSS. 
IGF1R-oe (n=20) and control mice (n=22) were treated with 2 mg / ml doxycycline to induce the 
overexpression of IGF1R and administered to AOM / DSS to induce intestinal tumor formation and 
inflammation. Mice were sacrificed when the tumors exhibited a score of 4 to 5 (after (Becker et al. 
2007), and the tumors were macroscopically analyzed. (a- c) No difference regarding the number of 
mice that have developed tumors between IGF1R-oe and control mice as well as between female and 
male mice was observed. (d) IGF1R-oe mice (n=17) formed on average 4.3 tumors, whereas control 
mice (n=20) developed an average number of 3.3 tumors. (e) IGF1R mice formed a higher number of 
distal tumors, but did not develop any tumors in the middle part of the colon as control mice. (f) IGF1R-
oe mice formed a higher number of tumors smaller than 2 mm in size, whereas the number of tumors 
bigger than 2 mm was nearly identical between IGF1R-oe and control mice. (student’s t test). 
 
Furthermore, intestinal tissue was fixed, paraffin-embedded and cut stepwise. Here, 
the first section was taken and the following ten sections were discarded. This process 
was repeated until three tissue sections were available. This process was performed 
to increase the probability to detect as many tumors as possible along the axis from 
distal to proximal for histopathological analyses. The three hematoxylin and eosin 
stainings were analyzed together with Dr. med. Felix Bremmer (Institute of Pathology, 
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University Medical Center Göttingen, Germany). Tumors were classified in low grade 
and high grade intraepithelial neoplasia, and intramucosal and invasive carcinoma, 
respectively. In Fig. 34a representative pictures of the different tumor stages are 
shown. As depicted in Fig. 34b, control mice displayed a reduced number of tumors 
with increasing tumor stage, whereas IGF1R-oe mice showed an increased number of 
intramucosal and even invasive carcinomas. In addition, the average tumor size per 
mouse was examined. Control mice developed tumors with an average size of 953 
µm2 per mouse. However, IGF1R-oe mice revealed a 66.2% increased average tumor 
size (1440 µm2) compared to control mice (Fig. 34c).  
 
Fig. 34: Histopathological analyses of the AOM / DSS-induced tumors developed in IGF1R-oe 
and control Villin-TRE-IGF1R mice. 
(a) Representative pictures of low and high grade neoplasia, and intramucosal and invasive carcinomas 
of Villin-TRE-IGF1R mice. Therefore, colonic tissue was fixed, paraffin-embedded and cut stepwise. 
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(b) IGF1R-oe mice (n=17) developed a lower number of low grade and high grade intraepithelial 
neoplasias than control mice (n=20), but formed nearly six-fold more intramucosal carcinomas 
compared to control mice. One IGF1R-oe mouse even developed one invasive carcinoma, which was 
not present in control mice. (c) The average tumor size per mouse was approx. 500 µm2 (66.2%) 
increased in IGF1R-oe mice compared to control mice (student’s t test). 
 
In addition, lymph nodes in the regional colonic fat tissue and liver tissue were excised 
from the mice to analyze the lymph node status and to screen for metastatic cells in 
the liver. The tissue samples were fixed and paraffin-embedded, cut as described in 
chapter 3.10 and hematoxylin and eosin stainings were prepared. Representative 
pictures of the hematoxylin and eosin stainings are shown in Fig. 35. Analyses of the 
lymph nodes and livers of IGF1R-oe and control mice performed by Dr. med. Felix 
Bremmer (Institute of Pathology, UMG, Germany) revealed no metastatic cells. 
 
Fig. 35: Representative hematoxylin and eosin staining of liver tissue and lymph nodes in 
regional colonic fat tissue of Villin-TRE-IGF1R mice. 
IGF1R-oe (n=20) and control mice (n=22) were administered to doxycycline to induce IGF1R 
overexpression and to AOM / DSS to induce colonic tumor formation and inflammation. After colonic 
tumors have developed, mice were sacrificed and the liver tissue and lymph nodes in regional colonic 
fat tissue were excised from the animals. Hematoxylin and eosin stainings of the tissue sections of 
IGF1R-oe (n=17) and control mice (n=20) were prepared and microscopically analyzed for metastatic 
cells. Metastatic cells could not be detected in liver tissues or lymph nodes of IGF1R-oe and control 
Villin-TRE-IGF1R mice. 
 
3.12 Confirmation of IGF1R overexpression in tumor tissue 
To check if the tumors of IGF1R-oe mice, which were induced by AOM / DSS, show 
IGF1R overexpression, colonic tissue sections were stained with an antibody specific 
for human IGF1R. Immunohistochemical (Fig. 36a) as well as immunofluorescence 
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stainings (Fig. 36b) revealed that the IGF1R is overexpressed in normal colonic as well 
as in colonic tumor tissue.  
 
Fig. 36: IGF1R overexpression in AOM / DSS-induced tumors developed in IGF1R-oe                  
Villin-TRE-IGF1R mice. 
(a) Immunohistochemical stainings (brown) of normal colonic and colonic tumor tissue of IGF1R-oe 
(n=10) and control mice (n=10). Cell nuclei were stained with hemalum solution (blue). 
(b) Immunofluorescence stainings of normal colonic tissue and colonic tumor tissue of IGF1R-oe (n=5) 
and control mice (n=5). The arrow marks normal colonic tissue, the star indicates intestinal tumor tissue. 
DAPI visualized cell nuclei (blue). Immunohistochemical and immunofluorescence stainings revealed 
IGF1R overexpression in normal colonic tissue as well as in colonic tumor tissue.  
 
3.13 Confirmation of villin expression in tumor tissue 
It is known from the literature that expression of villin is commonly lost in poorly 
differentiated colon cancer (Arango et al., 2012). To confirm that villin is expressed in 
the colonic tumor tissue of IGF1R-oe and control mice induced by AOM / DSS 
treatment, immunofluorescence staining using an antibody specific for villin was 
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performed. In Fig. 37 representative pictures of the fluorescence stainings are shown. 
Villin was expressed in normal colonic as well as in colonic tumor tissue. 
 
Fig. 37: Villin was expressed in AOM / DSS-induced tumors of Villin-TRE-IGF1R mice. 
Immunofluorescence staining showed villin expression (red) in normal colonic tissue as well as in colonic 
tumor tissue of IGF1R-oe (n=5) and control mice (n=5). The arrow marks normal colonic tissue, the star 
indicates intestinal tumor tissue. DAPI visualized cell nuclei (blue). 
 
3.14 IGF1R overexpression results in the activation of the 
downstream PI3K signaling pathway in colonic tumors 
To analyze if the downstream PI3K and MAPK signaling pathways are activated in the 
colonic tumors which developed in IGF1R-oe and control mice after AOM / DSS 
administration, proteins of the tumors were extracted and western blot (Fig. 38a) and 
subsequent densitometrical analyses (Fig. 38b- g) were performed. Additionally, 
proteins of epithelial cells derived from either the small intestine (SI) or from the colon 
were extracted and analyzed. 
IGF1Rα and IGF1Rβ expression was weakly increased in tumors developed in IGF1R-
oe mice compared to control mice (Fig. 38a- c). Interestingly, AKT was highly activated 
in tumors developed in IGF1R-oe mice compared to tumors from control mice when 
phosphorylated at the serine 473 (Ser 473) residue (pAKT), but the activity of AKT was 
decreased in tumors from IGF1R-oe mice compared to tumors from control mice when 
phosphorylated at the threonine 308 (Thr 308) residue (pAKT) (Fig. 38a, d, e). The 
activation level of ERK (pERK) was reduced in tumors from IGF1R-oe mice compared 
to tumors from control mice (Fig. 38a, f). These results demonstrated that the 
downstream PI3K and MAPK signaling pathways were activated in colonic tumors 
*
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induced by AOM / DSS. Tumors of IGF1R-oe mice displayed a 2-fold higher expression 
level of villin compared to tumors from control mice (Fig. 38a, g).  
Furthermore, IGF1Rα expression was approx. 10-fold increased in epithelial cells of 
the small intestine (SI) and colon of IGF1R-oe mice compared to control mice, whereas 
IGF1Rβ expression was evenly up to 30-fold elevated in the small intestine and colon 
of IGF1R-oe mice. Again, these data confirmed the inducible overexpression of IGF1R 
upon doxycycline administration (Fig. 38a- c). Interestingly, the phosphorylation level 
of AKT (pAKT) was only weakly increased in the small intestine and colon of IGF1R-
oe mice when phosphorylated at the Ser 473 residue, whereas the activity of AKT was 
up to 6-fold increased in the small intestine and colon of IGF1R-oe mice when 
phosphorylated at the Thr 308 residue compared to control mice (Fig. 38a, d, e). The 
activity of ERK (pERK) was weakly elevated in the small intestine of IGF1R-oe mice, 
whereas the phosphorylation level was reduced in the colon of IGF1R-oe mice 
compared to control mice (Fig. 38a, f). Villin was evenly expressed in the small intestine 
and colon in IGF1R-oe and control mice (Fig. 38a, g). 
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Fig. 38: Western blot and subsequent densitometrical analyses of colonic tumors induced by 
AOM / DSS as well as of epithelial cells of the small intestine (SI) and colon of Villin-TRE-IGF1R 
mice. 
Both IGF1R-oe (n=20) and control (n=22) Villin-TRE-IGF1R mice were administered to 2 mg / ml 
doxycycline. Additionally, mice were administered to AOM / DSS to induce colonic tumor formation and 
inflammation. After intestinal tumors have developed, mice were sacrificed and proteins of tumors as 
well as of epithelial cells of the small intestine and colon of one IGF1R-oe and one control mouse were 
extracted. Western blot (a) and subsequent densitometrical analyses (b- g) were performed on three 
tumors developed in IGF1R-oe mice and on four tumors formed in control mice. (a- c) Elevated levels 
of IGF1R expression could be observed in tumors developed in IGF1R-oe mice as well as in epithelial 
cells of the small intestine and colon of IGF1R-oe mice compared to control mice. (a, d, e) The 
phosphorylation level of AKT (pAKT Ser473) was highly increased in the tumors and epithelial cells of 
the small intestine and colon of IGF1R-oe mice compared to control mice. (a, f) The phosphorylation 
level of ERK (pERK) was decreased in tumors developed in IGF1R-oe mice compared to control mice, 
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to control mice. (a, g) Villin was expressed in tumors and in epithelial cells of the small intestine and 
colon of IGF1R-oe and control mice. M=SeeBlue® Plus2 Pre-Stained Standard. 
 
3.15 Tumors induced in Villin-TRE-IGF1R mice by AOM / DSS do not 
metastasize to the liver and nearby lymph nodes 
To analyze if tumors induced by AOM / DSS are able to grow invasive and metastasize 
to nearby lymph nodes and to the liver, IGF1R-oe and control Villin-TRE-IGF1R mice 
were administered to AOM / DSS. Tumor formation was regularly examined by 
colonoscopy (Fig. 39).  
 
Fig. 39: Colonoscopy of IGF1R-oe and control Villin-TRE-IGF1R mice administered to AOM / DSS. 
For colonoscopy, mice were anesthetized using isoflurane. The number of tumors was counted and 
tumor localization was determined. Both IGF1R-oe (n=16) and control mice (n=11) revealed a high 
number of tumors of score 3 to 4 or even 5 (after Becker et al. 2007). 
 
Twenty weeks after the AOM injection, the majority of tumors developed in IGF1R-oe 
and control mice had a score of 3 to 4 or even 5 related to Becker et al. (2007) and 
mice were sacrificed. The colon length of those mice that have developed tumors was 
measured using a caliper. Comparison of the average colon length revealed no 
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Fig. 40: Average colon length of IGF1R-oe and control Villin-TRE-IGF1R mice after tumor 
induction by AOM / DSS. 
No significant difference in the average colon length between IGF1R-oe (n=14) and control mice (n=7) 
could be observed (student’s t test). 
 
Macroscopic analyses of the colons revealed that seven out of eleven (63.6%) control 
mice and 14 out of 16 (87.5%) IGF1R-oe mice developed tumors (Fig. 41a). The 
differentiation between the sexes showed that five out of seven (71.4%) female control 
mice and two out of four (50%) male control mice formed tumors (Fig. 41b). In IGF1R-
oe mice, four out of six (66.7%) female mice and all ten (100%) male mice displayed 
tumor formation (Fig. 41c). These results indicated that both sexes had the same 
susceptibility to AOM / DSS administration. On average, control mice developed 
2.6 tumors, whereas IGF1R-oe mice formed on average 6.1 tumors (Fig. 41d). 
Regarding the localization of the tumors in the colon, the majority of mice developed 
tumors in the distal part. Here, IGF1R-oe mice formed more than twice as many tumors 
than control mice. A few IGF1R-oe and control mice formed tumors in the middle part 
of the colon, whereas two IGF1R-oe mice developed tumors in the proximal part of the 
colon (Fig. 41e). Furthermore, the number of tumors smaller than 2 mm as well as 
bigger than 2 mm was increased in IGF1R-oe mice compared to control mice. Both, 
control and IGF1R-oe mice, revealed an increased number of tumors bigger than 2 
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Fig. 41: Macroscopic analyses of the colonic tumors of Villin-TRE-IGF1R mice induced by 
AOM / DSS. 
(a) Approx. 88% IGF1R-oe mice (n=16) developed a tumor in the colon, whereas only 64% of control 
mice (n=11) formed a tumor. (b, c) One hundred percent of male and 67% of female IGF1R-oe mice 
showed tumor formation in the colon, whereas only in 50% of male and in 71% of female control mice 
tumor development could be observed. (d) IGF1R-oe mice (n=14) developed on average 6.1 tumors, 
control mice (n =7) formed only 2.6 tumors on average. (e) IGF1R-oe mice showed a 2-fold higher 
number of tumors in the distal part of the colon than control mice and an increased number of tumors in 
the middle and proximal part of the colon. (f) IGF1R-oe mice developed a higher number of tumors 
smaller than 2 mm as well as bigger than 2 mm compared to control mice. 
 
In addition, histopathological analyses were performed. Therefore, colonic tissue 
sections were cut and stained with hematoxylin and eosin. Of note, paraffin-embedded 
colonic tissue of the three IGF1R-oe mice #545, #546 and #557 was cut stepwise, 
because the first analyzed section revealed many intramucosal tumors. IGF1R-oe 
mice developed a higher number of tumors with increasing stage and even invasive 
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average tumor size of 189 µm2. In IGF1R-oe mice, the average tumor size was 
increased for 90.3% to 1948 µm2 (Fig. 42b). 
 
Fig. 42: Histopathological analyses of the AOM / DSS-induced tumors developed in IGF1R-oe 
and control Villin-TRE-IGF1R mice. 
(a) IGF1R-oe mice (n=14) developed a higher number of tumors with increasing stage and even invasive 
carcinomas compared to control mice (n=7). (b) Control mice formed tumors with an average tumor size 
of 189 µm2. The average tumor size of IGF1R-oe mice is increased for approx. 90% to 1948 µm2.  
 
To investigate if tumors that were induced by AOM / DSS are able to grow invasive 
and metastasize, liver tissue and lymph nodes in the regional colonic fat tissue were 
histopathologically analyzed together with Dr. med. Felix Bremmer (Institute of 
Pathology, University Medical Center Göttingen, Germany). Therefore, liver tissue and 
lymph nodes in the regional colonic fat tissue were fixed, paraffin-embedded, cut and 
hematoxylin and eosin staining was performed on the sections. Neither control nor 
IGF1R-oe mice revealed metastatic cells in the liver or lymph nodes, indicating that 
tumors induced by AOM / DSS did not develop metastases. 
 
3.16 Establishment of a mouse line used to induce the knockout of 
the murine Igf1r in the intestine 
In order to analyze if the Igf1r plays a role during the development of the intestine as 
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for an inducible knockout of the murine Igf1r was established, called                             
Villin-CreERT-Igf1r. The Villin-CreERT-Igf1r mouse represents a double transgenic 
mouse line and was generated by crossing the Villin-CreERT2 mouse line with the 
Igf1r(lox) mouse line. 
 
3.16.1 Genotyping of the Villin-CreERT2 mouse line 
The Villin-CreERT2 mouse line is a transgenic mouse expressing the tamoxifen-
dependent cre recombinase under the control of the murine villin promoter 
(chapter 2.9.2.5). To analyze if the newborn pubs expressed the Villin-CreERT2 
transgene, DNA of the tail was amplified by PCR using specific primers which were 
complementary to the villin promoter and the cre coding sequence, respectively           
(El Marjou et al. 2004). In Fig. 43 the result of a representative genotyping-PCR is 
shown. While mouse #193 carried the transgene, mice #190 to #192 did not contain 
the Villin-CreERT2 transgene in their genome. To maintain the population of              
Villin-CreERT2 mice, Villin-CreERT2-positive mice were crossed with                              
Villin-CreERT2-negative mice. Therefore, the Villin-CreERT2 mice were kept in a 
heterozygous stage. 
 
Fig. 43: Result of a representative genotyping-PCR of the Villin-CreERT2 mouse line. 
Tail DNA was extracted and used as a template in the PCR. Mouse #193 showed a band of 220 bp in 
size and thus carried the cre recombinase. Mice #190 to #192 did not carry the cre recombinase in their 
genome and were thus negative for the cre recombinase. M=1 Kb Plus DNA Ladder, Cre+=positive 
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3.16.2 Genotyping of the Igf1r(lox) mouse line  
The Igf1r(lox) mouse line is a cre-responder mouse line that carries loxP-modified alleles 
of the Igf1r gene (chapter 2.9.2.6). To check if the offspring of the Igf1r(lox) mice carried 
the loxP-modified alleles of the Igf1r in their genome, tail DNA was amplified by PCR. 
In Fig. 44 the result of a representative PCR amplification is shown. Mice #10 to #18 
and #20 carried the loxP-modified alleles of the Igf1r gene, whereas mouse #19 did 
not carry the loxP-modified allele of the Igf1r in its genome. For maintaining the mouse 
population, homozygous Igf1r(lox) mice were crossed with each other. 
 
Fig. 44: Result of a representative genotyping-PCR of the Igf1r(lox) mouse line. 
Tail DNA was extracted and amplified by PCR using primers specific for the Igf1r(lox) transgene. All mice 
except mouse #19 showed a band of 220 bp in size and therefore carried two loxP-modified alleles of 
the Igf1r. M=1 Kb Plus DNA Ladder, fl / fl=positive control of a mouse carrying two loxP-modified alleles 
of the Igf1r, H2O=negative control without DNA. 
 
3.16.3 Genotyping of the Villin-CreERT-Igf1r mouse line  
The Villin-CreERT-Igf1r mouse line is a model for the inducible knockout of the Igf1r 
specifically in epithelial cells of the murine intestine (chapter 2.9.2.7). For the 
generation of the tamoxifen-inducible Igf1r knockout mouse line, the transgenic    Villin-
CreERT2 mouse line was crossed with the transgenic Igf1r(lox) mouse line. To determine 
the genotype of the offspring, tail DNA was extracted and analyzed by PCR using 
specific primers for the Villin-CreERT2 transgene as well as specific primers used for 
the genotyping of the Igf1r(lox) mouse line. In Fig. 45 the result of a representative 
genotyping-PCR is shown. Mice #488, #490 and #493 carried the cre recombinase, 
whereas mice #485 to #487, #489, #491 to #492 and #494 were negative for the cre 
recombinase. Furthermore, mice #486, #487, #489, #492, #493 and #494 carried the 
wild type and one loxP-modified allele of the Igf1r and were therefore heterozygous, 
whereas mouse #488 carried two loxP-modified alleles of the Igf1r and was therefore 
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Fig. 45: Result of a representative genotyping-PCR of the Villin-CreERT-Igf1r mouse line. 
For the genotyping of the newborn pubs, DNA of tail biopsies was extracted and PCR-amplified using a 
primer pair specific for the Villin-CreERT2 transgene and primers specific for the Igf1r(lox) transgene. Mice 
#486, #487, #489, #492, #493 and #494 carried the cre recombinase in their genome, whereas mice 
#485, #486, #487, #489, #491, #492 and #494 were negative for the cre recombinase. Mice #486, #487, 
#489, #492, #493 and #494 carried a wild type (wt) and a loxP-modified allele of the Igf1r, and were 
therefore heterozygous mice, whereas mouse #488 carried two loxP-modified alleles of the Igf1r and 
was therefore a homozygous mouse. Two Igf1r wild type alleles were detected in mice #485, #490 and 
#491. M=1 Kb Plus DNA Ladder, Cre+=positive control of a mouse carrying the cre recombinase, 
fl / fl=positive control of a mouse carrying two loxP-modified alleles of the Igf1r. 
 
3.17 Induction of the knockout of Igf1r in the Villin-CreERT-Igf1r mice 
To study the influence of the Igf1r during the development of the intestine and during 
intestinal tumor formation and progression, the Villin-CreERT-Igf1r mouse line was 
used. As described in chapter 3.16.3, Villin-CreERT-Igf1r can have the following 
genotypes: Cre+/Igf1rfl/fl (homozygous Igf1r knockout mice), Cre+/Igf1rfl/+ (heterozygous 
Igf1r knockout mice) as well as Cre-/Igf1rfl/fl or Cre-/Igf1rfl/+ (control mice). The complete 
knockout of the Igf1r in epithelial cells of the intestine can only be induced in 
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and additionally carry the two loxP-modified alleles of the Igf1r gene. In contrast, 
Cre+/Igf1rfl/+ mice are in fact positive for the cre recombinase, but carry only one loxP-
modified allele of the Igf1r. Therefore, these mice are heterozygous and still express 
the Igf1r in the intestine. As control, both Cre-/Igf1rfl/fl and Cre-/Igf1rfl/+ mice were used 
for the following experiments. Indeed, these mice carry one or even two modified 
alleles of the Igf1r, but these mice do not express the cre recombinase. Therefore, the 
Igf1r cannot be deleted by the cre recombinase and is still expressed in these control 
mice. 
To induce the knockout of the Igf1r in the Villin-CreERT-Igf1r mice, Cre+/Igf1rfl/fl, 
Cre+/Igf1rfl/+ as well as Cre-/Igf1rfl/fl and Cre-/Igf1rfl/+ mice as control were injected with 
1 mg / day tamoxifen on five consecutive days (Fig. 46). The Villin-CreERT2 is a fusion 
construct of the cre recombinase with a mutated ligand-binding domain of the human 
estrogen receptor, resulting in a tamoxifen-dependent cre recombinase. Furthermore, 
the expression of this construct is under the control of the villin promoter leading to 
stable and homogenous expression of the cre recombinase in the small intestine and 
colon along the crypt-villus axis (El Marjou et al., 2004). Thus, administration of 
tamoxifen to the Villin-CreERT-Igf1r mouse line led to the deletion of exon 3 of the Igf1r 
gene specifically in the intestine of the mouse at a desired time point in Cre+/Igf1rfl/fl 
mice. 
 
Fig. 46: Treatment scheme for the induction of the Igf1r knockout in the intestine of                     
Villin-CreERT-Igf1r mice. 
To develop Igf1r knockout mice, Villin-CreERT-Igf1r mice were injected with tamoxifen on five 
consecutive days. Cre+/Igf1rfl/fl were homozygous knockout (ko) mice, Cre+/Igf1rfl/+ were heterozygous 
knockout (ko) mice. As control mice, both Cre-/Igf1rfl/fl and Cre-/Igf1rfl/+ mice were used. The green arrows 
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3.18 Confirmation of villin expression in epithelial cells of the       
Villin-CreERT-Igf1r mouse line via immunohistochemistry 
To confirm the expression of villin in all epithelial cells of the small intestine and colon 
of Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control Villin-CreERT-Igf1r mice injected with 
tamoxifen, tissue sections of the small intestine and colon were stained for villin 
expression. In Fig. 47 representative pictures of the villin stainings are shown. An 
intense staining for villin in the villi of the small intestine could be observed. In the crypt 
of the small intestine, villin expression was weak. In the colon, epithelial cells at the top 
of the crypts highly expressed villin, while cells at the bottom of the crypts showed only 
slight villin expression. These stainings led to the assumption that there was a gradient 
of villin expression from high expression in the villi of the small intestine as well as at 
the top of the crypts of the colon to low expression of villin in the crypts of the small 
intestine and at the bottom of the crypts of the colon. These results were similar to the 
results of the villin staining of Villin-TRE-IGF1R mice (chapter 3.3). Furthermore, an 
increasing gradient of villin expression from crypt to tip was also shown by other 
authors (Braunstein et al. 2002; Madison 2002). 
  
Fig. 47: Villin was expressed in epithelial cells of the small intestine (SI) and colon of the          
Villin-CreERT-Igf1r mouse. 
Tissue sections of the small intestine and colon of Cre+/Igf1rfl/fl (n=5), Cre+/Igf1rfl/+ (n=5) and control mice 
(n=5) injected with tamoxifen were stained for villin expression (brown). Cell nuclei were stained with 
hemalum solution (blue). Representative pictures of the villin stainings in control mice are shown. Villin 
was highly expressed in epithelial cells of the small intestine and colon. An increasing gradient of villin 
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3.19 Confirmation of the Igf1r knockout in Villin-CreERT-Igf1r mice 
by PCR on genomic DNA from the small intestine and colon 
To confirm the knockout of the Igf1r in Villin-CreERT-Igf1r mice, three mice with 
different genetic backgrounds (Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and Cre-/Igf1rfl/+) were injected 
once with tamoxifen on five consecutive days and genomic DNA from epithelial cells 
of the small intestine and colon was extracted nine days after the first tamoxifen 
injection, respectively. A PCR was performed using the three specific primers P1, P2 
and P3 to discriminate the wild type, Igf1rlox and Igf1rΔlox allele. The wild type and Igf1rlox 
alleles were detected using the forward primer P1, which is localized upstream of the 
second loxP site, and the reverse primer P2, which is localized downstream of the 
same loxP site. The Igf1rΔlox allele was detected using the forward primer P3 localized 
5’ of the loxP site in intron 2 and the reverse primer P2 (Xuan et al. 2002) (Fig. 48a). 
In Fig. 48b the result of the performed PCR analysis is shown. Only a single band of 
320 bp was visible for the small intestine and colon of the Cre+/Igf1rfl/fl mouse, 
confirming a complete knockout of both Igf1r alleles. The Cre+/Igf1rfl/+ mouse revealed 
the wild type band (120 bp) using the primers P1 and P2 as well as the band for the 
Igf1rΔlox allele (320 bp) using the primers P3 and P2. The mouse being negative for the 
cre recombinase (Cre-), but carrying one loxP-modified allele of Igf1r showed the band 
of 120 bp for the wild type allele as well as the band of 220 bp for the loxP-modified 
allele of Igf1r, confirming that the knockout was only induced if the cre recombinase is 
present. 
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Fig. 48: Confirmation of the Igf1r knockout in the intestine of Villin-CreERT-Igf1r mice injected 
with tamoxifen. 
Three mice with the indicated genotypes were injected with tamoxifen on five consecutive days and 
genomic DNA was isolated from the small intestine (SI) and colon (Co). A PCR using two different primer 
pairs specific for the wild type (wt), Igf1rlox and the Igf1rΔlox alleles was performed. (a) Diagrams of the 
Igf1r locus around exon 3 (square), the floxed (Igf1rlox) and the recombined floxed Igf1rΔlox alleles are 
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The Cre+/Igf1rfl/fl mouse (n=1) only showed a 320 bp band for the Igf1rΔlox allele. The Cre+/Igf1rfl/+ mouse 
(n=1) revealed a 120 bp band for the wild type allele as well as a 320 bp band for the Igf1rΔlox allele. In 
the Cre-/Igf1rfl/+mouse (n=1) a 120 bp band for the wild type allele and a 220 bp band for the Igf1rlox 
allele were detectable. M=1 Kb Plus DNA Ladder. P1=Primer P1 and P2 were used to detect the Igf1r 
wild type and Igf1rlox alleles. P3=Primer P2 and P3 were used to detect the Igf1rΔlox allele. 
 
3.20 Confirmation of the Igf1r knockout in the intestine of                 
Villin-CreERT-Igf1r mice via western blot analysis 
To confirm the knockout of the Igf1r in the small intestine (SI) and colon (Co) of   Villin-
CreERT-Igf1r mice, three Cre+/Igf1rfl/fl and two control Villin-CreERT-Igf1r mice were 
intraperitoneally injected with tamoxifen on five consecutive days and proteins of 
epithelial cells of the small intestine and colon were extracted, respectively. Western 
blot analysis revealed expression of the IGF1Rα in epithelial cells of the small intestine 
and colon of control mice, whereas IGF1Rα expression was not detectable in the small 
intestine and colon of Cre+/Igf1rfl/fl mice, confirming the knockout of the Igf1r in epithelial 
cells of the small intestine and colon of Cre+/Igf1rfl/fl mice. Of note, control mice showed 




Fig. 49: Confirmation of the Igf1r knockout in epithelial cells of the small intestine (SI) and colon 
(Co) of Cre+/Igf1rfl/fl Villin-CreERT-Igf1r mice. 
Protein was extracted from epithelial cells of the small intestine (SI) and colon of Cre+/Igf1rfl/fl and control 
Villin-CreERT-Igf1r mice, respectively, and western blot analysis using a specific antibody against the 
IGF1Rα was performed. Control mice (n=2) showed high expression of the IGF1Rα, whereas IGF1Rα 
expression was not visible in the small intestine and colon of Cre+/Igf1rfl/fl mice (n=3). 
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3.21 Morphological analyses of small intestinal and colonic villi and 
crypts of Villin-CreERT-Igf1r mice 
To examine if the Igf1r knockout has any influence on the morphology of the villi and 
crypts of the small intestine and colon, Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice were 
injected with tamoxifen to induce the Igf1 knockout (for treatment scheme see Fig. 46). 
To check for changes in the intestinal epithelium, colonoscopy was performed 
regularly. Changes in the colonic morphology were not observed by colonoscopy 
(Fig. 50). 
 
Fig. 50: Colonoscopy of Villin-CreERT-Igf1r mice 1.5 years after tamoxifen injections. 
Cre+/Igf1rfl/fl (n=6), Cre+/Igf1rfl/+ (n=5) and control mice (n=5) were injected with tamoxifen. To check for 
morphological changes in the colon, colonoscopy was regularly performed. After 1.5 years, the animals 
were sacrificed. Changes in the colonic morphology were not observed by colonoscopy. 
 
Four weeks, three months and 1.5 years after tamoxifen injection, mice were sacrificed, 
the small intestine and colon were excised from the animals, fixed, paraffin-embedded 
and hematoxylin and eosin staining was performed. Together with Dr. med. Felix 
Bremmer (Institute of Pathology, University Medical Center Göttingen, Germany) the 
morphology of the villi and crypts was examined. Unfortunately, hematoxylin and eosin 
stainings after 1.5 years after tamoxifen injection were not prepared and analyzed to 
date. In Fig. 51 representative pictures of the hematoxylin and eosin stainings of the 
intestinal tissues after 4 weeks and 3 months are shown. A difference in the 
morphology of the villi and crypts between Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice 
and between the two different time points was not observed. Thus, the stainings 
revealed that the Igf1r knockout did not alter the appearance of the villi and crypts of 
the small intestine and colon. 
Cre+/Igf1rfl/+ Cre+/Igf1rfl/flcontrol
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Fig. 51: Hematoxylin and eosin stainings of the small intestine and colon of Cre+/Igf1rfl/fl, 
Cre+/Igf1rfl/+ and control Villin-CreERT-Igf1r mice four weeks and three months after tamoxifen 
injection. 
Cre+/Igf1rfl/fl (n=5), Cre+/Igf1rfl/+ (n=5) and control mice (n=5) were injected with tamoxifen. After four 
weeks and 3 months, mice were sacrificed and hematoxylin and eosin stainings of the (a) small intestine 
and (b) colon were performed. Together with Dr. med. Felix Bremmer (Institute of Pathology, University 
Medical Center Göttingen, Germany) the morphology of the villi and crypts was examined. A difference 
in the morphology of the small intestine and colon between Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control animals 
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Additionally, the mice that were sacrificed 1.5 years after the tamoxifen injections were 
macroscopically analyzed. Four mice (two Cre+/Igf1rfl/fl mice, one Cre+/Igf1rfl/+ mouse 
and one control mouse) showed enlarged seminal vesicles. Furthermore, the length of 
the small intestine and colon of these mice was measured and compared between 
Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice. A difference in the average length of the 
small intestine and colon could not be observed (Fig. 52). 
 
Fig. 52: The Igf1r knockout did not influence the average length of the small intestine (SI) and 
colon. 
Cre+/Igf1rfl/fl (n=6), Cre+/Igf1rfl/+ (n=5) and control mice (n=5) were injected with tamoxifen. After 
1.5 years, mice were sacrificed and the small intestine and colon were excised from the animals. The 
comparison of the average length of the small intestine and colon, respectively, revealed no difference 
between Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice (student’s t test). 
 
3.22 Quantification of the different intestinal cell types of                
Villin-CreERT-Igf1r mice after four weeks, three months and 1.5 years 
For the determination of the number of the different cell types in the villi and crypts of 
the small intestine and in the crypts of the colon, small intestinal and colonic tissue 
sections were stained using antibodies specific for goblet cells (mucin 2), 
enteroendocrine cells (Chromogranin A), Paneth cells (lysozyme) and proliferating 
cells (Ki 67). Therefore, Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control Villin-CreERT-Igf1r mice 
were injected with tamoxifen on five consecutive days to induce the knockout of the 
Igf1r. After four weeks, three months and 1.5 years, mice were sacrificed, intestinal 
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types. The positive cells of 50 villi and 50 crypts per mouse of five mice per group were 
manually counted. 
 
3.22.1 The Igf1r knockout results in a significant increase in goblet cells in the 
small intestine 
To quantify the number of goblet cells in the small intestine and colon, tissue sections 
were stained for mucin 2. In the crypts of the small intestine the number of goblet cells 
was significantly increased in both Cre+/Igf1rfl/fl and Cre+/Igf1rfl/+ mice after three 
months and 1.5 years compared to control mice (Fig. 53a). However, in the villi of the 
small intestine, the number of goblet cells was significantly elevated only in Cre+/Igf1rfl/fl 
mice after three months and 1.5 years (Fig. 53b). In contrast, the number of goblet 
cells in the crypts of the colon was significantly reduced in both Cre+/Igf1rfl/fl and 
Cre+/Igf1rfl/+ mice after four weeks, whereas after three months the number was 
significantly increased in Cre+/Igf1rfl/+ mice. After 1.5 years, the number of goblet cells 
was again significantly decreased in Cre+/Igf1rfl/+ mice but there was no change for 
Cre+/Igf1rfl/fl mice (Fig. 53c). The number of goblet cells significantly decreased over 
time in the villi and crypts of the small intestine and colon of control mice. 
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Fig. 53: The Igf1r knockout led to a significant increase of the goblet cell number. 
For the quantification of goblet cells, Cre+/Igf1rfl/fl (n=5), Cre+/Igf1rfl/+ (n=5) and control mice (n=5) per 
time point were each injected with tamoxifen. After four weeks, three months and 1.5 years the mice 
were sacrificed and tissue sections of the small intestine and colon were stained with mucin 2.            
Mucin 2-positive cells of 50 villi and 50 crypts per mouse were manually counted. (a) In the small 
intestine, the number of goblet cells per crypt significantly increased in Cre+/Igf1rfl/fl and Cre+/Igf1rfl/+ mice 
after three months and 1.5 years compared to control mice. (b) The number of goblet cells per villus in 
the small intestine was significantly elevated in the Cre+/Igf1rfl/fl mice compared to control mice. (c) In 
the colon, Cre+/Igf1rfl/fl mice showed a significant reduction of the number of goblet cells per crypt after 
four weeks. * P <0.05, ** P < 0.01, *** P < 0.0001 (student’s t test). 
 
3.22.2 The Igf1r knockout results in a significant increase of enteroendocrine 
cells in the small intestine and a significant decrease in the colon 
For the quantification of the number of enteroendocrine cells, small intestinal and 
colonic tissue sections were stained for Chromogranin A (CHGA) and positive cells 
were counted per villus and crypt, respectively. In the small intestine, the number of 
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Cre+/Igf1rfl/+ and control mice. After 1.5 years, the number of enteroendocrine cells 
significantly increased in Cre+/Igf1rfl/fl and Cre+/Igf1rfl/+ mice compared to control mice 
(Fig. 54a). The number of CHGA-positive cells in the colon significantly decreased in 
Cre+/Igf1rfl/fl mice after four weeks and three months compared to Cre+/Igf1rfl/+ and 
control mice. After 1.5 years, a difference in the number of enteroendocrine cells was 
not observed (Fig. 54b). In the colon, a significant increase in the number of           
CHGA-positive cells over time was detected (Fig. 54b). 
 
 
Fig. 54: The number of enteroendocrine cells increased in the small intestine, but decreased in 
the colon of Cre+/Igf1rfl/fl mice. 
(a) The number of enteroendocrine cells per villus significantly increased in Cre+/Igf1rfl/fl (n=5) and 
Cre+/Igf1rfl/+ mice (n=5) after 1.5 years compared to control mice (n=5). (b) In the colon, the number of 
enteroendocrine cells per crypt significantly decreased in Cre+/Igf1rfl/fl mice after four weeks and three 
months. * P <0.05, ** P < 0.01, *** P < 0.0001 (student’s t test). 
 
3.22.3 The Igf1r knockout results in a significant reduction of Paneth cells in the 
small intestine 
The number of Paneth cells was quantified by staining sections of the small intestine 
for lysozyme. After three months, the number of Paneth cells decreased significantly 
in Cre+/Igf1rfl/fl and Cre+/Igf1rfl/+ mice compared to control mice. After 1.5 years, a 
significant reduction of Paneth cells was observed in Cre+/Igf1rfl/fl mice. A significant 
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Fig. 55: The Igf1r knockout resulted in a significant reduction of Paneth cells in the small 
intestine. 
The number of Paneth cells significantly decreased in the crypts of the small intestine of Cre+/Igf1rfl/fl 
(n=5) and Cre+/Igf1rfl/+ mice (n=5) after three months and 1.5 years compared to control mice (n=5). 
* P <0.05, ** P < 0.01, *** P < 0.0001 (student’s t test). 
 
3.22.4 The effect of the Igf1r knockout regarding the number of proliferating cells 
per crypt is time-dependent 
For the quantification of proliferating cells, tissue sections of the small intestine and 
colon were stained for Ki 67 and positive cells per crypt were counted. The number of 
proliferating cells per crypt in the small intestine significantly decreased after four 
weeks, but increased after three months and 1.5 years in Cre+/Igf1rfl/fl mice compared 
to control mice. Altogether, the number of Ki 67-positve cells per crypt in the small 
intestine significantly decreased over time in Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice 
(Fig. 56a). In the colon, the number of proliferating cells per crypt significantly 
decreased after four weeks, but increased after three months and 1.5 years in 
Cre+/Igf1rfl/fl mice compared to control mice. Altogether, the number of proliferating 
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Fig. 56: The number of proliferating cells per crypt differed over time. 
To quantify the number of proliferating cells, small intestinal and colonic tissue sections were stained for 
Ki 67 and positive cells of 50 crypts per mouse were counted. (a, b) In the crypts of the small intestine 
and colon, the number of proliferating cells significantly decreased over time in Cre+/Igf1rfl/fl (n=5), 
Cre+/Igf1rfl/+ (n=5) and control mice (n=5). (b) In the colon, Cre+/Igf1rfl/fl mice showed a significant 
reduction of Ki 67-positive cells after four weeks, whereas after three months the number of proliferating 
cells significantly increased. ** P < 0.01, *** P < 0.0001 (student’s t test). 
 
3.22.5 The knockout of the Igf1r does not influence the presence of enterocytes 
To analyze if the Igf1r has any influence on the presence of enterocytes in the intestinal 
epithelium of Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control Villin-CreERT-Igf1r mice, alkaline 
phosphatase stainings (AP-staining) to detect enterocytes were performed on tissue 
sections of the small intestine and colon. In Fig. 57 representative pictures of the         
AP-stainings are shown. A difference in the presence of enterocytes between 
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Fig. 57: The presence of enterocytes in the epithelium of the small intestine and colon of          
Villin-CreERT-Igf1r mice. 
To detect enterocytes, alkaline phosphatase stainings on tissue sections of the small intestine and colon 
of Cre+/Igf1rfl/fl (n=5), Cre+/Igf1rfl/+ (n=5) and control mice (n=5) were performed. Enterocytes were 
stained brown, cell nuclei were stained with hemalum solution (blue). A difference in the presence of 
enterocytes between Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice was not observed. 
 
3.23 The Igf1r knockout inhibits intestinal tumor formation and 
progression (AOM model) 
To analyze the effect of the Igf1r knockout on tumor formation and progression, 
Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control Villin-CreERT-Igf1r mice were injected with 
tamoxifen on five consecutive days. In addition, the mice were intraperitoneally injected 
with four weekly repeated injections of 10 mg / ml AOM to induce colonic tumor 
formation (Fig. 58). To screen for the development of tumors, colonoscopy was 
regularly performed (Fig. 59). Importantly, this experiment was merely a preliminary 
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Fig. 58: Treatment scheme for the analysis if the Igf1r has any influence on colonic tumor 
progression (AOM model). 
Cre+/Igf1rfl/fl (n=3), Cre+/Igf1rfl/+ (n=4) and control (n=4) Villin-CreERT-Igf1r mice were injected with 
tamoxifen to induce the knockout of the Igf1r in the intestine. In addition, the mice were injected four 
times with azoxymethane (AOM) to induce colonic tumor formation. To check if tumors had developed, 
colonoscopy was regularly performed. Between the period of 22 and 62 weeks after the first AOM 
injection, mice were sacrificed and the tumors were counted and measured. 
 
 
Fig. 59: Colonoscopy of Villin-CreERT-Igf1r mice after AOM injection. 
To induce the Igf1r knockout, Cre+/Igf1rfl/fl (n=3), Cre+/Igf1rfl/+ (n=4) and control (n=4) Villin-CreERT-Igf1r 
mice were injected with tamoxifen. For the induction of tumor formation, the mice were afterwards 
injected with AOM. Regular colonoscopies were performed to check for intestinal tumor formation. 
Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice revealed colonic tumor formation. Stars mark the tumors. The 
numbers indicate the score of the tumor (after Becker et al. 2007). 
 
When the mice had developed tumors, they were sacrificed, the small intestinal and 
colonic tissues were excised from the mice and the tumors were macroscopically 
analyzed. Interestingly, tumor progression differed strongly between the mice. 
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allowed tumor size (score 5). For this reason, a survival curve of the different mouse 
groups could be determined. Fifty percent of the control mice had to be sacrificed after 
approx. 20 weeks, whereas the other 50% were sacrificed after 62 weeks. Fifty percent 
of Cre+/Igf1rfl/+ mice had to be sacrificed between week 22 and 25, whereas the other 
50% of the Cre+/Igf1rfl/+ mice were sacrificed after 62 weeks. One Cre+/Igf1rfl/fl mouse 
was sacrificed in week 22, the second mouse was sacrificed in week 33 and the third 
Cre+/Igf1rfl/fl mouse was sacrificed in week 62. All mice sacrificed in week 62 showed 
no tumor formation. These data led to the assumption that the Igf1r did not influence 
the time point of colonic tumor formation (Fig. 60a). Regarding the number of mice with 
and without tumors, respectively, 50% of control mice formed tumors. Only one out of 
four (25%) Cre+/Igf1rfl/+ mice developed any tumors, while two out of three (66.7%) 
Cre+/Igf1rfl/fl mice showed tumor formation (Fig. 60b). Discrimination between the 
sexes showed that 50% of female as well as 50% of male control mice revealed tumor 
development (Fig. 60c). In Cre+/Igf1rfl/+ mice, 50% of the female and no male mouse 
formed any tumors (Fig. 60d). The one female mouse (100%) and 50% of the male 
Cre+/Igf1rfl/fl mice showed tumor formation (Fig. 60e). The results indicated that both 
sexes were similarly sensitive to AOM. For further analyses only those mice which had 
developed tumors were included. Control mice developed on average 1.5 tumors, the 
Cre+/Igf1rfl/+ mouse formed one tumor and Cre+/Igf1rfl/fl mice developed on average one 
tumor (Fig. 60f). Regarding tumor localization, control mice developed 3-fold more 
tumors than Cre+/Igf1rfl/fl mice and 2-fold more tumors than Cre+/Igf1rfl/+ mice in the 
distal part of the colon. However, only Cre+/Igf1rfl/fl mice formed tumors in the middle 
part of the colon (Fig. 60g). Analyzing both the tumor size and tumor number 
demonstrated that Cre+/Igf1rfl/fl mice developed only half the number of tumors smaller 
than 2 mm in diameter than control mice. The number of tumors bigger than 2 mm was 
identical between Cre+/Igf1rfl/fl and control mice. Cre+/Igf1rfl/+ mice revealed the same 
number of tumors smaller than 2 mm compared to control mice, but displayed no 
development of tumors bigger than 2 mm (Fig. 60h).  
Taken together, these results indicated that the Igf1r knockout in the intestine led to 
decreased tumor formation (< 2 mm) in the distal part of the colon after AOM 
administration. However, because only a small number of mice was used for the 
experiments described above, the data is still preliminary and has to be verified in 
future experiments with an increased number of mice. 
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Fig. 60: Macroscopic analyses of intestinal tumors induced in Villin-CreERT-Igf1r mice by AOM 
injection. 
(a) Survival curve of Cre+/Igf1rfl/fl (n=3), Cre+/Igf1rfl/+ (n=4) and control mice (n=4) after induction of tumor 
formation by AOM. Tumor progression differed strongly between the mice. For this reason, the mice 
were sacrificed gradually. (b) Fifty percent of control mice, 25% of Cre+/Igf1rfl/+ mice and 50% of 
Cre+/Igf1rfl/fl mice formed tumors in the colon. (c) Fifty percent of female and 50% of male control mice 
formed tumors. (d) Fifty percent of female and no male Cre+/Igf1rfl/+ mouse showed intestinal tumor 
formation. (e) The one female mouse and 50% of male Cre+/Igf1rfl/fl mice developed tumors. (f) Control 
mice (n=2) developed on average 1.5 tumors, the Cre+/Igf1rfl/+ mouse (n=1) formed 1 tumor and 
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than Cre+/Igf1rfl/fl mice and 2-fold more tumors than Cre+/Igf1rfl/+ mice in the distal part of the colon. Only 
Cre+/Igf1rfl/fl mice formed tumors in the middle part of the colon. (h) Cre+/Igf1rfl/fl mice developed half the 
number of tumors smaller than 2 mm than control mice. The number of tumors bigger than 2 mm was 
identical between Cre+/Igf1rfl/fl and control mice. Cre+/Igf1rfl/+ mice revealed the same number of tumors 
smaller than 2 mm compared to control mice, but showed no development of tumors bigger than 2 mm.  
 
3.24 The Igf1r knockout does not influence intestinal tumor formation 
but inhibits tumor progression (AOM / DSS model) 
In order to analyze if the knockout of the Igf1r in the intestine influences tumor 
formation and progression, Cre+/Igf1rfl/fl and control Villin-CreERT-Igf1r mice were 
injected with tamoxifen and treated with AOM / DSS to induce colonic tumor formation 
and inflammation. Importantly, Cre+/Igf1rfl/+ mice were not involved in the following 
experiment. 
 
Fig. 61: Treatment scheme for the analysis if the Igf1r knockout in the intestine has any influence 
on colonic tumor progression (AOM / DSS model). 
Cre+/Igf1rfl/fl (n=11) and control (n=13) Villin-CreERT-Igf1r mice were injected with tamoxifen (tam). 
Furthermore, mice were once injected with AOM to induce colonic tumor formation and administered to 
two cycles of 2% DSS over the drinking water to induce intestinal inflammation. Cereal mush was given 
between and after DSS treatment to avoid dehydration of the mice. To screen for tumor development, 































3 Results  111 
Regular colonoscopies were performed to check for tumor formation in the colon of the 
Cre+/Igf1rfl/fl and control mice (Fig. 62). 
 
Fig. 62: Colonoscopy of Cre+/Igf1rfl/fl and control Villin-CreERT-Igf1r mice administered to 
AOM / DSS. 
Cre+/Igf1rfl/fl (n=11) and control (n=13) Villin-CreERT-Igf1r mice were injected with tamoxifen. 
Afterwards, mice were administered to AOM / DSS to induce colonic tumor formation and inflammation. 
To examine if tumors have developed in the colon of the mice, colonoscopy was performed regularly. 
Cre+/Igf1rfl/fl and control mice showed colonic tumor formation after AOM / DSS treatment. Stars mark 
the tumors. The numbers indicate the score of the tumor (after Becker et al. 2007). 
 
Seven weeks after the AOM injection, some tumors had reached the maximum size 
(score 4 to 5) and the mice were sacrificed. Intestinal tissue was excised from the 
animals, the colon length of the mice that have developed tumors was measured and 
the tumors were macroscopically and histopathologically analyzed. The average colon 
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Fig. 63: Average colon length of Cre+/Igf1rfl/fl and control Villin-CreERT-Igf1r mice after 
development of tumors induced by AOM / DSS. 
Cre+/Igf1rfl/fl (n=11) and control mice (n=13) were injected with tamoxifen and additionally administered 
to AOM / DSS to induce colonic tumor formation and inflammation. Mice were sacrificed and the colon 
was excised from the animals and measured. The comparison of the average length of the colon 
between Cre+/Igf1rfl/fl and control mice showed no significant difference (student’s t test). 
 
Macroscopic analyses revealed tumor formation in twelve out of 13 (92.3%) control 
mice and in nine out of eleven (81.8%) Cre+/Igf1rfl/fl mice (Fig. 64a). Distinguishing 
between the sexes, all eight (100%) female control and four out of five (80%) male 
control mice developed intestinal tumors (Fig. 64b). Furthermore, tumors were 
observed in all five (100%) female and in four out of six (66.7%) male Cre+/Igf1rfl/fl mice 
(Fig. 64c), leading to the assumption that female mice could be more sensitive to 
AOM / DSS administration. Regarding the average tumor number, the tumor 
localization and tumor size, only mice which had developed colonic tumors were 
included. Here, control mice developed on average 5.25 tumors, whereas Cre+/Igf1rfl/fl 
mice formed on average 6 tumors (Fig. 64f). Cre+/Igf1rfl/fl mice showed a higher number 
of distal tumors per mouse, but a decreased number of tumors in the middle and 
proximal part of the colon compared to control mice (Fig. 64e). Regarding the size of 
the tumors analyzed, Cre+/Igf1rfl/fl mice developed a higher number of tumors smaller 
than 2 mm as well as bigger than 2 mm compared to control mice (Fig. 64f). In 
summary, a difference in the number of developed tumors induced by AOM / DSS 
between Cre+/Igf1rfl/fl and control mice could not be observed, indicating that the Igf1r 
knockout in the intestine had no influence on intestinal tumor formation using the 
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Fig. 64: Macroscopic analyses of Villin-CreERT-Igf1r mice administered to AOM / DSS to induce 
colonic tumor formation and inflammation. 
To analyze the influence of the Igf1r on colonic tumor formation and progression, Cre+/Igf1rfl/fl (n=11) 
and control (n=13) Villin-CreERT-Igf1r mice were injected with tamoxifen to induce the Igf1r knockout 
and were administered to AOM / DSS to induce colonic tumor formation and inflammation. To check for 
tumor formation in the colon of the mice, colonoscopy was performed regularly. Seven weeks after AOM 
injection, mice were sacrificed and the small intestine and colon were excised from the animals. The 
developed tumors were counted and measured. (a) Ninety-two percent of control mice developed 
colonic tumors, whereas only 82% of Cre+/Igf1rfl/fl mice showed tumor formation. (b) Discrimination 
between the sexes showed that 100% of the female and 80% of the male control mice formed colonic 
tumors. (c) In Cre+/Igf1rfl/fl mice, 100% of female and approx. 67% of male mice formed tumors in the 
colon. (d) Cre+/Igf1rfl/fl mice (n=9) formed on average 6.25 tumors, whereas control mice (n=12) formed 
on average 5.25 tumors. (e) Cre+/Igf1rfl/fl mice displayed an increased number of distal tumors, but a 
decreased number of tumors in the middle and proximal part of the colon compared to control mice. 
(f) The Cre+/Igf1rfl/fl mice formed a higher number of tumors smaller than 2 mm as well as bigger than 
2 mm compared to control mice. 
 
For histopathological analyses, colonic tissues were fixed, paraffin-embedded and cut 
stepwise. For this purpose, the first section was taken whereas the following ten 
sections were discarded. This process was repeated until three tissue sections were 
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available. This process was done to increase the probability to detect as many tumors 
as possible along the axis from distal to proximal for histopathological analyses. 
Hematoxylin and eosin stainings were prepared and analyzed together with Dr. med. 
Felix Bremmer (Institute of Pathology, University Medical Center Göttingen, Germany). 
The developed tumors were classified in low and high grade intraepithelial neoplasia, 
and intramucosal and invasive carcinoma, respectively. Representative pictures of the 
different tumor stages were already shown in Fig. 34a (chapter 3.11). 
Histopathologically, the developed tumors of Villin-CreERT-Igf1r mice induced by 
AOM / DSS were comparable to those of Villin-TRE-IGF1R mice (IGF1R 
overexpression). As depicted in Fig. 65a, Cre+/Igf1rfl/fl mice showed a decreased 
number of low grade intraepithelial neoplasias, an increased number of high grade 
intraepithelial neoplasias, whereas the number of intramucosal carcinomas was 
reduced compared to control mice. Neither Cre+/Igf1rfl/fl nor control mice formed 
invasive carcinomas. In addition, the average tumor size per mouse was examined. 
Cre+/Igf1rfl/fl mice developed tumors with an average size of 1555.94 µm2 per mouse, 
while control mice revealed a 30.1% reduced average tumor size (1087.57 µm2)      
(Fig. 65b).  
 
Fig. 65: Histopathological analyses of AOM / DSS-induced tumors of Cre+/Igf1rfl/fl and control 
Villin-CreERT-Igf1r mice. 
(a) Cre+/Igf1rfl/fl mice (n=9) developed a decreased number of low grade intraepithelial neoplasias and 
intramucosal carcinomas but a higher number of high grade intraepithelial neoplasias than control mice 
(n=12). Neither Cre+/Igf1rfl/fl mice nor control mice developed invasive carcinomas. (b) No significant 
difference in the average tumor size per mouse between Cre+/Igf1rfl/fl and control mice was observed 
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3.25 The knockout of the Igf1r results in diminished downstream 
PI3K signaling in colonic tumors 
To examine the influence of the Igf1r knockout on the downstream PI3K and MAPK 
signaling pathways, Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice were injected with 
tamoxifen, respectively. Additionally, the mice were administered to AOM / DSS to 
induce colonic tumor formation and inflammation. After tumors had developed, mice 
were sacrificed, tumors were excised from the colon, proteins of the tumors were 
extracted and western blot (Fig. 66a) and subsequent densitometrical analyses 
(Fig. 66b- e) were performed. IGF1Rα and IGF1Rβ expression was shown to be 
approx. 75% decreased in tumors of Cre+/Igf1rfl/fl mice compared to control mice, 
demonstrating that Igf1r expression was also reduced in the developed tumors of Igf1r 
knockout mice (Fig. 66a- c). The activity of AKT (pAKT) was more than 2-fold reduced 
in tumors of Cre+/Igf1rfl/fl mice compared to control mice. This result indicated that the 
downstream PI3K signaling pathway was diminished in tumors that developed in 
Cre+/Igf1rfl/fl mice (Fig. 66a, d). Interestingly, the phosphorylation level of ERK (pERK) 
was highly elevated in tumors of Cre+/Igf1rfl/fl mice compared to control mice. This data 
showed that the knockout of Igf1r did not reduce the activation of the downstream 
MAPK signaling pathway (Fig. 66a, e). 
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Fig. 66: Western blot and subsequent densitometrical analyses of colonic tumors of                  
Villin-CreERT-Igf1r mice induced by AOM / DSS. 
Cre+/Igf1rfl/fl (n=1), Cre+/Igf1rfl/+ (n=5) and control (n=7) Villin-CreERT-Igf1r mice were injected with 
tamoxifen and additionally administered to AOM / DSS to induce colonic tumor formation and 
inflammation. After intestinal tumors had developed, mice were sacrificed and proteins of the tumors 
were extracted. (a) Western blot and (b- e) subsequent densitometrical analyses were performed. (a- c) 
The expression level of IGF1Rα and IGF1Rβ highly decreased in Cre+/Igf1rfl/fl mice compared to control 
mice. (a, d) The activity of AKT (pAKT) was highly reduced in Cre+/Igf1rfl/fl mice compared to control 
mice. (a, e) The phosphorylation level of ERK (pERK) was 3-fold higher in Cre+/Igf1rfl/fl mice compared 
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3.26 Growth inhibitory effects through simultaneous inhibition of 
IGF1R and EGFR in addition to combined 5-FU-based RCT in vivo 
Recent experiments have shown that simultaneous inhibition of the IGF1R and EGFR 
in addition to combined RCT based on 5-fluoruracil (5-FU) results in a significant 
reduction of CRC cell survival in vitro (Seemann 2013). To investigate if similar growth 
inhibitory effects also occur in vivo, xenograft tumors of either DLD-1, CaCo-2 or 
SW837 cells were simultaneously treated with the small molecule kinase inhibitors 
AEW541 and erlotinib in addition to combined RCT.  
Therefore, 7.5 x 105 DLD-1, 2 x 106 CaCo-2 or 2 x 106 SW837 cells were 
subcutaneously injected into each flank of immune-deficient 6 to 8 weeks old female 
nude mice (RjOrl:NMRI-Foxn1nu/Foxn1nu, see chapter 2.9.2.1), respectively, 
depending on the proliferation rate of the cells. When the tumors have reached a 
volume of approx. 300 mm3, mice were randomized into either a treatment group of 
AEW541 (40 mg / kg; dissolved in 25 mM L(+)-Tartaric acid (Sigma-Aldrich, 
Deisenhofen, Germany)), erlotinib (100 mg / kg; dissolved in 0.2% (w / v) 
Carboxymethylcellulose with 0.1% Tween 80), the combination of AEW541 and 
erlotinib or a control group. The mice were treated with combined 5-FU-based RCT 
(50 mg / kg, dissolved in DPBS followed by 1.8 Gy irradiation per day) in addition to 
inhibitor treatment. The mice in the control group received combined RCT like the 
treatment groups in combination with the same amount of the solvent. Importantly, the 
treatment scheme depended on the growth rate of the tumors. DLD-1 xenograft mice 
were treated with combined RCT on five consecutive days. In addition, inhibitors were 
administered on eight consecutive days (Fig. 67a). Unfortunately, the mice did not 
tolerate the treatment. Therefore, a second experiment with DLD-1 cells was 
performed in cooperation with Dr. rer. nat. Melanie Spitzner (Department of General, 
Visceral and Pediatric Surgery). Here, the mice were administered to combined RCT 
on the first three days of treatment as well as on the days ten and eleven. Inhibitors 
were applied in two cycles. The first cycle started on day one of treatment and lasted 
for four days, whereas the second cycle started on day seven and lasted for five days 
(Fig. 67b). Interestingly, the mice showed improved tolerance to the alternative 
treatment compared to the first treatment.  
In the following CaCo-2- and SW837 xenograft experiments, the xenograft mice 
received combined RCT on the first three days as well as on days eleven and twelve 
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of treatment. Inhibitors were applied in three cycles of five consecutive days each with 
two days break in between (Fig. 67c, d).  
Tumor volume was measured daily using a caliper. For the determination of the tumor 
volume, the formula “V = width2 x length x 0.5” was used. When the tumors reached a 
volume of approx. 1500 mm3, mice were sacrificed, the tumors were dissected from 
the mice, weighed and measured. Here, tumor volume was calculated using the 
formula “V = width x length x height x π / 6”.  
 
Fig. 67: Treatment schemes for the xenograft mice implanted with DLD-1, CaCo-2 or SW837 cells. 
For the xenograft mouse experiments, DLD-1, CaCo-2 and SW837 cells were implanted subcutaneously 
into immune-deficient RjOrl:NMRI-Foxn1nu/Foxn1nu mice, respectively. The therapy with the IGF1R 
inhibitor AEW541, with the EGFR inhibitor erlotinib, the combination of AEW541 and erlotinib or with the 
solvent as control in addition to combined RCT was started when the tumors reached an average tumor 
volume of 300 mm3. (a) Mice implanted with DLD-1 cells were administered to the inhibitors on eight 
consecutive days in addition to RCT on five consecutive days. Unfortunately, some mice did not tolerate 
this treatment. For this reason, a second experiment with DLD-1 cells was performed. (b) Adapted 
treatment scheme for DLD-1 xenograft mice. Mice received inhibitor treatment in two cycles. The first 
cycle lasted for four days. The second cycle started at day seven of treatment and lasted for five days. 
Combined RCT was also administered in two cycles. The first cycle lasted for three days and the second 
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cycle was on days ten and eleven of treatment. (c, d) Mice implanted with CaCo-2 or SW837 cells were 
treated with three cycles of inhibitors on five consecutive days each with two days break in between in 
addition to RCT on the first three days and the days eleven and twelve of treatment. When the tumors 
reached a volume of approx. 1500 mm3, the mice were sacrificed and the tumors were prepared. 
 
Tumors of the DLD-1 xenografted cells grew very fast. In the first experiment, the 
treatment with the inhibitors in addition to combined RCT was started already 16 days 
after injection. Single treatment with erlotinib and simultaneous treatment with 
AEW541 / erlotinib in addition to combined RCT resulted in a significant reduction of 
the tumor volume compared to the control (Fig. 68).  
 
Fig. 68: Progression of the volume of the DLD-1 xenograft tumors after inhibition of the IGF1R 
and EGFR in addition to combined RCT (experiment I). 
DLD-1 cells were subcutaneously implanted into immune-deficient nude mice. After tumors have 
developed, mice were administered to the IGF1R inhibitor AEW541 (n=3), the EGFR inhibitor erlotinib 
(n=3), the combination of both inhibitors (n=3) or the solvent as control (n=3) in addition to combined 
RCT. The treatment scheme is shown in Fig. 67a. Single inhibition of the EGFR by erlotinib and 
simultaneous inhibition of the IGF1R by AEW541 and EGFR by erlotinib resulted in a significant 
reduction of the tumor volume. ** P < 0.01, *** P < 0.0001 (student’s t test). 
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In the second experiment with DLD-1 xenografted cells, the treatment scheme was 
adapted (Fig. 67b). Interestingly, single inhibition of the IGF1R as well as simultaneous 
inhibition of the IGF1R and EGFR in addition to combined RCT led to a significant 
decrease in the tumor volume compared to the control, whereas single inhibition of the 
EGFR showed no significant reduction in tumor volume (Fig. 69a). Noteworthy was the 
extreme difference in tumor volume between the inhibitor-treated and the control group 
at the beginning of the treatment. For this reason, the tumor volume increase was 
additionally determined (Fig. 69b). Interestingly, neither single nor simultaneous 
inhibitor treatment in addition to combined RCT resulted in a significant reduction in 
the increase in tumor volume.  
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Fig. 69: Progression of the volume of the DLD-1 xenograft tumors after inhibition of the IGF1R 
and EGFR in addition to combined RCT (experiment II). 
DLD-1 cells were subcutaneously implanted into immune-deficient nude mice. After tumors have 
developed, mice were administered to the IGF1R inhibitor AEW541 (n=3), the EGFR inhibitor erlotinib 
(n=3), the combination of both inhibitors (n=4) or the solvent as control (n=4) in addition to combined 
RCT. The treatment scheme is shown in Fig. 67b. (a) Single inhibition of the IGFR and simultaneous 
inhibition of the IGF1R and EGFR resulted in a significant reduction of the tumor volume compared to 
the control. (b) Neither single nor simultaneous inhibition of the IGF1R and EGFR led to a significant 
reduction of the tumor volume increase compared to the control. ** P < 0.01, *** P < 0.0001           
(student’s t test). 
 
Thirty-one days after DLD-1 tumor cell implantation, the mice were sacrificed, the 
tumors were dissected from the animals, measured and weighed (Fig. 70). Single 
inhibition of the IGF1R and simultaneous inhibition of the IGF1R and EGFR in addition 
to combined RCT resulted in a weak reduction of the tumor volume compared to the 
control, whereas single inhibition of the EGFR showed no difference in the tumor 
volume compared to the control (Fig. 70a). Regarding tumor weight, single inhibition 
of the IGF1R displayed a weak reduction of the tumor weight, whereas single inhibition 
of the EGFR led to a slight increase of the tumor weight compared to the control. The 
comparison of the tumor weight after simultaneous inhibition of the IGF1R and EGFR 
with the control showed no difference (Fig. 70b). 
 
Fig. 70: Determination of the tumor volume and tumor weight of DLD-1 xenograft tumors 
(experiment II). 
DLD-1 cells were injected into immune-deficient nude mice. Mice were treated with the small molecule 
kinase inhibitors AEW541 (n=3), erlotinib (n=3) or the combination of AEW541 and erlotinib (n=4) or the 
solvent as control (n=4) in addition to combined RCT. When the tumors reached a volume of 1500 mm3, 
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as well as simultaneous treatment with AEW541 / erlotinib in addition to combined RCT resulted in a 
weak reduction of the tumor volume compared to the control. (b) Single inhibition of the IGF1R showed 
a weak reduction of the tumor weight, whereas single inhibition of the EGFR as well as simultaneous 
inhibition of the IGF1R and EGFR led to a slight increase in the tumor weight compared to the control. 
(student’s t test). 
 
Tumors of the CaCo-2 xenografted cells grew extremely slow. The treatment with 
inhibitors and combined RCT was started not before 102 days after tumor cell injection. 
Treatment with the inhibitors in addition to combined RCT resulted in a highly 
significant decrease in tumor volume compared to the control. Interestingly, single 
inhibition of either IGF1R or EGFR showed a stronger reduction of the tumor volume 
than simultaneous inhibition of the IGF1R and EGFR in addition to combined RCT 
(Fig.71a). At the beginning of the treatment with the inhibitors in addition to combined 
RCT the average tumor volume of the control mice differed extremely from the average 
tumor volume of the other treatment groups. For this reason, the increase in the tumor 
volume was additionally analyzed. This analysis revealed a slight elevation of tumor 
volume increase after single inhibition of the EGFR as well as simultaneous inhibition 
of the IGF1R and EGFR. Single inhibition of the IGF1R resulted in a significant 
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Fig. 71: Progression of the volume of the CaCo-2 xenograft tumors after inhibition of the IGF1R 
and EGFR in addition to combined RCT. 
CaCo-2 cells were implanted into immune-deficient nude mice. After tumors have developed, mice were 
administered to the IGF1R inhibitor AEW541 (n=5), the EGFR inhibitor erlotinib (n=5), the combination 
of both inhibitors (n=6) or to the solvent as control (n=4) in addition to combined RCT. The treatment 
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scheme is shown in Fig. 67c. (a) Single inhibition of the IGF1R, the EGFR and simultaneous inhibition 
of the IGF1R and EGFR in addition to combined RCT resulted in a highly significant slower tumor 
progression compared to control mice. (b) Simultaneous inhibition of the IGF1R and EGFR in addition 
to combined RCT led to a significant reduction in tumor increase compared to the control.  ** P < 0.01, 
*** P < 0.0001 (student’s t test). 
 
One hundred twenty-five days after CaCo-2 tumor cell injection, the mice were 
sacrificed, the tumors were excised from the animals, weighed and measured (Fig. 72). 
Single as well as simultaneous inhibition of the IGF1R and EGFR resulted in a 
decrease in tumor volume compared to the control mice (Fig. 72a). Treatment of the 
xenograft mice with the inhibitors in addition to combined RCT did not lead to a change 
in tumor weight compared to the control (Fig. 72b). 
 
Fig. 72: Determination of the tumor volume and tumor weight of CaCo-2 xenograft tumors. 
CaCo-2 cells were injected into immune-deficient nude mice. Mice were treated with the inhibitor 
AEW541 (n=5), erlotinib (n=5), the combination of AEW541 and erlotinib (n=6) or the solvent as control 
(n=4) in addition to combined RCT. When the tumors reached an average volume of 1500 mm3, mice 
were sacrificed, the tumors were excised from the animals and measured and weighed. (a) Single as 
well as simultaneous inhibition of the IGF1R and EGFR resulted in decreased tumor volume compared 
to control mice. (b) Treatment of the xenograft mice with the inhibitors did not lead to a reduction in 
tumor weight compared to the control. (student’s t test). 
 
For the SW837 xenograft experiment, SW837 cells were injected and the treatment 
was started already 27 days after injection. The xenograft tumors of the SW837 cells 
showed a decrease in tumor volume when treated with AEW541 in addition to 
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and simultaneous treatment of the tumors with AEW541 and erlotinib in addition to 
combined RCT revealed a significant reduction of the tumor volume (Fig. 73). 
 
Fig. 73: Progression of the volume of the SW837 xenograft tumors after inhibition of the IGF1R 
and EGFR in addition to combined RCT. 
Immune-deficient nude mice were implanted with the rectal cancer cell line SW837. After tumors have 
developed, mice were administered to the IGF1R inhibitor AEW541 (n=6), the EGFR inhibitor erlotinib 
(n=6), the combination of both inhibitors (n=7) or the solvent as control (n=7) in addition to combined 
RCT. The treatment scheme is shown in Fig. 67d. Single inhibition of the EGFR and simultaneous 
inhibition of the IGF1R and EGFR in addition to combined RCT resulted in a highly significant slower 
tumor progression compared to control mice. *** P < 0.0001 (student’s t test). 
 
On day 57, the mice were sacrificed and tumor tissues were dissected and measured. 
The SW837 xenograft mice treated with either AEW541 or erlotinib showed a reduction 
in tumor volume and weight compared to control mice. A significant reduction in tumor 
volume and weight could be observed in mice simultaneously treated with the 
combination of AEW541 and erlotinib in addition to combined RCT (Fig. 74). 
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Fig. 74: Determination of the tumor volume and tumor weight of SW837 xenograft tumors.  
SW837 cells were implanted into immune-deficient nude mice and treated with the small molecule 
kinase inhibitors AEW541 (n=6), erlotinib (n=6), the combination of AEW541 / erlotinib (n=7) or the 
solvent as control (n=7) in addition to combined RCT. After reaching an average tumor volume of 
1500 mm3, mice were sacrificed and the tumors were measured and weighed. (a) Single inhibition of 
the EGFR as well as simultaneous inhibition of the IGF1R and EGFR resulted in a significantly reduced 
tumor volume compared to control mice. (b) Regarding tumor weight, simultaneous inhibition of the 
IGF1R and EGFR in addition to combined RCT led to a significant reduction compared to the control. 
* P <0.05 (student’s t test). 
 
3.27 Simultaneous inhibition of IGF1R and EGFR is associated with 
diminished downstream signaling in vivo 
To assess whether inhibition of the IGF1R and EGFR affects the downstream PI3K 
and MAPK signaling pathways, western blot and subsequent densitometrical analyses 
with proteins of the SW837 xenograft tumors were performed (Fig. 75). Single as well 
as simultaneous inhibition of the IGF1R and EGFR resulted in a significant reduction 
of IGF1Rβ expression compared to the control, however, treatment with both inhibitors 
could not increase single treatment effects (Fig. 75b). The level of IGF1R activity 
decreased when xenograft tumors were treated with erlotinib or the combination of 
AEW541 and erlotinib compared to the control. Single treatment with AEW541 did not 
change IGF1R activity (Fig. 75c). Single treatment of the xenograft tumors with 
AEW541 or erlotinib led to a reduction of activated AKT (pAKT) and ERK (pERK), 
respectively. However, simultaneous treatment with AEW541 and erlotinib even further 
decreased activation of AKT (pAKT) and ERK (pERK) in comparison to single 
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Fig. 75: Expression patterns of the IGF1R and members of the downstream PI3K and MAPK 
signaling pathways after treatment with the small molecule kinase inhibitors AEW541 and 
erlotinib in addition to combined RCT. 
Immune-deficient nude mice were injected with SW837 cells and treated with the small molecule kinase 
inhibitors AEW541, erlotinib or the combination of AEW541 and erlotinib in addition to combined RCT. 
The tumors were excised from the mice, proteins were isolated from the tumors and western blot (a) and 
subsequent densitometrical analyses (b- e) were performed. (a) IGF1Rβ was highly expressed in the 
tumors of control animals. The phosphorylation level of AKT (pAKT) and ERK (pERK) was reduced in 
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The expression of IGF1Rβ decreased significantly after single inhibition of the IGF1R, the EGFR and 
the simultaneous inhibition of the IGF1R and EGFR. (c) No significant difference in the level of activated 
IGF1R between the different inhibitor treatments was visible. (d, e) A significant reduction of the activity 
of AKT (pAKT) and ERK (pERK), respectively, was visible after simultaneous inhibition of the IGF1R 
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4 Discussion 
 
4.1 Summary of the results 
The insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine kinase (RTK) 
that is overexpressed in a variety of cancer entities, including colorectal cancer (CRC). 
In the course of the present study, the role of the IGF1R / Igf1r during intestinal 
development and during colonic tumor formation and progression was analyzed. For 
this reason, two inducible mouse models were generated. The Villin-TRE-IGF1R 
mouse line drives villin-guided expression of human IGF1R in the small intestine and 
colon induced by doxycycline administration. IGF1R overexpression and the activation 
of its downstream PI3K signaling pathway could be confirmed in the small intestine 
and colon by immunohistochemistry and western blot analysis. Immunofluorescence 
stainings revealed a gradient of high IGF1R overexpression in the villi of the small 
intestine and at the tip of the colonic crypts to low IGF1R overexpression in the crypts 
of the small intestine and at the bottom of the colonic crypts. Goblet cells, 
enteroendocrine cells, Paneth cells and proliferating cells could be excluded as cell 
type of IGF1R overexpression by immunofluorescence double stainings. To analyze if 
IGF1R overexpression was capable of inducing intestinal tumor formation,                 
Villin-TRE-IGF1R mice were administered to 2 mg / ml doxycycline for 1.5 years to 
induce IGF1R overexpression. Colonoscopy was regularly performed to screen for 
colonic tumors, but villin-guided IGF1R overexpression was not sufficient to induce 
intestinal tumor formation. Interestingly, a possible effect of IGF1R overexpression on 
intestinal morphology and epithelial cell composition was hypothesized. De facto, 
IGF1R overexpression could be proven to significantly extend the average crypt depth 
in the small intestine. In addition, a reduced goblet and Paneth cell density and an 
increased number of proliferating cells were detected in IGF1R-overexpressing 
(IGF1R-oe) mice. These findings indicated that the IGF1R promotes epithelial cell 
proliferation and inhibits epithelial cell differentiation, pointing to a role of the IGF1R in 
normal intestine homeostasis.  
Since IGF1R overexpression was proven to be not sufficient to induce intestinal tumor 
formation, it was hypothesized to promote tumor progression. To verify this hypothesis, 
Villin-TRE-IGF1R mice were administered to doxycycline to induce IGF1R 
overexpression and additionally treated with the mutagenic agent AOM or the 
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combination of AOM and the inflammatory agent DSS, respectively, to induce colonic 
tumor formation and inflammation. When using AOM as CRC-inducing agent, only 
IGF1R-oe mice developed intramucosal and even invasive carcinomas, whereas no 
difference was observed regarding adenoma development. Furthermore, this IGF1R-
induced tumor progression was clearly shown when using AOM / DSS for CRC 
induction. In this mouse model, IGF1R-oe mice revealed an extremely elevated 
number of intramucosal carcinomas. IGF1R-oe mice even developed invasive 
carcinomas, whereas control mice did not. Metastases in the liver and lymph nodes of 
IGF1R-oe mice were not detected. In addition, the average tumor size of IGF1R-oe 
mice was increased by 66.2% compared to the tumor size of control mice. Moreover, 
western blot analysis was performed on the tumors to investigate the effect of IGF1R 
overexpression on the downstream PI3K and MAPK signaling pathways. The 
phosphorylation level of AKT (pAKT) was strongly elevated, whereas ERK activity was 
diminished in tumors which developed in IGF1R-oe mice compared to control mice, 
indicating that the PI3K and MAPK signaling pathways were activated and involved in 
the IGF1R-driven promotion of tumor progression. Taken together, these results 
impressively indicate that IGF1R overexpression promotes colonic tumor progression 
and influences the differentiation of the intestinal epithelium. 
To study the function of murine Igf1r in the intestine and tumor development in more 
detail, the Villin-CreERT-Igf1r mouse line was established which expressed a cre 
recombinase fused with a modified ligand binding site of the human estrogen receptor 
and carried Igf1r alleles flanked by loxP sites. Tamoxifen administration to Cre+/Igf1rfl/fl 
Villin-CreERT-Igf1r mice resulted in the deletion of exon 3 of the Igf1r gene specifically 
in the epithelium of the small intestine and colon. The Igf1r knockout was confirmed by 
PCR on genomic DNA and western blot analysis. Detailed analyses of the 
differentiation in the intestinal epithelium revealed an increase of goblet cells and a 
decrease of proliferating cells in Cre+/Igf1rfl/fl mice compared to control mice, supporting 
the hypothesis that the Igf1r could function as a promoter of epithelial cell proliferation 
and as an inhibitor of epithelial cell differentiation. The influence of the Igf1r knockout 
on colonic tumor formation and progression was examined using both the AOM and 
AOM / DSS mouse models. AOM administration resulted in a moderate decrease in 
the number of colonic tumors in Cre+/Igf1rfl/fl mice compared to control mice. However, 
AOM / DSS administration revealed opposing results with a slight increase in the 
colonic tumor number in Cre+/Igf1rfl/fl mice compared to control mice. Regarding the 
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tumor stage, Cre+/Igf1rfl/fl mice revealed a reduced number of colonic tumors with 
advanced stage compared to control mice. Western blot analysis on the colonic tumors 
showed a reduction of AKT activity (pAKT) but an increase in ERK activity (pERK) in 
Cre+/Igf1rfl/fl mice compared to control mice, which leads to the hypothesis that tumor 
development in Igf1r knockout mice follows different driver mechanisms. 
Since it is known that the IGF1R is highly upregulated in CRC, the IGF1R was 
predicted to be an important molecular target to treat patients with advanced CRC. In 
vitro studies, in which the IGF1R and EGFR were simultaneously inhibited in addition 
to a combined 5-FU-based radiochemotherapy (RCT) revealed a decrease in the 
survival fraction compared to single inhibition of either IGF1R, EGFR or control 
treatment in the CRC cell line DLD-1 and in the rectal cancer cell line SW837. In the 
CRC cell line CaCo-2, simultaneous inhibition of IGF1R and EGFR in addition to 
combined RCT even resulted in a complete loss of survival. One main aim of the 
present study was to analyze if these in vitro results can also be observed in vivo. To 
answer this question, DLD-1, CaCo-2 and SW837 cells were subcutaneously 
implanted into immune-deficient nude mice and resulting tumors were treated with the 
small molecule kinase inhibitors AEW541 (directed against the IGF1R), erlotinib 
(directed against the EGFR), the combination of AEW541 / erlotinib or the solvent as 
control in addition to combined RCT. In DLD-1 as well as in CaCo-2 xenograft mice, 
single or simultaneous inhibition of IGF1R and EGFR did not result in a significant 
reduction of tumor volume increase, tumor volume or weight. In contrast, in SW837 
xenograft mice tumor progression, tumor volume and weight were significantly reduced 
after simultaneous treatment with AEW541 / erlotinib. Western blot analysis was 
performed on the SW837 tumors to investigate the effect of simultaneous inhibition of 
IGF1R and EGFR on the downstream PI3K and MAPK signaling pathways. AKT 
(pAKT) and ERK (pERK) activity were significantly reduced after simultaneous 
treatment with AEW541 / erlotinib. These results indicated that simultaneous inhibition 
of IGF1R and EGFR might be a potential treatment opportunity for advanced CRC. 
 
4.2 Development, cellular organization and function of the intestine 
The intestine is a winding muscular tube extending from the stomach to the anus. It 
consists of the small and large intestine. The main function of the small and large 
intestine is the digestion and absorption of nutrients, which is facilitated by numerous 
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epithelial infoldings that result in the extension of the surface area (Jaladanki and Wang 
2011). The wall of the intestine is divided into four layers: mucosa, submucosa, 
muscularis propia and serosa. The mucosa lines the lumen of the intestine and is 
further divided into the epithelium, which is composed of a single-cell-layer of epithelial 
cells, the lamina propia, which consists of connective tissue and lymph nodes and the 
muscularis mucosae, which is a continuous sheet of smooth muscle cells (Bustos-
Fernández 1983; Jaladanki and Wang 2011).  
In human, the small intestine is a hollow tube of approx. 6 to 7 m length and a narrowing 
diameter from the beginning to the end. The small intestine is the longest part of the 
gastrointestinal tract and extends from the pyloric orifice of the stomach to the ileocecal 
fold. The small intestine is divided into the duodenum, the jejunum and the ileum 
(Drake and Gray 2010). The inner lining of the small intestine is covered with a 
columnar epithelium with invaginations, known as the crypts of Lieberkuhn (in the 
following text named crypts) and villi (Jaladanki and Wang 2011). Villi are 0.2 to 1 mm 
tall and 0.15 mm thick finger-like projections containing the majority of differentiated 
absorptive cells. The surface of the mucosa is 7- to 14-fold enlarged by the presence 
of the villi and crypts. The main function of the villi is the resorption of nutrients, while 
secretion and regeneration of cells take place in the crypts (Benninghoff et al. 2008).  
The ontogeny of the small intestine is a process with three successive phases, 
containing morphogenesis and cell proliferation, cell differentiation, and cellular and 
functional maturation. In contrast to rodents, development of the human intestine is 
largely completed before birth. In human, mucosal remodeling and villus formation 
starts cranial and proceeds caudally beginning at 9 to 10 weeks of gestation. At first, 
crypts appear as solid cords of epithelial cells but form a small lumen lined by 
undifferentiated columnar cells by 12 weeks of gestation. Undifferentiated absorptive 
cells, goblet cells, and enteroendocrine cells are localized in the stratified epithelium 
before the villi have formed, whereas Paneth cells are observed at the base of 
developing crypts at weeks 11 to 12 of gestation. Enteroendocrine cells firstly appear 
by 12 weeks of gestation. In rodents, villus length, crypt depth, and the number of 
epithelial cells increase with development and finally reach maturity during the weaning 
period. Numerous potential extrinsic regulators of the human intestinal development 
have been identified, containing many growth factors and their receptors, such as EGF, 
IGF-2 and TGF-β (Montgomery et al. 1999). 
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The large intestine extends from the distal end of the ileum to the anus (Drake and 
Gray 2010). In the adult human, the large intestine is approx. 1.5 m in length        
(Bustos-Fernández 1983; Jaladanki and Wang 2011). The large intestine consists of 
the cecum, appendix, colon, rectum and the anal canal. The main functions of the large 
intestine are the absorption of fluids and salts from the intestinal contents, thus forming 
the feces (Drake and Gray 2010). In contrast to the small intestine, the epithelium of 
the large intestine is not covered with villi but contains tubular invaginations, the crypts 
(Jaladanki and Wang 2011). Due to the fact that the colon is the largest part of the 
large intestine (Benninghoff et al. 2008), the large intestine is simply called colon in the 
further text. 
The development of the colon is very similar to that of the small intestine. It is marked 
by three stages of cell differentiation. At first, a primitive stratified epithelium appears 
at weeks 8 to 10 of gestation. At weeks 12 to 14 of gestation, this stratified epithelium 
is converted to a villus epithelium with developing crypts. At around 30 weeks of 
gestation, the remodeling of the epithelium occurs and the villi disappear, resulting in 
the adult-type epithelium with crypts but without villi (Montgomery et al. 1999).  
The intestinal epithelium exhibits a remarkable constant and rapid renewal capacity on 
a weekly basis (Bustos-Fernández 1983; Medema and Vermeulen 2011). Crucial for 
the homeostasis of the intestinal epithelium are the intestinal stem cells (ISCs) that 
reside at the bottom of the crypts in both, the small intestine and colon (Medema and 
Vermeulen 2011). The undifferentiated ISCs divide and thus constantly provide new 
cells (Bustos-Fernández 1983). Interestingly, ISCs divide asymmetrically and thus give 
rise to one daughter stem cell and one progenitor cell (Jaladanki and Wang 2011). 
Therefore, all different intestinal cell types have their origin in one single stem cell. 
Several studies about the localization and identification of intestinal stem cells exist, 
predicting that the +4 cells (+4 cells are localized predominantly four cells above the 
cells of the crypt =+4 position (Sangiorgi and Capecchi 2008)) as well as the crypt base 
columnar cells (CBCCs) function as ISCs. Paneth cells are localized between the 
CBCCs in the crypts of the small intestine, and, of note, are not detected in the colon. 
The remainder of the crypts of the small intestine and colon largely consists of the 
rapidly proliferating progenitor cells, also known as transit-amplifying (TA) cells, that 
reside within the crypts for two to three days and divide approx. twice a day          
(Bustos-Fernández 1983; Sato et al. 2009; Medema and Vermeulen 2011). When the 
newly divided TA cells reach the top of the crypts, cell proliferation halts and the           
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TA cells rapidly differentiate into mature epithelial cells (Jaladanki and Wang 2011). 
The intestinal epithelial layer consists of either secretory cells, namely the mucus-
secreting goblet cells, the hormone-secreting enteroendocrine cells and the 
antimicrobial-secreting Paneth cells, or enterocytes (Medema and Vermeulen 2011; 
Konsavage et al. 2012). Interestingly, the goblet cells, enteroendocrine cells and 
enterocytes migrate upward towards the intestinal lumen, whereas Paneth cells of the 
small intestine migrate downward towards the base of the crypt (Konsavage et al. 
2012).  
 
Fig. 76: Cellular organization of the colonic crypt and the small intestinal crypt and villus. 
At the bottom of the intestinal crypts, pluripotent intestinal stem cells (ISCs) are localized, namely 
+4 cells and crypt base columnar cells (CBCCs). Additionally, at the bottom of the small intestinal crypt, 
Paneth cells are localized, whereas Paneth cells are not detected in the colon. ISCs divide and thus 
give rise to progenitor cells also known as transit-amplifying (TA) cells. TA cells divide and rapidly 
differentiate into goblet cells, Paneth cells, enteroendocrine cells or enterocytes when they reach the 
crypt-villus junction (modified after Medema and Vermeulen, 2011).  
 
The goblet cells are localized in the small intestine and colon (Medema and Vermeulen 
2011). The number of goblet cells increases caudally from the small intestine to the 
colon, in concordance with the rising number of microbial organisms that are present 
in the proximal intestine to the colon (Benninghoff et al. 2008; Kim and Ho 2010). In 
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10 of gestation. The main function of goblet cells is the synthesis and secretion of 
bioactive molecules, such as secretory mucin glycoproteins like mucin 2 (MUC2) and 
epithelial membrane-bound mucins (MUC1, MUC3 and MUC17), which are 
components of the mucus. The major function of intestinal goblet cells and mucin as 
their main secretory product is the formation of the intestinal mucus layers. The small 
intestine has only a monolayer of mucus, whereas the mucus of the colon is                 
two-layered (Johansson et al. 2011). The intestinal mucus layers mainly consist of the 
gel-forming MUC2 mucin and serve as the physical and chemical barrier against 
endogenous and exogenous irritants, such as bacteria, toxins of bacteria or the 
environment, or some dietary components (Specian and Oliver 1991; Kim and Ho 
2010). Nevertheless, intestinal mucus layers allow the transport of nutrients (Kim and 
Ho 2010). A correlation between the volume density of goblet cells and malignant 
transformation is not known to date. Interestingly, alterations in mucin production were 
observed during intestinal neoplasia. In human tumors of the small intestine, mucin 
secretion was found to be dramatically decreased or even absent, and histologically 
the mucins showed an altered pattern (Specian and Oliver 1991). Furthermore, a link 
between the fibroblast growth factor 10 (Fgf10) expression and the number of goblet 
cells was shown (Al Alam et al. 2015). Al Alam et al. (2015) proved that Fgf10 
overexpression in the murine small intestine induced goblet cell differentiation and a 
decrease in the number of Paneth cells, indicating that Fgf10 influences the balance 
between goblet and Paneth cells. FGF10 belongs to the FGF family and is the ligand 
for the fibroblast growth factor receptor 1 (FGFR1) and FGFR2, which are 
transmembrane tyrosine kinase receptors (Ahmad et al. 2012). To date, studies 
showing a correlation between the IGF1R expression and goblet cell differentiation and 
the maintenance of the goblet cell population are not available. 
Paneth cells are specialized secretory cells in the epithelium of the small intestine. Like 
the other epithelial cells, Paneth cells originate from the adjacent leucine-rich-repeat-
containing G protein-coupled receptor 5 (LGR5)-positive intestinal stem cells (Bevins 
and Salzman 2011). Paneth cells are localized at the base of the crypts and synthesize 
and secrete antimicrobial peptides and proteins (Elphick 2005; Clevers and Bevins 
2013). In humans, the development of Paneth cells starts in the colon and small 
intestine at a gestational stage of 13.5 weeks. After 17 weeks of gestation, Paneth cells 
are mainly restricted to the small intestine and are not found in the colon anymore 
(Bevins and Salzman 2011). On average, each small intestinal crypt contains 5 to 
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12 Paneth cells. As already mentioned, in contrast to other epithelial cells, Paneth cells 
migrate downward from the stem cell zone to the bottom of the crypt, where they can 
reside for approx. 1 month (Elphick 2005; Clevers and Bevins 2013). The localization 
of the Paneth cells close to the Lgr5-expressing CBCCs indicate a functional 
interaction between these cells, and indeed it was shown that Paneth cells provide 
large amounts of essential niche signals to the CBCCs (Clevers and Bevins 2013). 
Paneth cells contain numerous cytoplasmic granules which are released into the crypt 
lumen upon microbial challenge (Elphick 2005; Bevins and Salzman 2011). 
Antimicrobials are the most prominent proteins in the granules and are able to prevent 
microbial invasion of the crypt (Bevins and Salzman 2011). Among several 
antimicrobial peptides of Paneth cells, lysozyme is an antimicrobial protein found in 
many human secretions, such as tears, breast milk and small intestinal secretions. 
Lysozyme is predominantly active against Gram positive bacteria (Elphick 2005; 
Bevins and Salzman 2011).  
Interestingly, a link between the insulin receptor (IR) and the intestinal Paneth cell 
number was proven by Andres et al. (2015). These authors showed that during high-
fat diet-induced obesity the number of Paneth cells decreased in mice that harbor an 
IR disruption in intestinal cells. Furthermore, they predicted that the IR expressed in 
the intestinal epithelium contributes to an increase in Paneth cell-derived mRNAs 
during high-fat diet-induced obesity (Andres et al. 2015). However, a link between the 
IGF1R, which is closely related to the IR, and Paneth cell differentiation and 
maintenance is not known. 
Enteroendocrine cells (EECs) are the basis of the largest endocrine system in the 
body, the intestine. EECs secrete multiple regulatory peptide hormones which control 
physiological and homeostatic functions and act as sensors of nutrients in the digestive 
tract (Moran et al. 2008; Gunawardene et al. 2011). EECs develop from the pluripotent 
stem cells and are localized as single cells in the intestinal crypts and villi, interspersed 
by non-endocrine epithelial cells (Moran et al. 2008; Gunawardene et al. 2011). EECs 
express the cell surface protein Notch and prevent the differentiation of adjacent cells 
into EECs by lateral inhibition (Gunawardene et al. 2011). From the duodenum to the 
rectum, the highest number of EECs can be found proximally, then the number of EECs 
falls steadily with the lowest number in the colon and rises again within the rectum 
(Gunawardene et al. 2011). The turnover of EECs is very rapidly with a lifespan of 
approx. 4 to 6 days (Moran et al. 2008). EECs contain secretory vesicles holding 
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chromogranin A, which is a matrix-soluble glycoprotein that transports biogenic 
amines, and synaptophysin, which is a membrane glycoprotein (Gunawardene et al. 
2011). Of importance, publications presenting data about a crosslink between EECs 
and the IGF1R do not exist to date. 
Enterocytes are the absorptive cells in the intestinal epithelium. Enterocytes develop, 
similarly as the goblet, Paneth and enteroendocrine cells, from the intestinal stem cells. 
The enterocytes differentiate and migrate within 3 to 4 days from the crypt to the villus 
tip, where they are released into the lumen of the intestine. Microvilli at the apical 
surface of enterocytes increase the absorptive surface area of the cells (Overeem et 
al. 2016). The main function of enterocytes is the uptake of ions, water, nutrients, 
vitamins and the absorption of unconjugated bile salts during digestion. Furthermore, 
enterocytes cooperate with cells of the intestinal mucosa-associated lymphoid tissue 
(MALT). Together, these cells preserve a non-reactivity state toward dietary and 
microbial antigens. Thus, enterocytes are actively involved in the immunological 
tolerance to ingested proteins (Miron and Cristea 2012). Of note, a connection between 
the Igf-axis and enterocytes was shown in growing rats after mid small bowel resection. 
Treatment with ectopic Igf-1 increased the proliferation level of enterocytes and even 
expanded the size of the proliferative compartment in the crypt after resection (Dahly 
et al. 2003). A direct link between the IGF1R and enterocytes and regarding to CRC is 
not known to date. 
 
4.3 Physiological role of the IGF1R in the intestine 
Several studies have proven that the IGF1R is overexpressed in colorectal and rectal 
cancer biopsies (Freier et al. 1999; Hakam et al. 1999; Weber et al. 2002; Li 2013; 
Zhang et al. 2013; Wu et al. 2014). In contrast, only little is known about the role of the 
IGF1R in normal intestinal tissue. In vivo, an influence of the IGF1R and its ligands on 
murine embryonal growth could be shown by Baserga (1995). At birth, mouse embryos 
with disrupted Igf1r and Igf-2 genes were smaller than their wild type littermates. 
Furthermore, cells derived from the knockout embryos revealed growth deficits, which 
could be abrogated by transfection of the cells with wild type Igf1r cDNA. These facts 
indicated that the Igf1r is important for growth (Baserga 1995). Dong et al. (2014) found 
a connection between the glucagon-like peptide-2 (GLP-2) and the Igf1r in the 
intestine, respectively. They showed that GLP-2 requires the Igf1r, expressed in the 
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intestinal epithelium, to promote intestinal growth and to modulate intestinal barrier 
function (Dong et al. 2014). In addition, the insulin receptor substrate 1 (IRS1), that is 
known to mediate downstream signaling (Sachdev and Yee 2007; Ekyalongo et al. 
2013), was proven to be expressed in the colonic crypt epithelium and was predicted 
to play a role in CRC progression (Esposito et al. 2012). Astonishingly, only one 
publication was found in which the expression of components of the IGF-axis and 
therefore the expression of IGF1R in normal human colorectal tissue was examined. 
The researchers observed staining of the IGF1R in the colonic crypts of all 46 colonic 
and 43 rectal biopsies in both, the cytoplasm and cell membrane, with significantly 
stronger expression of IGF1R in the rectum compared to the colon (Vrieling et al. 
2009). Of note, van Landeghem et al. (2015) analyzed the effect of a short-term human 
IGF-1 administration on ISCs during normal intestinal renewal, and crypt regeneration 
after injury induced by high-dose radiation. They showed that IGF-1 administration in 
uninjured mice stimulated mucosal growth indicated by a significant increase in crypt 
density as well as significant increases in crypt depth and villus height. In addition, they 
proved that IGF-1 administration stimulated the expansion of CBCCs, which was 
indicated by the significant increase in the number of CBCCs per crypt section. 
Interestingly, these authors further observed enriched mRNA levels of the Igf1r in 
CBCCs, indicating involvement of the Igf1r in the effects of IGF-1 on ISCs (van 
Landeghem et al. 2015). In general, it was shown that the IGF1R / Igf1r plays a crucial 
role in maintaining normal growth and development (Reinmuth et al. 2002). In the skin, 
an association between elevating Igf1r levels and increased cell proliferation could be 
proven. Lack of Igf1r expression was shown to be associated with decreased 
proliferation and with the facilitation of the differentiation process in primary skin 
keratinocytes (Sadagurski et al. 2006). In the mammary terminal end bud, which is the 
proliferative compartment within the virgin mouse mammary gland, the loss of Igf1r 
resulted in decreased proliferation (Bonnette and Hadsell 2001).  
In the present study, one aim was the examination of the physiological role of the 
IGF1R / Igf1r in the intestine. For this purpose, an IGF1R overexpression                   
(Villin-TRE-IGF1R mice) and an Igf1r knockout mouse model (Villin-CreERT-Igf1r 
mice), respectively, were established.  
No data exist demonstrating morphological changes in the intestine as a consequence 
of an IGF1R overexpression or an Igf1r knockout. Van Landeghem et al. (2015) 
demonstrated that IGF-1 administration induced significant changes in intestinal 
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morphology, such as increased crypt depth and villus height, and predicted an 
involvement of the Igf1r. The present study shows that the small intestine and colon 
are intact in IGF1R-overexpressing (IGF1R-oe) (see chapter 3.8) and Igf1r-knockout 
(Cre+/Igf1rfl/fl) mice (see chapter 3.21). However, a significant increase in the average 
depth of the small intestinal crypts was found in IGF1R-oe mice compared to the 
particular control mice (see chapter 3.8). As already described, the Igf1r is known to 
promote cell proliferation in the skin (Sadagurski et al. 2006), and IGF-1 administration 
was shown to stimulate mucosal growth and expansion of CBCCs in the intestine (van 
Landeghem et al. 2015). Additionally, it is also known that proliferation in the intestine 
takes place in the crypts, whereas cell differentiation occurs in the villi of the small 
intestine (Medema and Vermeulen 2011). Thus, a prolonged small intestinal crypt 
could possibly account for an elevated level of cell proliferation. A controversial issue 
is the fact that no significant increase of the colonic crypt depth was observed, because 
proliferating ISCs are not only localized in the crypts of the small intestine, but also in 
the crypts of the colon. Thus, further investigations are required. Epithelial cell 
differentiation and proliferation was examined by the quantification of goblet cells, 
enteroendocrine cells, Paneth cells and proliferating cells of IGF1R-oe and Cre+/Igf1rfl/fl 
mice. The overall results are summarized in table 1. 
 
Table 1: Results of the quantification of the different intestinal cell types in IGF1R-
overexpressing (IGF1R-oe) and Igf1r knockout mice (Cre+/Igf1rfl/fl) compared to the particular 
control. 
↑=increased -, ↓=decreased -, →=unchanged number of the particular cell type; SI=small intestine. 
4 w= quantification of proliferating cells four weeks after the Igf1r knockout was induced. 
3 m= quantification of proliferating cells three months after the Igf1r knockout was induced. 
Cell type IGF1R-oe Cre+/Igf1rfl/fl 
 SI colon SI colon 
Goblet cells ↓ ↓ ↑ ↑ 
Enteroendocrine 
cells 
→ → → → 
Paneth cells ↓  ↓  
Proliferating cells 
(Ki 67-positive) 
↑ ↓ ↓    ↓ 4 w   ↑ 3 m 
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In the small intestine, IGF1R-oe mice revealed a reduction of goblet and Paneth cells, 
whereas the number of enteroendocrine cells did not alter after IGF1R overexpression. 
Numbers of proliferating cells increased in the crypts of the small intestine. These 
results support the hypothesis that the extended crypt depth in the small intestine is 
the consequence of increased cell proliferation promoted by the IGF1R 
overexpression. Under physiological conditions, stem cells at the base of the crypts 
divide to self-renew and give rise to daughter progenitor cells. The progenitor cells 
divide approx. six times and rapidly differentiate as they migrate along the crypt-villus 
axis (Jaladanki and Wang 2011; van Landeghem et al. 2015). However, upon IGF1R 
overexpression, the progenitor cells do not differentiate, but rather keep on proliferating 
promoted by the IGF1R. As a consequence, the proliferative compartment is extended, 
indicated by the elongated crypt depth. This hypothesis is supported by the fact, that 
the density of goblet cells and Paneth cells is reduced upon IGF1R overexpression in 
the small intestine, showing that differentiation is inhibited by IGF1R overexpression. 
Interestingly, comparable results in primary skin keratinocytes were published by 
Sadagurski et al. (2006) who proved that loss of Igf1r expression is associated with 
decreased proliferation and increased differentiation. 
If this hypothesis of the IGF1R as a proliferation-promoting and a differentiation-
inhibiting factor is true, opposing results are expected in Cre+/Igf1rfl/fl mice. Indeed, 
Cre+/Igf1rfl/fl mice revealed an increase in goblet cells as expected, but a decrease in 
Paneth cells. The number of proliferating cells in the small intestine was reduced. 
Again, the density of enteroendocrine cells did not change, indicating that the Igf1r 
seems to have no influence on the differentiation of this cell type. Both, the increase in 
the number of goblet cells and the reduction of proliferating cells in the small intestine 
support the hypothesis that the Igf1r promotes cell proliferation and inhibits epithelial 
cell differentiation in this tissue.  
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Fig. 77: Schematic representation of the influence of the IGF1R overexpression and the              
Igf1r knockout on epithelial cell proliferation and differentiation in the small intestine. 
In the normal state, CBCCs are localized at the bottom of the crypts and Paneth cells are localized in 
between. +4 cells are localized above the Paneth cells on position +4. CBCCs and +4 cells divide and 
thus give rise to progenitor cells, also known as transit-amplifying (TA) cells. TA cells divide as they 
migrate upwards along the crypt-villus-axis and differentiate into goblet cells, Paneth cells, 
enteroendocrine cells or enterocytes when they reach the crypt-villus junction. Upon IGF1R 
overexpression, the progenitor cells keep on proliferating instead of differentiating which results in an 
elongated proliferative compartment and the reduction of goblet and Paneth cells. In contrast, upon Igf1r 
knockout, the number of proliferating cells decreases, whereas the density of goblet cells increases, 
leading to the shrinkage of the proliferative compartment (modified after Hägebarth 2005; Medema and 
Vermeulen 2011).  
 
In the crypts of the colon, IGF1R-oe mice showed a decreased number of goblet cells, 
Paneth cells and, against expectation, also proliferating cells. The number of 
enteroendocrine cells did not change after IGF1R overexpression compared to control 
mice. In Cre+/Igf1rfl/fl mice, the number of goblet cells increased, the Paneth cell number 
decreased and the number of enteroendocrine cells did not change compared to the 
cell numbers in control mice. The number of proliferating cells revealed opposing 
effects in the colonic crypts of Cre+/Igf1rfl/fl mice. Four weeks after the Igf1r knockout 
was induced, the number of proliferating cells decreased, whereas it increased three 















4 Discussion  143 
affect colonic crypt depth as well as the fact that in IGF1R-oe mice the number of 
proliferating cells in the colonic crypts was decreased, whereas it was increased in 
Cre+/Igf1rfl/fl mice three months after Igf1r knockout induction seem to dispute the 
hypothesis of IGF1R / Igf1r being a promoter of cell proliferation and an inhibitor of cell 
differentiation. Of note, the IGF1R overexpression and the Igf1r knockout were also 
confirmed in the colon. An explanation for these observations in the colon could be the 
fact that villin expression was observed to be lower in the colon compared to the small 
intestine in both Villin-TRE-IGF1R and Villin-CreERT-Igf1r mice (see chapter 3.3, 3.5 
and 3.18). Since the villin promoter guides IGF1R overexpression and the Igf1r 
knockout, lower villin expression in the colon could indicate that also IGF1R 
overexpression and the Igf1r knockout are impaired in the colon and that the villin 
promoter is not a suitable promoter in studies of the colon (see chapter 4.5.1). In fact, 
IGF1R overexpression in the Villin-TRE-IGF1R mouse model was shown to be more 
prominent in the small intestine than in the colon. 
Interestingly, a concordant expression pattern of villin expression and IGF1R 
overexpression in Villin-TRE-IGF1R mice was not observed. As already described, 
villin was expressed in epithelial cells of the small intestine and colon with a gradient 
from high expression in the villi of the small intestine and at the tip of the colonic crypts 
to low villin expression in the crypts of the small intestine and at the bottom of the 
colonic crypts (see chapter 3.3). In contrast, IGF1R overexpression was indeed evenly 
distributed over the villi, but only some particular cells overexpressed IGF1R, whereas 
in other cells IGF1R overexpression was hardly visible (see chapter 3.4 and 3.6). Since 
IGF1R overexpression was guided by the villin promoter, which is expressed in all 
epithelial cells along the crypt-villus axis, IGF1R was also expected to be 
overexpressed by all epithelial cells. These observations led to the assumption that, 
despite the fact that the villin promoter guides IGF1R overexpression, not all epithelial 
cells but only a special intestinal cell type overexpressed IGF1R upon doxycycline 
treatment. Furthermore, endogenous Igf1r was shown to be strongly expressed at the 
base of the crypts with intense staining in CBCCs (van Landeghem et al. 2015). 
Consistent with these findings were Igf1r stainings of small intestinal and colonic tissue 
sections of control Villin-TRE-IGF1R mice in the present study which showed that 
endogenous Igf1r is abundantly localized at the base of the crypts in the small intestine 
and colon. Along the crypt-villus-axis, immunoreactivity of endogenous Igf1r was 
observed to decline (Fig. 78). 
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Fig. 78: Immunofluorescence stainings of endogenous Igf1r in the small intestine (SI) and colon 
using an antibody against murine Igf1rβ. 
A gradient of low endogenous Igf1r expression (red) in the villi (SI) and at the tip of the crypts (colon) to 
strong expression in the crypts (SI) and at the base of the crypts (colon) is visible. DAPI visualized cell 
nuclei (blue). 
 
In contrast, ectopic IGF1R induced by IGF1R overexpression was predominantly 
observed to be localized at the tip of the crypts as described in chapter 3.4, raising the 
suggestion that endogenous Igf1r and ectopic villin-guided IGF1R were expressed by 
different epithelial cell types. The identification of the cell type that endogenously and 
exogenously expressed IGF1R / Igf1r was part of the present study. Unfortunately, 
double stainings with endogenous Igf1r did not lead to evaluable results due to the fact 
that the antibodies specific for goblet cells, enteroendocrine cells and Paneth cells and 
specific for endogenous Igf1r were of the same host species. In addition, the 
establishment of a new purchased antibody for endogenous Igf1r did also not lead to 
feasible results. In contrast, double stainings with exogenous IGF1R induced by IGF1R 
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A concordant staining could not be observed for IGF1R with mucin2, CHGA or 
lysozyme, indicating that neither goblet cells, nor enteroendocrine cells nor Paneth 
cells overexpressed IGF1R in Villin-TRE-IGF1R mice (see chapter 3.6). Double 
staining experiments of the IGF1R and Ki 67 as a marker for proliferating cells did not 
precede to suitable results. Nevertheless, proliferating cells as the cell type 
overexpressing the IGF1R could be excluded since IGF1R expression was prevalently 
observed at the tips of the crypts and in the villi (see chapter 3.6), whereas proliferation 
is known to occur at the base of the crypts (Medema and Vermeulen 2011). In addition, 
enterocytes could also be excluded to be the cell type overexpressing the IGF1R, 
because enterocytes are known to be arranged as a monolayer (Overeem et al. 2016) 
and represent the vast majority of epithelial cells in the intestine (Ye et al. 1998; Gerbe 
et al. 2012), which was not comparable to the IGF1R overexpression pattern seen in 
the fluorescence stainings of the present study. Hence, these facts led to the question 
which cell type overexpressed the IGF1R. Although seven different cell types have 
been described in the intestinal epithelium, the three cell lineages of microfold (M) cells, 
cup cells and tuft cells are often not considered (Gerbe et al. 2012). Of note, these 
three cell types were also not considered in the present study and still remain as 
candidates of cells overexpressing the IGF1R. 
Altogether, these results raised several questions: 
1. Why did we observe different expression patterns for villin expression and 
IGF1R overexpression despite the fact that the villin promoter guides IGF1R 
overexpression? 
2. Does the IGF1R promote cell proliferation and inhibit cell differentiation in 
the colon as can be seen in the small intestine? 
3. Which epithelial cell type of the intestine overexpressed the IGF1R? 
4. Was the villin promoter the accurate promoter for the present study? 
These questions show that further experiments are needed to analyze if IGF1R 
overexpression and the Igf1r knockout, respectively, affect cell proliferation and 
epithelial cell differentiation, and to identify the epithelial cell type overexpressing the 
IGF1R. A detailed discussion about the villin promoter and the question if the villin 
promoter was the accurate promoter for the guided IGF1R overexpression and the 
Igf1r knockout in the murine intestine can be found in chapter 4.5. 
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4.4 The role of the IGF1R in carcinogenesis 
Carcinogenesis is defined as tumor / cancer formation and requires the conversion of 
benign, hyperplastic cells to malignant cells (Holland et al. 2003). The hallmarks of 
cancer comprise eight biological features that enable the tumor to grow and 
metastasize, namely sustaining proliferative signaling, evading growth suppressors, 
activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis, resisting cell death, reprogramming of energy metabolism and evading 
immune destruction (Hanahan and Weinberg 2000, 2011). There is strong 
experimental and clinical evidence that the IGF1R is involved in neoplasia 
(Pollak 2008). In general, the IGF1R is crucial for cell proliferation and differentiation 
(Zhang et al. 2013). In vivo, it could be shown that the Igf1r and its ligands control 
approx. 70% of murine embryonal growth. Mouse embryos with disrupted Igf1r and   
Igf-2 genes were at birth only 30% of the size of wild type littermates. Cells derived 
from the Igf1r knockout embryos grew at a lower rate compared to cells derived from 
wild type mice. However, these growth deficits could be abrogated by transfection of 
the cells with wild type Igf1r cDNA, indicating that the Igf1r is important for cell growth. 
Even more interestingly is the fact that cells derived from the Igf1r knockout mice could 
not be transformed by the SV40 T antigen or the ras oncogene. However, transfection 
of these cells with a plasmid expressing wild type Igf1r cDNA abolished this 
transformation defect, indicating that the Igf1r is obligatory for transformation 
(Baserga 1995). Furthermore, Coppola et al. (1994) even proved that cells derived 
from the Igf1r knockout mice, which overexpress the human EGFR, were unable to 
grow and could not be transformed, and that the mitogenic and transforming potential 
of EGFR was restored by transfection with wild type Igf1r, indicating that also other 
growth factor receptors are dependent on Igf1r. In addition, a correlation between an 
increase in apoptosis and decreasing levels of Igf1r was observed in vivo, revealing 
the anti-apoptotic potential of the Igf1r (Resnicoff et al. 1995). Additionally, it could be 
shown that IGF1R overexpression in NIH 3T3 cells resulted in vitro in anchorage-
independent growth and promoted in vivo tumor formation in nude mice (Kaleko et al. 
1990). Interestingly, in humans, IGF1R is well known to be overexpressed in a variety 
of malignancies, including hepatocellular carcinoma (Höpfner et al. 2006), pancreatic, 
gastric and esophageal cancer (Shiratsuchi et al. 2011), breast cancer (Jones et al. 
2007) and colorectal cancer (Garrouste et al. 1997; Freier et al. 1999; Hakam et al. 
1999; Fürstenberger and Senn 2002; Reinmuth et al. 2002; Adachi et al. 2009; 
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Shiratsuchi et al. 2011; Li 2013; Zhang et al. 2013). A correlation of IGF1R expression 
and tumor stage (Hakam et al. 1999), tumor size and depth of invasion (Shiratsuchi et 
al. 2011) were proven. Adachi et al. (2009) observed that a dominant-negative inhibitor 
for IGF1R reduced the invasiveness of three gastrointestinal cancer cell lines by 
suppression of the matrix metalloproteinase matrilysin, which function is the proteolytic 
degradation of the extracellular matrix. Furthermore, studies demonstrated that the 
IGF1R / Igf1r also plays a role in angiogenesis and metastasis. Human colon cancer 
cells transfected with truncated IGF1R revealed strongly impaired induction of VEGF 
expression. In vivo, KM12L4 colon cancer cells transfected with the truncated IGF1R 
showed significantly reduced growth, decreased proliferation and importantly, 
decreased blood vessel formation and failure to form liver metastases (Reinmuth et al. 
2002). In addition, lymphatic vessel density was found to positively correlate with the 
IGF1R expression level and lymphatic metastasis, indicating that the IGF1R induced 
lymphangiogenesis and thus promoted lymph node metastasis of CRC (Li 2013).  
Of note, Carboni et al. (2005) demonstrated that constitutively active IGF1R in 
transgenic mice resulted in the development of salivary and mammary 
adenocarcinomas. They generated a novel mouse model that overexpressed a 
constitutively active receptor constructed by the fusion of the cytoplasmic sequence of 
the human IGF1R to the extracellular and transmembrane sequences of the human   
T-cell antigen CD8α under the control of the mouse mammary tumor virus (MMTV) 
promoter. In addition, Jones et al. (2007) proved that the exclusive overexpression of 
the IGF1R was even sufficient for the induction of mammary tumor formation in vivo. 
These authors generated a transgenic mouse line that contained the human IGF1R 
cDNA under a doxycycline-inducible TRE promoter and the transactivator protein 
rtTA2 under the control of the MMTV promoter. Induction of IGF1R overexpression by 
administration of doxycycline over the drinking water resulted in mammary epithelial 
hyperplasia and the formation of palpable mammary tumors (Jones et al. 2007). 
These findings of Jones et al. (2007) led to the hypothesis that IGF1R overexpression 
is also sufficient to induce intestinal tumor formation. To verify this hypothesis, 
transgenic mice that contained the human IGF1R cDNA under the doxycycline-
inducible TRE promoter and the transactivator protein rtTA2-M2 under the villin 
promoter were generated in the present study (Villin-TRE-IGF1R mice). Administration 
of doxycycline over the drinking water induced the overexpression of IGF1R in 
particular epithelial cells of the intestine. In contrast to the results obtained by            
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Jones et al. (2007), tumor formation in the intestine was not observed in the present 
study. Even after 1.5 years of continuous doxycycline administration, the IGF1R-oe 
mice had not developed any tumors, indicating that in contrast to mammary tumor 
formation, IGF1R overexpression seems not to be sufficient to induce intestinal tumor 
formation. However, in contrast to El Marjou et al. (2004) who proved villin-guided 
expression of the cre recombinase in all epithelial cells of the intestine, in the present 
study villin-guided IGF1R overexpression was only observed in particular epithelial 
cells of the intestine (see chapter 4.3). This fact could also contribute to the finding that 
IGF1R overexpression per se did not induce colonic tumor formation and raised the 
question if the villin promoter was the accurate promoter for the present study. 
Altogether, these results indeed disproved the hypothesis of IGF1R overexpression 
being sufficient for intestinal tumor formation, but led to the suggestion that the IGF1R 
might promote intestinal tumor progression. To investigate the role of IGF1R / Igf1r 
during colonic tumor progression, the well-established AOM- and AOM / DSS-based 
CRC models were used. 
 
4.4.1 Chemical induction of colonic tumor formation 
Among several naturally mutant or genetically modified rodent models, which are 
predominantly used to study hereditary CRC and which will be discussed later (see 
chapter 4.5.3), inducible tumor models to study non-hereditary tumor development 
exist (Neufert et al. 2007). Azoxymethane (AOM) is a specific colon carcinogen that is 
used to mimic sporadic CRC (Bissahoyo 2005; Rosenberg et al. 2008). Of note, AOM 
itself is not the final carcinogenic metabolite, it is rather a pro-carcinogen that requires 
metabolic activation (Neufert et al. 2007; Rosenberg et al. 2008). The first step of 
metabolism is the conversion of AOM to methylazoxymethanol (MAM) by hydroxylation 
catalyzed by CYP2E1 in the liver, which is an alcohol-inducible cytochrome P-450 
isoform (Sohn et al. 2001; Rosenberg et al. 2008). MAM, which is an unstable 
compound that spontaneously decomposes to formaldehyde and methyldiazonium, is 
transported to the colon via the bloodstream (Rosenberg et al. 2008). Methyldiazonium 
is responsible for the alkylation of guanine and thymine and thereby facilitates base 
mispairings, which, if not repaired, result in initiation of tumorigenesis (Sohn et al. 2001; 
Neufert et al. 2007). Bissahoyo (2005) performed mouse experiments to standardize 
AOM treatment. They revealed significant dose- and strain-dependent susceptibility to 
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AOM, and predicted 10 mg AOM per kg body weight as the standard dose that is 
maximal tolerated for tumor induction. They showed four weekly intraperitoneally 
treatments as the best route of administration, and did not observe any sex-dependent 
differences. They revealed that AOM is not only a tumor initiator, but also a tumor 
promoter. Interestingly, AOM-induced tumors were predominantly found in the distal 
colon, which is also the predominant localization in humans. Furthermore, the tumors 
were pathologically similar to sporadic CRC in humans (Bissahoyo 2005; Neufert et al. 
2007). In addition, AOM-induced tumors also mirrored human CRC at the molecular 
level. As already described, mutations in the tumor suppressor gene APC occur early 
during colorectal tumorigenesis (see chapter 1.2.1 and Powell et al. 1992) and were 
predicted to be the initiating events in the development of CRC (Maltzman et al. 1997). 
APC is known to be mutated in more than 70% of sporadic cancers (Kheirelseid et al. 
2013). Maltzman et al. (1997) investigated the role of Apc in murine colorectal tumors 
induced by AOM by immunofluorescence staining of Apc. They observed Apc staining 
in the small intestine and in the colon. Interestingly, Apc staining was absent in 96.7% 
of the analyzed adenomas and carcinomas induced by AOM, indicating that wild type 
Apc is lost in AOM-induced colonic tumors, which mirrors the situation in human CRCs 
(Maltzman et al. 1997).  
Fifty percent of human colonic tumors that carry an intact APC gene reveal mutations 
of the β-catenin gene at codons 33, 41 and 45 leading to constitutive transcriptional 
activation (Takahashi et al. 2000b). Analyzing ten murine colonic tumors induced by 
AOM revealed that all tumors had mutations in the β-catenin gene at codons 33, 34, 
37 and 41 (Takahashi et al. 2000b). 
Cyclin D1 is a positive regulator of cell cycle progression. Cyclin D1 forms a complex 
with Cdk4 and Cdk6, which regulate the progression of the G1 phase and the                   
G1 / S phase transition. Overexpression of cyclin D1 was found in human colon cancer 
and concurrent overexpression of cyclin D1 and Cdk4 was reported in adenomatous 
polyps of the human colon (Wang et al. 1998). Interestingly, examination of               
AOM-induced murine tumors revealed a significant increase in cyclin D1 and             
Cdk4 mRNA levels compared to control colonic tissue (Wang et al. 1998).  
The K-RAS oncogene was also proven to play a role during the development of human 
CRC as described earlier (see chapter 1.2.1). In humans, mutations of K-RAS have 
been reported in 50% of CRCs (Luceri 2000). Takahashi et al. (2000a) investigated    
K-ras gene mutations in tumors induced by AOM in F344 rats and found that K-ras 
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gene mutations were as frequent in rat colonic carcinogenesis induced by AOM as in 
human CRCs. 
In addition, Takahashi et al. (2000a) observed elevated levels of inducible nitric oxide 
synthase (iNOS) and cyclooxygenase (COX)-2 in rat colon adenocarcinomas induced 
by AOM. Interestingly, expression of iNOS and COX-2 are known to be often increased 
in human colon tumors.  
Thus, the AOM-based model is a suitable tool to analyze sporadic CRC and 
advantages of AOM-induced carcinogenesis are for example high potency, simple 
route of administration, low price and the comparability to human colonic tumors at the 
molecular level. However, one major disadvantage is the lack of invasiveness and the 
rareness of metastases (Neufert et al. 2007).  
In addition to the AOM-based tumor model, which mimics sporadic human CRC, a 
colitis model based on dextran sodium sulfate (DSS) exists (Tanaka et al. 2003). DSS 
is a pro-inflammatory reagent with highly variable molecular weight that is extremely 
toxic to the epithelial lining of the colon, leading to severe colitis with bloody diarrhea 
(Neufert et al. 2007; Perše and Cerar 2012). Since the DSS model is known to reflect 
clinical and histopathological features seen in human chronic colitis (Perše and Cerar 
2012), this model is particularly used to study tumor progression driven by chronic 
colitis, which is known to be the case in ulcerative colitis and Crohn’s disease (Neufert 
et al. 2007). In rodents, DSS is given over the drinking water (Neufert et al. 2007). The 
response of mice to DSS highly varies and was predicted to be dependent on e.g. the 
molecular weight of DSS, DSS concentration and the duration of DSS administration, 
but also on the strain and the sex of the mice (Perše and Cerar 2012). Analyses of 
uptake and tissue distribution revealed that DSS penetrates the mucosal membrane in 
the intestine, and that DSS was mainly detected in the liver Kupffer cells and in 
macrophages in the mesenteric lymph node and colon (Kitajima et al. 1999). A 
disadvantage of this colitis model based on DSS is the fact that a long period or 
repeated administration of DSS is needed to induce colitis or colitis-associated CRC, 
and that the incidence of induced tumors is relatively low (Tanaka et al. 2003). Tanaka 
et al. (2003) developed a new mouse model based on the combination of AOM and 
DSS. This model for colitis-associated cancer consists of a single intraperitoneal 
administration of 10 mg AOM per kg body weight and a one-week administration of    
2% DSS over the drinking water. In week 20, colonic adenocarcinomas with             
100% incidence and adenomas with 38% incidence with the presence of dysplasia and 
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colitis with mucosal ulceration have developed. Examination of the developed tumors 
by immunohistochemistry and immunofluorescence stainings revealed that all of the 
induced colonic adenocarcinomas were positive for β-catenin, COS-2 and iNOS, but 
were negative for p53 (Tanaka et al. 2003).  
 
4.4.2 The IGF1R promotes progression of colonic tumors induced by AOM and 
AOM / DSS 
The present study revealed that IGF1R overexpression did not result in the induction 
of colonic tumor formation per se, indicating that IGF1R overexpression is not the 
initiating event for intestinal tumorigenesis. However, IGF1R overexpression might 
play a role during colonic tumor progression. For the verification of this hypothesis, 
IGF1R overexpressing (IGF1R-oe) and Igf1r knockout mice (Cre+/Igf1rfl/fl) were treated 
with AOM and AOM / DSS, respectively, to induce colonic tumor formation and 
inflammation. To screen for colonic tumors, colonoscopy was regularly performed. 
Macroscopic and histopathologic analyses were performed to examine if the 
IGF1R / Igf1r influences tumor growth and progression. 
Four weekly repeated intraperitoneal injections in IGF1R-oe and control                     
Villin-TRE-IGF1R mice with 10 mg AOM per kg body weight revealed colonic tumor 
formation within 35 weeks. Thirty-five weeks after the first AOM injection mice were 
sacrificed and tumor growth and progression were analyzed. The average colon 
length, which is used as an indicator for acute intestinal inflammation (Ito et al. 2006), 
revealed no significant differences between IGF1R-oe and control mice (see chapter 
3.10), indicating that IGF1R overexpression did not influence the susceptibility of the 
mice to AOM. Remarkably, the incidence for tumor formation of IGF1R-oe mice with 
approx. 55% was twice the incidence of control mice with approx. 27%, indicating that 
IGF1R overexpression promotes tumor formation. Strikingly, an extreme female 
preference for tumor development was observed since only female IGF1R-oe and 
control mice showed any tumor formation. This finding was strongly contradictory to 
the observations of Bissahoyo (2005), who did not observe any sex-dependent 
responses of mice to AOM. Of note, in the present study only five control males and 
even only one IGF1R-oe male mouse were included. To investigate if female            
Villin-TRE-IGF1R mice are indeed more sensitive to AOM, further studies with a higher 
number of animals have to be performed. Additionally, Bissahoyo (2005) observed 
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strong strain-dependent responses to AOM in AKR/J, SWR/J and A/J mouse strains, 
and Nambiar et al. (2003) reported that FVB/N mice showed a remarkable 
susceptibility to AOM, whereas C57BL/6J mice revealed low sensitivity to AOM. Since 
Villin-TRE-IGF1R mice were a crossing between the C57BL/6 and the FVB mouse 
strains, the observed sex-dependent responses to AOM could additionally depend on 
the mouse strain. A prevalence of tumor occurrence in the distal part of the colon was 
observed in the present study, whereas no tumor formation was seen in the proximal 
part. These observations are consistent with reports of other researchers (Nambiar et 
al. 2003; Bissahoyo 2005; Neufert et al. 2007). Impressively, this finding mirrored 
human sporadic CRC since human tumors are predominantly localized in the distal 
part of the colon (Neufert et al. 2007). IGF1R-oe mice revealed tumors with an increase 
in the average tumor size of approx. 23% compared to control mice. Strikingly, in 
contrast to control mice, one IGF1R-oe mouse even developed an intramucosal and 
invasive adenocarcinoma, indicating that IGF1R promotes colonic tumor progression 
and even tumor cell invasion.  
Furthermore, remarkable results were also obtained using the AOM / DSS model. 
Villin-TRE-IGF1R mice were intraperitoneally injected with 10 mg AOM per kg body 
weight and administered to two cycles of 2% DSS to induce colonic tumor formation 
and inflammation. Twelve weeks after AOM injection, several IGF1R-oe and control 
mice had developed tumors of a score of four to five (Becker et al. 2007). No difference 
concerning tumor initiation was observed between IGF1R-oe and control mice. The 
Villin-TRE-IGF1R mice revealed no sex-dependent responses to AOM / DSS, which 
was oppositional to the observations in AOM-only-treated Villin-TRE-IGF1R mice. 
Again, tumors were found to be predominantly localized in the distal part of the colon, 
which reflects the feature of human sporadic CRC. Histopathologically, control mice 
showed a reduced number of tumors with advanced stage, whereas IGF1R-oe mice 
developed an elevated number of intramucosal and even invasive adenocarcinomas. 
Additionally, tumors of IGF1R-oe mice exhibited a 66.2% increased average tumor size 
compared to control mice, indicating that the IGF1R influenced tumor progression. In 
order to analyze if IGF1R overexpression even promotes metastasis, liver tissues and 
lymph nodes in regional colonic fat tissue were examined for the presence of CRC 
cells. Metastases were not found, which was consistent with observations of other 
groups (Nambiar et al. 2003; Neufert et al. 2007). Remarkably, activating invasion and 
metastasis is one of the eight biological features of cancer cells (Hanahan and 
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Weinberg 2000, 2011). It could be shown that transfection of the human MDA-MB-435 
metastatic breast cancer cells with a dominant negative form of the IGF1R inhibited 
cellular adhesion to laminin and collagen. In vivo, injection of MDA-MB-435 cells 
transfected with the dominant negative form of the IGF1R did not suppress primary 
tumor growth, but significantly decreased metastasis to the lungs, livers and lymph 
nodes, demonstrating that the IGF1R plays a crucial role in adhesion, invasion and 
metastasis of breast cancer (Dunn et al. 1998). Furthermore, injection of the human 
CRC cell line HCT116 overexpressing the IGF1R into nude mice resulted in highly 
invasive tumors and the development of distant metastases whereas the implantation 
of parental HCT116 cells did not (Sekharam et al. 2003). To study CRC colonization, 
Nguyen et al. (2016) performed a large-scale in vivo RNAi screen and identified the 
IGF1R as a driver of metastatic liver colonization (Nguyen et al. 2016). In addition, a 
positive correlation of IGF1R expression and the lymph node status as well as the 
UICC stage was shown in a study of 120 rectal cancer patients (unpublished data of 
the working group). Consistent with these findings are the observations of the present 
study. Here, only IGF1R-oe mice formed invasive carcinomas after AOM / DSS 
administration, whereas control mice did not, pointing to the IGF1R as being essential 
for CRC cells to grow in an invasive manner and clearly indicating that IGF1R 
overexpression strongly promotes colonic tumor invasiveness. Despite the fact that 
IGF1R-oe mice developed invasive carcinomas, metastatic cells in the liver and lymph 
nodes in regional colonic fat tissue examined were not detected. The fact that 
AOM / DSS-induced tumors are known to rarely exhibit metastases (Thaker et al. 
2012) or the assumption that the tumors grew too fast might be the reasons for this 
finding. To investigate if IGF1R overexpression affects metastasis of CRC cells, 
another CRC model in which metastasis is common would be needed.  
Interestingly, western blot analysis revealed that AKT (pAKT) was highly activated, 
whereas ERK activation (pERK) was reduced in tumors induced by AOM / DSS in 
IGF1R-oe mice compared to control mice. Furthermore, the activation level of the PI3K 
signaling pathway was elevated in tumors derived in IGF1R-oe mice compared to the 
intestinal epithelial cells. These facts indicated that tumor progression was mediated 
via the PI3K signaling pathway rather than the MAPK signaling pathway. Deregulated 
AKT is known to contribute to the development and progression of cancer. Some 
investigations have demonstrated that elevated AKT activity was predominantly found 
in high grade, late stage and metastatic breast and ovarian tumors, whereas other 
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researchers did not find a correlation between elevated AKT activity and tumor stage 
or grade (Altomare and Testa 2005). Interestingly, Itoh et al. (2002) performed 
immunohistochemical analyses on a total of 65 human colorectal carcinomas and 
observed a significant correlation of AKT activity with several clinicopathological 
parameters, such as depth of invasion, venous vessel infiltration, tumor stage and 
lymph node metastasis. Furthermore, the AKT phosphorylation level was found to 
significantly correlate with the Ki 67 growth index. These findings indicate that AKT 
activation is associated with the progression of colorectal carcinomas by promoting 
tumor cell growth (Itoh et al. 2002). In the present study, AKT activity was increased in 
AOM / DSS-induced colonic tumors derived in IGF1R-oe mice compared to control 
mice (see chapter 3.14), predicting that IGF1R overexpression and thus activation of 
AKT might promote colonic tumor progression. These findings were consistent with 
observations of Saglam et al. (2007) who stained 99 human invasive colorectal 
carcinomas, 28 tubular colorectal adenomas and 18 samples of normal colonic 
mucosa with a monoclonal antibody against phospho-AKT. They found AKT activity 
predominantly in the invasive carcinomas, whereas 78% of normal colonic mucosa 
was pAKT negative, demonstrating increasing activation of AKT during CRC 
progression (Saglam et al. 2007). In the present study, western blot analysis was only 
performed on a small number of tumors and tumors examined were not discriminated 
regarding their stage. To clearly prove a correlation of AKT activity and colonic tumor 
progression, western blot analysis should be repeated with a higher number of tumor 
samples. Furthermore, the tumors should be discriminated regarding their stage to 
compare AKT activity between colorectal adenomas and carcinomas. Additionally, 
immunohistochemical stainings of low and high grade intraepithelial neoplasias and 
intramucosal and invasive carcinomas with an antibody against pAKT would also 
contribute to the clarification if increased AKT activity due to IGF1R overexpression is 
associated with CRC progression. 
Analyses of the tumors induced by AOM / DSS and also by AOM at the molecular level 
are lacking in the present study and should be performed in order to investigate the 
influence of IGF1R on e.g. the K-ras and β-catenin mutation status. 
Interestingly, AOM was shown to be a potent tumor promoter in addition to its role as 
a tumor initiator (Bissahoyo 2005). For this reason one could claim that not IGF1R but 
rather AOM is responsible for the tumor growth promoting effects observed in       
IGF1R-oe mice after AOM and AOM / DSS administration. Since not only               
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IGF1R-oe mice, but also control mice were treated with AOM and AOM / DSS in the 
present study, the increasing tumor size and the presence of even intramucosal and 
invasive adenocarcinomas in IGF1R-oe mice can be referred to IGF1R overexpression 
and not to AOM treatment. Furthermore, Nanda et al. (2016) reported recently that 
doxycycline enhanced the efficacy of DMH (metabolic precursor of AOM and MAM) in 
tumor progression, indicated by stimulated progression of colonic tumor growth from 
adenomas to adenocarcinomas. This finding could argue against the results of the 
present study since IGF1R overexpression in Villin-TRE-IGF1R mice was induced by 
continuous administration of doxycycline over the drinking water. Importantly, in this 
experiment not only the IGF1R-oe mice but also the control mice were administered to 
doxycycline. The control group consisted of mice that carried only the Villin-rtTA2-M2 
transgene, but not the TRE-IGF1R transgene and thus were impotent for the induction 
of IGF1R overexpression by doxycycline administration. Thus, the tumor growth 
promoting effects observed were the effect of IGF1R overexpression rather than the 
effect of doxycycline treatment. 
In order to prove the hypothesis that the Igf1r is essential in intestinal tumor 
development, Villin-CreERT-Igf1r mice were treated with both, AOM and AOM / DSS, 
to induce colonic tumor formation and inflammation, respectively. In the AOM-only 
setting, the time points of tumor formation strongly differed between individual mice 
regardless of their Igf1r status. There was no difference in tumor initiation between 
Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and control mice, indicating that the Igf1r is not essential for 
tumor development as seen in cell culture models (Reinmuth et al. 2002; Sachdev et 
al. 2004). Since only a small number of mice was used for the AOM-only setting and 
no difference in tumor initiation was observed between Cre+/Igf1rfl/fl, Cre+/Igf1rfl/+ and 
control mice, the AOM-based experiment was not continued.  
Treatment of Villin-CreERT-Igf1r mice with AOM / DSS resulted in the development of 
tumors within seven weeks after AOM injection, pointing to a strong susceptibility of 
C57BL/6 to AOM / DSS. Interestingly, C57BL/6 mice are known to be less sensitive to 
AOM (Nambiar et al. 2003; Neufert et al. 2007), whereas these mice are relatively 
susceptible to DSS (Suzuki et al. 2006). This shows that the AOM / DSS model even 
enables tumor growth in mouse strains that possess lower sensitivity to AOM (Neufert 
et al. 2007). Measurement of the colon length as an indicator for acute intestinal 
inflammation revealed no significant differences between Cre+/Igf1rfl/fl and control mice 
(see chapter 3.24), indicating that the Igf1r rather than inflammation is responsible for 
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the observed differences between Cre+/Igf1rfl/fl and control mice. As in the AOM-only 
setting, the AOM / DSS-based setting exhibited no hint that Igf1r expression in the 
intestine is essential for the development of tumors, i.e., both Cre+/Igf1rfl/fl and control 
mice developed tumors to a high extent (81% vs. 92%). A slight preference for tumor 
development was observed in female mice (100% (in both Cre+/Igf1rfl/fl and control 
mice) vs. 80% (male control mice) and 67% (male Cre+/Igf1rfl/fl mice)). Cre+/Igf1rfl/fl and 
control mice revealed only a slight difference in the number of developed tumors, but 
histopathological analyses showed that Cre+/Igf1rfl/fl mice developed an elevated 
number of high grade intraepithelial neoplasias and a reduced number of intramucosal 
and invasive adenocarcinomas compared to control mice. These findings support the 
prediction of IGF1R / Igf1r being a strong promoter of colonic tumor invasiveness 
based on the results of the histopathological analyses of tumors derived in                
Villin-TRE-IGF1R mice administered to AOM / DSS. The fact that no significant 
difference in tumor initiation between Cre+/Igf1rfl/fl and control mice was observed, but 
Cre+/Igf1rfl/fl mice developed a decreased number of intramucosal carcinomas 
compared to control mice supports the hypothesis that the IGF1R / Igf1r promotes 
colonic tumor progression rather than tumor formation.  
In addition, tumors of Cre+/Igf1rfl/fl mice revealed decreased phosphorylation levels of 
AKT (pAKT) and thus diminished signaling via the PI3K signaling pathway compared 
to control mice. Instead, the activation level of ERK was elevated in Cre+/Igf1rfl/fl mice, 
indicating that signaling was mediated via the MAPK signaling pathway. Again, these 
findings fit to the elevated levels of activated AKT in tumors derived in                          
Villin-TRE-IGF1R mice after AOM / DSS administration compared to normal intestinal 
epithelial cells, and led to the suggestion that tumor progression promoted by IGF1R 
overexpression is mediated via the PI3K signaling pathway in tumors derived in       
Villin-TRE-IGF1R mice administered to AOM / DSS. In mice harboring the Igf1r 
knockout, signaling via the downstream PI3K pathway is diminished indicated by 
reduced AKT activation (pAKT) and thus results in inhibited progression of the colonic 
tumors, indicated by the reduced number of intramucosal carcinomas. Controversial is 
the fact that ERK activation (pERK) was highly elevated in colonic tumors derived in 
Cre+/Igf1rfl/fl mice compared to control mice since MAPK signaling is known to be 
activated by RTKs and to play an important role in the progression of CRC (Fang and 
Richardson 2005). Since the Igf1r was not available in Cre+/Igf1rfl/fl mice to activate the 
ERK cascade, and the number of intramucosal carcinomas was reduced in    
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Cre+/Igf1rfl/fl mice compared to control mice, the result of the western blot and 
subsequent densitometrical analyses of ERK phosphorylation should be analyzed in 
more detail. It is known, that the IGF1R is not capable of activating MAPK signaling 
itself, instead it was shown that an active EGFR is essential in CRC cells (Kaulfuß et 
al. 2009). To clearly investigate the role of MAPK signaling in colonic tumor 
progression, western blot analysis with antibodies against phosphorylated ERK 
(pERK) and total ERK (ERK) should be performed with a high number of colonic tumors 
of different stages. 
Again, the molecular analysis of the mutation status of e.g. Apc and K-ras is lacking in 
the present study. Analysis of the K-ras mutation status of the colonic tumors derived 
after AOM / DSS administration could also contribute to the clarification if MAPK 
signaling is involved in CRC progression since it is known that constitutively active      
K-RAS due to single nucleotide point mutations result in the activation of downstream 
pro-proliferative pathways (Tan and Du 2012). 
In summary, the present study revealed that the IGF1R / Igf1r plays no crucial role 
during colonic tumor formation, and IGF1R overexpression is not sufficient for the 
induction of colonic tumor development. Instead, results of the IGF1R overexpression 
and the Igf1r knockout experiments of the present study impressively show that the 
IGF1R / Igf1r strongly promotes colonic tumor progression and that tumor progression 
is mediated via the PI3K signaling pathway. 
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Fig. 79: Schematic overview of the influence of IGF1R overexpression and Igf1r knockout in the 
intestine alone or after AOM and AOM / DSS administration, respectively, on colonic tumor 
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(a) IGF1R overexpression in the intestine alone did not induce tumor formation. IGF1R overexpression 
in the intestine after AOM and AOM / DSS administration, respectively, resulted in an increased number 
of tumors, demonstrating moderate influence of the IGF1R on colonic tumor initiation, an increased 
number of tumors with advanced stage, indicating an influence of the IGF1R on tumor progression, and 
in the development of invasive carcinomas, pointing to influence of the IGF1R on tumor invasion.            
(b) The Igf1r knockout in the intestine after AOM administration resulted in a decreased number of 
tumors, whereas it led to an increased number of tumors after AOM / DSS administration, indicating that 
the Igf1r might have a moderate influence on tumor initiation. The Igf1r knockout in the intestine after 
AOM and AOM / DSS administration, respectively, led to a decreased number of tumors with advanced 
stage, clearly demonstrating a role of the Igf1r on tumor progression. The effect of the Igf1r knockout on 
tumor invasion was not analyzed in the AOM-only setting, whereas no invasive carcinomas were 
detected in tumors derived in mice after AOM / DSS administration, indicating that the Igf1r has influence 
on colonic tumor invasion. #= number. n.a.= not analyzed. Modified after Johns Hopkins Medicine 
Gastroenterology & Hepatology. 
 
4.4.3 Why does IGF1R overexpression in colorectal epithelial cells not induce 
tumor development? A comparison with the literature 
Baserga (1995) proved that the Igf1r is obligatory for the transformation by the 
SV40 T antigen or the ras oncogene in vitro. In vivo, Carboni et al. (2005) 
demonstrated that constitutively activated IGF1R specifically in the mammary and 
salivary glands of transgenic mice resulted in the development of salivary and 
mammary adenomas and adenocarcinomas. Since Jones et al. (2007) showed that 
IGF1R overexpression is sufficient for the induction of mammary tumor formation in 
vivo, we expected that IGF1R overexpression is also sufficient to induce intestinal 
tumor formation in vivo. Against our expectation, IGF1R overexpression in the mouse 
intestine per se did not result in intestinal tumor development in the present study. 
These findings lead to the following questions: 
1. Why was IGF1R overexpression sufficient to induce mammary tumor 
formation, but was not sufficient for the induction of intestinal tumor 
development? 
2. Does the expression pattern of the two different promoters that guide IGF1R 
overexpression in the mammary gland and intestine, respectively, play a role 
for the successful / failed induction of tumor formation? 
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These questions point to the necessity of a comparison of the mouse mammary tumor 
virus (MMTV) promoter that directed the constitutively activated IGF1R expression and 
IGF1R overexpression in the mammary glands in the studies of Carboni et al. (2005) 
and Jones et al. (2007), respectively, and the villin promoter that controlled intestine-
specific IGF1R overexpression in the present study.  
The MMTV promoter was shown to drive transgene expression throughout the 
epithelium of the mammary gland (Albanese et al. 2000). MMTV-guided transgene 
expression was additionally detected in the salivary gland (Albanese et al. 2000), the 
seminal vesicle and thymus (Gunther et al. 2002), but not in the liver, heart, spleen, 
kidney, ureter, ovary or uterus (Albanese et al. 2000). However, the expression level 
of the transgene in the salivary gland, seminal vesicle and thymus were very low, 
confirming that MMTV-driven transgene expression was mammary gland specific 
(Albanese et al. 2000; Gunther et al. 2002). In addition, Gunther et al. (2002) proved 
MMTV-guided transgene expression in all stages of postnatal mammary gland 
development, including puberty, pregnancy, lactation and postlactational involution 
(Gunther et al. 2002). 
The MMTV is an oncoRNAvirus and belongs to the Retroviridae family. Once activated, 
MMTV causes breast tumors. The predominant replication site of MMTV are the 
alveolar epithelial cells of the mammary gland (Taneja et al. 2009). These alveolar 
epithelial cells are functionally differentiated secretory luminal cells which form a single 
layer in the alveolar structures (Gajewska et al. 2013).  
Comparing the activity of the MMTV promoter with the activity of the villin promoter 
reveals that both promoters are more or less tissue-specific. The MMTV promoter 
predominantly drives transgene expression in the mammary gland, only weak MMTV 
promoter-directed transgene expression was detected in the salivary gland, seminal 
vesicle and thymus (Albanese et al. 2000; Gunther et al. 2002). The villin promoter is 
mainly intestine-specific, it drives transgene expression in the small intestine and 
colon. However, villin-guided expression was also observed in the kidney (El Marjou 
et al. 2004; Roth et al. 2009). Interestingly, both promoters guide transgene expression 
in epithelial cells (Albanese et al. 2000). The MMTV promoter drives transgene 
expression in mammary epithelial cells, whereas the villin promoter targets intestinal 
epithelial cells (El Marjou et al. 2004; Roth et al. 2009). In addition, these epithelial 
cells are secretory cells in the mammary epithelium, namely luminal epithelial cells, 
and in the intestinal epithelium, namely goblet cells, enteroendocrine cells and Paneth 
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cells. Remarkably, villin was proven to also be active in the progenitor cells, leading to 
villin-guided transgene expression for more than 60 days despite the rapid renewal of 
the intestine (El Marjou et al. 2004). Interestingly, MMTV was also predicted to infect 
stem cells in the mammary gland (Callahan and Smith 2008), indicating that the MMTV 
promoter also drives transgene expression in mammary gland stem cells. 
Taken together, this comparison of the MMTV promoter with the villin promoter 
indicated that both promoters share particular features. The only difference was their 
tissue-specificity. Thus, the villin promoter seemed not to be the reason for the fact that 
villin-guided IGF1R overexpression was not sufficient to induce intestinal tumor 
formation. This finding led again to the question why IGF1R overexpression induced 
mammary but not intestinal tumor formation. Therefore, we hypothesized that the 
downstream PI3K and MAPK signaling pathways, which mediate the cell to proliferate, 
were not activated although the IGF1R was overexpressed in intestinal epithelial cells. 
For this reason, in the present study, the expression level of IGF1R as well as of 
activated and total AKT and ERK, respectively, were examined in IGF1R-oe and 
control Villin-TRE-IGF1R mice which were additionally injected with IGF-1. De facto, 
serum IGF-1 concentration was found to be significantly higher in CRC patients 
compared to healthy controls. Interestingly, serum IGF-1 and mucosal IGF1R mRNA 
levels were shown to significantly correlate in CRC patients (Zhang et al. 2013). In 
vitro, Li (2013) demonstrated that IGF-1 promoted migration and invasion of the human 
CRC cell line LoVo. Furthermore, they showed that daily administration of IGF-1 to 
LoVo cell xenograft mice resulted in significantly higher lymphangiogenesis (Li 2013).  
In the present study, IGF1R-oe and control Villin-TRE-IGF1R mice were administered 
to doxycycline to induce IGF1R overexpression in the intestinal epithelium. In addition, 
Villin-TRE-IGF1R mice were intravenously injected with 4.8 µg human IGF-1 (GroPep, 
Thebarton, Australia). Afterwards, proteins of small intestinal and colonic epithelial 
cells were extracted and western blot analysis was performed (Fig. 80).  
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Fig. 80: Western blot analysis of epithelial cells of the small intestine and colon of                        
Villin-TRE-IGF1R mice injected with IGF-1. 
IGF1R-oe (n=4) and control (n=4) Villin-TRE-IGF1R mice were administered to doxycycline and 
intravenously injected with IGF-1. Immediately after IGF-1 injection, mice were sacrificed, the small 
intestine (SI) and colon (C) were excised from the animals and proteins were extracted from the epithelial 
cells. Western blot analysis was performed. IGF1R-oe mice injected with IGF-1 revealed high IGF1Rβ 
expression compared to control mice injected with IGF-1 as well as IGF1R-oe and control mice which 
were not injected with IGF-1. The AKT phosphorylation level (pAKT) is highly increased in IGF1R-oe 
mice injected with IGF-1. Activation of ERK (pERK) is strong in control and IGF1R-oe mice as well as 
in the small intestinal epithelial cells of IGF1R-oe mice injected with IGF-1. HSC-70 was used as loading 
control.  
 
Interestingly, high IGF1Rβ expression was detected in IGF1R-oe mice which were 
injected with IGF-1, whereas control and IGF1R-oe mice not injected with IGF-1 as 
well as control mice injected with IGF-1 showed low or even no IGF1Rβ expression. 
Furthermore, AKT was highly activated (pAKT) in IGF1R-oe mice injected with IGF-1, 
whereas the other treatment groups revealed low phosphorylation levels of AKT. In 
fact, IGF1R overexpression was confirmed in epithelial cells of the small intestine and 
colon by immunohistochemical (see chapter 3.4) and immunofluorescence staining 
(see chapter 3.6) as well as western blot analysis (see chapter 3.5), but not only 
overexpression but rather activation of the IGF1R is needed for activation of the 
downstream signaling pathways. The finding that AKT was only highly phosphorylated 
in IGF1R-oe mice injected with IGF-1 could indicate that IGF1R-oe mice indeed 
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further enhanced with elevated IGF-1-levels. Furthermore, this result could be the 
reason for the fact that IGF1R overexpression in the intestinal epithelium of IGF1R-oe 
mice did not result in the development of intestinal tumors. Interestingly, in the 
mammary glands overexpression of the IGF1R alone was sufficient to induce 
mammary tumor formation (Jones et al. 2007), indicating that in the mammary gland 
high levels of endogenous Igf, which is able to activate the overexpressed IGF1R, 
might be present. For this reason, analysis of the endogenous Igf-level in the intestine 
would be of high interest. Of note, Jones et al. (2007) used transgenic mice with a    
FVB background, whereas in the present study IGF1R overexpression was induced in 
mice with a mixed FVB and C57BL/6 background. This leads to the suggestion that 
the different mouse strains might display strain-dependent Igf-levels, which can 
influence the activity of the IGF1R.  
Controversial is the finding that the phosphorylation level of ERK (pERK) is high in 
small intestinal and colonic epithelial cells of control and IGF1R-oe mice which were 
not injected with IGF-1 as well as in small intestinal epithelial cells of IGF1R-oe mice 
injected with IGF-1 (Fig. 80). The fact that ERK activation is low in colonic epithelial 
cells of IGF1R-oe mice injected with IGF-1 might also explain why IGF1R 
overexpression per se did not induce colonic tumor formation. 
Taken together, it would be of high interest to analyze if IGF-1 overexpression in 
addition to IGF1R overexpression in the intestine would induce colonic tumor 
formation. Therefore, a tri-transgenic mouse line or the continuous injection of the 
ligand IGF-1 is needed. 
 
4.5 Mouse models of CRC – which model to choose? 
One main aim of the present study was to analyze which role the IGF1R / Igf1r plays 
during the development and maintenance of the intestine, colonic tumor formation and 
progression in vivo. In order to answer these questions, a suitable mouse model had 
to be chosen.  
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4.5.1 Directing the IGF1R overexpression and the Igf1r knockout to the intestinal 
epithelium 
In order to investigate the role of the IGF1R during intestinal development and 
maintenance as well as during intestinal tumor formation and progression in vivo, we 
wanted to specifically overexpress the human IGF1R and to knockout endogenous 
Igf1r, respectively, in the murine intestinal epithelium. For this purpose a suitable 
promoter had to be selected. To date, several promoters that guide transgene 
expression in the intestine are known. In the following chapter the different established 
mouse lines in which transgene expression is under the control of an intestine-specific 
promoter will be discussed: 
Pinto et al. (1999) reported that a 9 kb regulatory region of the mouse villin gene is 
sufficient to direct high and tissue-specific transgene expression in epithelial cells 
along the crypt-villus axis in the small intestine and colon. Additionally, this region was 
found to maintain a gradient of transgene expression from the crypts to the tips of the 
villi that is precisely similar to that exhibited by the murine villin gene (Pinto et al. 1999). 
Madison (2002) generated a 12.4 kb variant of the regulatory region of the villin gene 
that was proven to drive high expression of two reporter genes within the entire 
intestinal epithelium. Both the 9 kb and the 12.4 kb promoter variants have been 
successfully used to generate several intestine-specific transgenic mouse models 
(Roth et al. 2009). El Marjou et al. (2004) generated a mouse expressing the tamoxifen-
dependent cre recombinase under the 9 kb villin promoter construct and thus provided 
an inducible model for the tissue- and time-specific cre recombinase-mediated 
recombination in the intestinal epithelium. Interestingly, the recombined locus lasted, 
despite rapid and continuous intestinal renewal, for 60 days after tamoxifen 
administration, indicating that epithelial progenitor cells have been targeted (El Marjou 
et al. 2004). Roth et al. (2009) generated a transgenic doxycycline-inducible mouse 
model that expresses the rtTA2-M2 under the control of the 12.4 kb villin promoter, and 
proved transgene expression throughout the entire intestine from the pyloric area to 
the distal colon and rectum. Furthermore, expression was observed in all epithelial 
cells of the small intestine and colon, with decreased levels in the crypts of the small 
intestine and the lower half of colonic crypts, respectively (Roth et al. 2009). The 
advantage of the villin promoter is due to the fact that transgene expression is restricted 
to epithelial cells throughout the intestine. Only a small amount of villin expression was 
found in the proximal tubules of the kidney. However, the big disadvantage of the villin 
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promoter is the finding that transgene expression is not limited to epithelial cells of the 
colon, but was also observed in epithelial cells of the small intestine and in the kidney. 
For this reason several attempts have been performed to generate a model with a more 
limited expression pattern (Johnson and Fleet 2013): 
Saam and Gordon (1999) generated a mouse model that expresses the rtTA under the 
control of transcriptional regulatory elements from the fatty acid-binding protein gene 
(Fabp) as well as the cre recombinase under the control of tet operator sequences. 
This mouse model allowed the induction of the recombination only in the intestine in 
the presence of doxycycline. Upon doxycycline administration, recombination occurred 
in the small intestinal, cecal and colonic epithelium. The recombined locus was shown 
to persist for at least 60 days after doxycycline withdrawal, indicating that 
recombination has occurred in the intestinal epithelial progenitor cells (Saam and 
Gordon 1999). 
Means et al. (2008) generated the so called K19CreERT mouse in which the tamoxifen-
dependent CreERT was knocked into the endogenous cytokeratin 19 locus. K19 is 
known to be highly expressed in the ducts of the adult pancreas and of the liver. The 
K19CreERT mouse revealed recombination in epithelial cells of pancreatic and hepatic 
ducts, the stomach and the intestine (Means et al. 2008). 
Barker et al. (2007) generated a tamoxifen-inducible mouse in which expression of the 
lacZ reporter was under the control of Lgr5-expressing cells. Therefore, they integrated 
the enhanced green fluorescent protein (EGFP)-IRES-creERT2 cassette into the first 
exon of the Lgr5 gene. Subsequently, they crossed the                                                       
EGFP-IRES-creERT2 knock-in allele with the cre-activatable Rosa26-lacZ reporter 
strain. Thus, by injecting tamoxifen the CreERT2 fusion protein was activated in        
Lgr5-expressing cells. They found lacZ expression at the typical CBCC position, 
indicating that Lgr5-positive cells are the small intestinal and colonic stem cells (Barker 
et al. 2007). However, Lgr5 was further found to be expressed in e.g. hair follicle and 
mammary glands and is therefore a more general marker of adult stem cells rather 
than an intestine-specific stem cell marker (Barker et al. 2007; Johnson and Fleet 
2013). 
Hinoi et al. (2007) generated a mouse that drives cre recombinase expression under 
the CDX2P-NLS promoter and that carries a loxP-modified Apc allele. The human 
CDX2 homeobox gene is known to be expressed in epithelial cells throughout the adult 
small intestine and colon. They found that mice carrying the                                          
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CDX2P-NLS Cre recombinase transgene and a floxed Apc allele develop colorectal 
adenomas and even carcinomas in approx. 15 to 20% of mice. Unfortunately, they 
observed β-gal reporter expression in the tail bud and caudal part of the neural tube in 
CDX2P-NLS Cre recombinase transgenic embryos, whereas transgene expression 
was limited to distal small intestine, cecum, colon and rectum in adult mice. 
Furthermore, they also found tumor development in the small intestine and predicted 
that the small intestinal tumor burden inhibits the development and progression of 
colorectal tumors in the mouse (Hinoi et al. 2007). 
Xue et al. (2010) generated a transgenic mouse in which cre recombinase expression 
is restricted to epithelial cells of the colon. Therefore, a 10.6 kb colon-specific promoter 
and a 2.5 kb erythroid / colon enhancer fragment of the mouse carbonic anhydrase 1 
(mCA1) gene, which is conserved between mouse and human, were used to drive cre 
recombinase expression (CAC). They found transgene expression limited to epithelial 
cells of the colon. Afterwards, the CAC mice were crossed with APC580S mice             
(see chapter 4.5.3), which carry loxP sites flanking the introns 13 and 14 of the             
Apc gene, to generate heterozygous (CAC;APC580S/+) and homozygous 
(CAC;APC580S/580S) Apc knockout mice, and observed adenomas predominantly in the 
distal part of the colon. However, carcinomas were not detected in this mouse model 
(Xue et al. 2010). 
In the present study, the villin promoter was chosen to drive intestinal-specific IGF1R 
overexpression and the Igf1r knockout, respectively. As previously described, several 
intestine-specific promoters are known, leading to the question if the villin promoter is 
the accurate promoter to drive transgene expression in the present study. 
The main advantage of the villin promoter is the fact that it is known to drive stable and 
homogeneous expression of transgenes in all epithelial cells of the small intestine and 
colon along the crypt-villus axis (El Marjou et al. 2004). However, this advantage could 
be interpreted at the same time as a disadvantage since tumor development occurs 
predominantly in the distal colon and rectum in human sporadic CRC and familial 
adenomatous polyposis (FAP). In addition, the villin promoter was found to be active 
in the putative undifferentiated stem cell compartment of the intestinal epithelium 
(El Marjou et al. 2004; Roth et al. 2009). This fact is a big advantage of the villin 
promoter, because it was shown that villin-guided transgene expression thus lasted for 
more than 60 days (El Marjou et al. 2004) despite the remarkable constant and rapid 
renewal capacity of intestinal epithelial cells (Bustos-Fernández 1983; Medema and 
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Vermeulen 2011). If transgene expression is directed by a promoter that is only active 
in differentiating epithelial cells in the intestine, the recombination efficacy could 
become too low due to the loss of differentiating epithelial cells during intestinal 
renewal (El Marjou et al. 2004). A general disadvantage of the villin promoter is the 
fact that it also drives transgene expression in the proximal tubules of the kidney (Roth 
et al. 2009), indicating that the villin promoter is not intestine-specific. In addition,       
villin-guided transgene expression was observed to be stronger in the differentiated 
cells compared to cells of the crypts in the small intestine and cells of the lower half of 
the crypts in the colon (El Marjou et al. 2004; Roth et al. 2009). Regarding the present 
study, this finding is a big disadvantage of the villin promoter since endogenous Igf1r 
reveals an opposing expression pattern with high expression in the crypts of the small 
intestine and at the bottom of the crypts of the colon and low expression in the villi of 
the small intestine and at the tip of the crypts of the colon (see chapter 4.3). These 
opposing expression gradients of villin and endogenous Igf1r lead to the assumption 
that the Igf1r knockout may be impaired in the crypts because villin expression is low 
(for detailed discussion see chapter 4.5.2). Furthermore, also IGF1R overexpression 
is suggested to be not optimal, because villin-guided ectopic IGF1R is predominantly 
expressed in the villi of the small intestine and at the tip of the colonic crypts                
(see chapter 3.6), whereas endogenous Igf1r is mainly expressed in the crypts of the 
small intestine and at the bottom of the colonic crypts (see chapter 4.3). Thus,           
villin-guided ectopic IGF1R expression reveals a different localization compared to 
endogenous Igf1r expression, which might have influenced the results of the present 
study.  
Comparison of the villin promoter with the other described promoters shows that also 
the other promoters exhibit advantages and disadvantages. The main advantages and 
disadvantages of the different promoters are summarized in table 2. The advantage of 
the Fabp promoter is that it also targets the progenitor cells of the intestine, leading to 
recombination that lasts for more than 60 days, which was also shown for the villin 
promoter. The disadvantage of the Fabp promoter is that it drives transgene expression 
in the small intestine, cecum and colon (Saam and Gordon 1999). Transgene 
expression under control of the CDX2P-NLS promoter is found in epithelial cells 
throughout the adult small intestine and colon, which is also true for the villin promoter. 
Interestingly, CDX2P-NLS Cre (CPC) mice and Villin-Cre mice were crossed with mice 
carrying loxP-modified Apc alleles (ApcloxP/loxP) and tumor development was compared 
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between these two mouse lines. CPC;Apc mice developed 5 to 8 tumors per mouse in 
the colon and 3 tumors per mouse in the small intestine, whereas Vilin-Cre;Apc mice 
revealed formation of approx. 36 tumors per mouse, but of which the vast majority 
developed in the small intestine (Hinoi et al. 2007). On the one hand, this comparison 
shows that the CDX2P-NLS promoter seems to be the better choice, because the 
majority of tumors developed in the colon. On the other hand, the villin promoter 
appears to be the superior choice, because the incidence of tumor formation is much 
higher than under the control of the CDX2P-NLS promoter. The Lgr5 promoter drives 
transgene expression in the Lgr5-positive CBC stem cells. However, Lgr5 is also 
expressed in hair follicle and mammary glands, and thus, Lgr5 is more a general 
marker of adult stem cells rather than an intestine-specific stem cell marker (Barker et 
al. 2007). Transgene expression under the control of the mCA1 promoter was found to 
be limited to epithelial cells of the colon (Xue et al. 2010) which is a big advantage over 
the villin promoter. Furthermore, mCA1-guided β-galactosidase expression was found 
to reach from the crypt base to the luminal surface (Xue et al. 2010) which is more 
consistent with the expression pattern of endogenous Igf1r than villin expression. This 
comparison leads to the suggestion that the mCA1 promoter could be a better choice 
to drive transgene expression than the villin promoter in the present study. Of note, a 
mouse model that expresses a reverse tetracycline transactivator under the control of 
the mCA1 promoter does not exist to date. Thus, for the present study a mouse for the 
mCA1-guided overexpression of the IGF1R had to be generated first.  
 
Table 2: Summary of the advantages and disadvantages of the different intestine-specific 
promoters. 
Promoter Advantage Disadvantage Reference 
Villin villin-guided transgene 
expression in all epithelial 
cells of the intestine 
 




expression in small 
intestine, colon and kidney 
 
reduced expression levels 
in crypts of the small 
intestine and in lower half of 
colonic crypts 
El Marjou et al. 
2004 
 
Roth et al. 
2009 
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mouse with villin-guided 
CreERT2 transgene 
expression available 
Fabp is active in progenitor cells Fabp-guided transgene 
expression in small 
intestine, cecum and colon  
Saam and 
Gordon 1999 
Lgr5 is active in CBCCs Lgr5-guided transgene 
expression also in hair 
follicle and mammary 
glands 





transgene expression in 
epithelial cells in adult 
small intestine and colon 
CDX2P-NLS-guided 
transgene expression also 
in tail bud and caudal part 
of neural tube in embryos 
 
CDX2P-NLS-guided 
transgene expression also 
in small intestine, cecum, 
colon and rectum in adults 
Hinoi et al. 
2007 
mCA1 mCA1-guided transgene 
expression limited to 
epithelial cells of the colon 
mouse with mCA1-guided 
rtTA2 transgene 
expression not available 
Xue et al. 2010 
 
 
Taken together, the promoters described above exhibit advantages and disadvantages 
over the villin promoter. In regard to choose the right promoter the work of Janssen et 
al. (2002) was of high interest. They generated a transgenic mouse line expressing     
K-rasV12G, which is the most frequent point mutation in human tumors, under the control 
of the 9 kb murine villin promoter variant. At nine months of age more than 80% of the 
transgenic mice had developed tubuloglandular adenomas and malignant 
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adenocarcinomas predominantly in the small intestine (90%), but also in the colon (7%) 
(Janssen et al. 2002). However, Cheung et al. (2010) generated a mouse line with a 
cre-regulable null allele of the Apc gene and crossed these Apcfle1-15 mice to Villin-Cre 
transgenic mice. At approx. 4 months of age, the Apc+/fle1-15; Villin-Cre mice developed 
several adenomas in their small intestines and colons. However, carcinomas were not 
detected (Cheung et al. 2010). These examples in which transgene expression guided 
by the villin promoter induced intestinal tumor formation further indicate that the villin 
promoter was a suitable promoter for the present study. Since the Villin-rtTA2-M2 
mouse line expressing the reverse tetracycline transactivator and the Villin-CreERT2 
mouse line expressing the cre recombinase under the control of the villin promoter, 
respectively, were available, we decided to utilize these mouse lines for the present 
study to generate the IGF1R overexpressing and Igf1r knockout mice.  
 
4.5.2 Different expression patterns of endogenous Igf1r and villin 
In the present study, the villin promoter was used to direct the overexpression of the 
human IGF1R and the knockout of the endogenous Igf1r, respectively. Villin is a 
cytoskeletal protein localized in the intestinal and kidney brush border of epithelial cells, 
contributing in the absorption process (Ferrary et al. 1999; Pinto et al. 1999; Madison 
2002). During mouse embryogenesis, villin was first detected in endodermal cells at 
day 6 in the early post implantation stage (Maunoury et al. 1988). Villin expression is 
upregulated during remodeling of the intestinal epithelium and the formation of the villi. 
Once the intestinal crypts have been established, villin is expressed along the crypt-
villus axis with higher expression at the tips of the villi than in the crypts (Braunstein et 
al. 2002; Madison 2002). Furthermore, epithelial cells of all four lineages express villin 
(Braunstein et al. 2002). In the human, villin expression was studied during embryonic 
development using a cell extract prepared from the intestinal tube of an 8-week-old 
human fetus. At 8 weeks, villin expression was already detected, and in a 16-week-old 
fetus, villin expression was observed in the small intestine and colon, demonstrating 
the early expression of villin during embryonic development (Robine et al. 1985). In the 
adult rat intestine, villin expression was found in epithelial cells, but not in the 
underlying mucosa. In addition, mature enterocytes at the tips of the villi revealed a 
10-fold higher amount of villin expression than immature crypt cells (Robine et al. 
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1985). Nevertheless, villin is also expressed in stem cells and proliferative cells 
localized in the intestinal crypts (Pinto et al. 1999). 
The crypt-villus gradient of villin expression is of high interest regarding the Igf1r 
knockout experiments of the present study. Here, the knockout of endogenous Igf1r 
was directed to the intestinal epithelium by using the villin promoter. As already 
described in chapter 4.3, staining of endogenous Igf1r using an antibody against the 
Igf1rβ revealed an opposing gradient with decreasing Igf1r expression from the 
intestinal crypts to the villi in the small intestine and from the bottom to the top of the 
colonic crypts, respectively, compared to that of villin expression. The existence of 
these opposing expression gradients supports the idea that in the present study the 
villin-guided knockout of endogenous Igf1r in epithelial cells of the intestine might be 
impaired. In the intestinal crypts strong endogenous Igf1r expression was observed, 
whereas weak villin expression was found, which guides the Igf1r knockout by 
controlling the amount of expressed cre recombinase. These observations lead to the 
assumption that a low amount of cre recombinase in the intestinal crypts is not able to 
delete exon 3 of the highly expressed Igf1r gene. This hypothesis would further explain 
why the knockout of the endogenous Igf1r in the present study did not significantly 
influence the number of the different cell types in the intestinal crypts, whereas 
differences were observed in the small intestine (see chapter 3.22). In addition, a 
difference in the number of tumors derived in control and Cre+/Igf1rfl/fl                                          
Villin-CreERT-Igf1r mice was also not visible in the present study (see chapter 3.23 
and 3.24), supporting the hypothesis that the Igf1r knockout could be impaired. For the 
analysis if the Igf1r knockout is in fact extenuated, staining of small intestinal and 
colonic tissue sections of control and Cre+/Igf1rfl/fl Villin-CreERT-Igf1r mice for 
endogenous Igf1r should be performed. Unfortunately, staining of intestinal tissue 
sections using an antibody against endogenous Igf1rβ did not reveal valuable results 
in the present study.  
In conclusion, the opposing expression patterns of endogenous Igf1r and villin point to 
the assumption that the villin promoter is not suitable to induce a sufficient Igf1r 
knockout in the intestinal epithelium. Since the villin promoter was primarily used for 
the overexpression of human IGF1R in the present study, it was also chosen for the 
Igf1r knockout experiment. However, several intestine-specific promoters are known 
(see 4.5.1). The Lgr5-EGFP-IRES-creERT2 mouse was demonstrated to drive 
transgene expression in Lgr5-expressing CBCCs (Barker et al. 2007), which are 
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localized at the bottom of the intestinal crypts (see chapter 4.2 and Medema and 
Vermeulen 2011). Using the Lgr5-EGFP-IRES-creERT2 mouse, the Igf1r knockout 
would be guided to the intestinal crypts where high Igfr expression was observed. In 
order to prove if the Igf1r knockout in the intestinal epithelium indeed has no significant 
influence on epithelial cell proliferation and differentiation as well as on colonic tumor 
formation, the Igf1r knockout experiments of the present study should be repeated with 
the Lgr5-EGFP-IRES-creERT2 mouse.  
 
4.5.3 Combining IGF1R models with well characterized models of CRC to study 
IGF1R-induced tumor progression 
The present study displayed that IGF1R overexpression per se is not sufficient to 
induce CRC development. Instead, we hypothesized that the IGF1R / Igf1r is involved 
in tumor progression. To analyze this hypothesis in detail, we had to cross our IGF1R 
mouse models (Villin-TRE-IGF1R and Villin-CreERT-Igf1r mouse models) either with 
a mouse model that develops CRC or to use a chemically induced CRC mouse model. 
A detailed literature search revealed several genetic as well as chemically induced 
CRC mouse models. In the next section the advantages and disadvantages of these 
mouse models are described and the choice for the AOM / DSS model is explained. 
The APC tumor suppressor gene is known to be mutated in more than 70% of sporadic 
CRCs (Kheirelseid et al. 2013). The majority of mutations in APC result in a truncated 
protein (Chung 2000; HGMD® Professional 2016.1). Patients with familial 
adenomatous polyposis (FAP) are carriers of a germline mutation in one APC allele 
and develop large numbers of adenomas in their colon and rectum (Heyer et al. 1999; 
Karim and Huso 2013). The so called multiple intestinal neoplasia (Min) mouse was 
the first mouse that contained a mutation in the Apc gene. The mutation was identified 
to be a nonsense mutation resulting in a truncated protein of 850 amino acids. The 
ApcMin homozygous mice are embryonically lethal, whereas ApcMin heterozygotes are 
born normally, but show a reduced lifespan of approx. 150 days. ApcMin heterozygous 
mice can develop more than 100 adenomas in the small intestine (Heyer et al. 1999), 
which is similar regarding the number of adenomas in FAP patients (Karim and Huso 
2013). A disadvantage of the ApcMin mouse is the fact that the adenomas are localized 
in the small intestine, whereas FAP patients develop adenomas in the colon and 
rectum. 
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In recent years, many mouse models which carry specific Apc mutations leading to a 
truncated protein were generated, such as the Apc1638N (Fodde et al. 1994), ApcΔ716 
(Oshima et al. 1995), Apc580S (Shibata et al. 1997), Apc1638T (Smits et al. 1999), 
ApcΔ474 (Sasai et al. 2000), Apc1322T (Pollard et al. 2009), ApcΔ14/+ (Colnot et al. 2004) 
and the ApcΔ15 mouse (Robanus-Maandag et al. 2010). Almost all mouse models 
revealed a predominant or even absolute induction of tumor formation in the small 
intestine, such as the ApcMin, Apc1638N, ApcΔ716 and Apc1322T mice. Since sporadic CRC 
and FAP are characterized by tumor formation mainly in the colon and rectum, these 
models are not suitable to mimic the human features of CRC. Another disadvantage is 
the fact that homozygous mice of some mouse models were not viable which was 
described for ApcMin, Apc1638N, ApcΔ716 and ApcΔ14 mice. To circumvent this 
homozygous lethality, inducible knockout models were established, such as the Apc580 
mouse, which seems to be a good choice since homozygous Apc580 mice developed 
adenomas in the colorectum within 4 weeks. However, all tumors were 
histopathologically diagnosed as carcinomas (Shibata et al. 1997). 
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant 
inherited form of CRC. HNPCC shows high penetrance and an early onset of 
tumorigenesis. Patients suffering from HNPCC often develop extracolonic cancers, 
such as gastric, endometrial, ovarian and renal cancers (Heyer et al. 1999; Fearon 
2011). The characteristic feature of HNPCC is the small number or even the absence 
of polyps (Bosman 2010). Genes mutated in HNPCC patients are found to be involved 
in DNA repair, such as MLH1 and MSH2 (Haggar and Boushey 2009). Several mouse 
models for HNPCC exist, such as the Msh2-deficient mice, that are known to develop 
gastrointestinal and skin tumors, and Msh6-deficient mice, that develop invasive B and 
T cell lymphomas and tumors in the gastrointestinal tract (Heyer et al. 1999). Since the 
major aim of the present study was the investigation of the role of the IGF1R / Igf1r in 
sporadic CRC, these mouse models are not discussed in detail. 
Besides genetically modified mice, also chemically induced CRC models exist, 
including models based on AOM and DSS, which were already discussed in 
chapter 4.4.1. In addition to these agents, other carcinogens that induce colonic tumors 
are available. Dimethylhydrazine (DMH) is a metabolic precursor of MAM and was 
frequently used in the past to induce colonic tumors in rodents which also mirror many 
of the pathological features seen in human sporadic CRC (Rosenberg et al. 2008). 
However, more recently, AOM is used, because it shows enhanced potency and 
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greater stability in dosing solution compared to DMH (Neufert et al. 2007; Rosenberg 
et al. 2008).  
Heterocyclic amines (HCAs), such as 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) 
(Kleman et al. 1993) produced from food pyrolysis and 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) produced during the cooking of meat and fish, are 
highly mutagenic and tumorigenic agents that cause cancer induction in the colon, 
mammary gland and prostate of rodents. Unfortunately, tumor incidence was reported 
to be very low and tumors were predominantly localized in the small intestine, only few 
tumors were found in the colon (Rosenberg et al. 2008). 
Dimethylaminoborane (DMAB) is an aromatic amine with carcinogenic potential. It was 
described to induce multiple colon tumors in F344 rats upon 20 weekly subcutaneous 
injections with 50 mg DMAB per kg body weight. Interestingly, DMAB-induced tumors 
were benign adenomas as well as malignant adenocarcinomas. The disadvantages of 
the DMAB-based model is on the one hand, that multiple DMAB injections are 
necessary to induce colonic tumors, and on the other hand that also several 
extracolonic tumors are induced by DMAB, such as adenocarcinomas of mammary 
glands, sarcomas of the salivary gland and squamous cell carcinomas of the ear duct 
and skin (Rosenberg et al. 2008). 
N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-nitrosourea (MNU) are 
direct-acting carcinogens that do not need metabolic activation (Rosenberg et al. 
2008). Rats and mice which have been orally administered to MNNG and MNU show 
a high incidence of neoplasias in the stomach, small intestine, colon, kidney, skin, lung 
and thymus. When administered via the rectum, MNU induces a high incidence of 
colonic tumors, but also thymic lymphomas (Johnson and Fleet 2013). Intrarectal 
administration of MNNG in F344 rats induced colonic tumors with an incidence of 
100%. Forty-three percent of the induced tumors were adenocarcinomas, whereas 
57% were adenomas. Although selectively colorectal tumors were induced by MNNG 
and MNU when administered intrarectally, the big disadvantage of this model is the 
fact that intrarectal instillation is a highly challenging form of administration and 
requires good technical skills (Rosenberg et al. 2008). 
Taken together, many of the described models, either based on genetic modifications 
or induced by genotoxic agents, possess one disadvantage: the development of 
tumors predominantly in the small intestine. Since patients with sporadic CRC develop 
tumors in the colon and rectum, the AOM- and AOM / DSS-based CRC models, 
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respectively, are suitable models to mimic the patient’s situation. In addition, the short 
period of colonic tumor development (mice treated with AOM / DSS developed tumors 
in as little as 7 to 10 weeks (see chapter 3.11, 3.24 and Thaker et al. 2012), the high 
incidence of tumor development (see chapter 3.11, 3.15 and 3.24), the fact that     
AOM- and DSS- administration does not require professional skills (compare with 
intrarectal instillation of MNNG) and the fact that the AOM- and AOM / DSS- induced 
colonic tumors histologically resemble human CRC (see chapter 3.10, 3.11 and Thaker 
et al. 2012) are further advantages of the AOM- and AOM / DSS-based CRC models. 
For this reason, the AOM- and AOM / DSS-based CRC models were chosen for 
analyzing the IGF1R-induced colonic tumor development and progression in the 
present study. 
 
4.6 Current treatment of CRC  
The present study proved that the IGF1R / Igf1r plays a crucial role during colonic 
tumor progression. This finding indicates that targeting and thereby inhibiting IGF1R 
signaling could improve the treatment and outcome of CRC patients. De facto, targeted 
therapy against the IGF1R and also other RTKs, such as the EGFR, PDGFR and 
VEGFR are used in the clinics for e.g. the treatment of lung cancer, head and neck 
cancer and advanced CRC (Huether et al. 2006; Wheeler et al. 2008; Lin and Bivona 
2012; Tang et al. 2013; Suda et al. 2014; Seow et al. 2016) (see table 3).  
In the clinical setting, treatment of patients with CRC depends on tumor stage. 
Furthermore, for treatment, colon cancer is distinguished from rectal cancer (American 
Cancer Society; National Cancer Institute). The current standard treatment options 
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Table 3: The current standard treatment options according to the stage for colon and rectal 
cancer (after American Cancer Society; National Cancer Institute). 
  Current standard treatment options 
Tumor 
stage 
Characteristics of stage Colon cancer Rectal cancer 
0 cancer has not grown beyond 
the inner lining of the colon 
surgery surgery 
I cancer has grown into the 
layers of the colon wall, but has 
not spread outside the colon 
wall 
surgery surgery 
II cancer has grown through the 
colon wall and have possibly 
affected nearby tissue, but has 












III cancer has spread to nearby 
lymph nodes, but has not yet 








IV cancer has spread from the 
colon to distant organs and 
tissues, such as the liver, lungs 
and distant lymph nodes 
surgery  
+  




neoadjuvant RCT  
+  
surgery 




4.6.1 RTK-targeted therapy as treatment option for advanced CRC 
As depicted in table 3, targeted therapy is an applied treatment option for patients with 
advanced CRC. The major targets in these therapy strategies for advanced CRC are 
the EGFR and VEGFR. The current biologic agents used for targeted therapy of 
advanced CRC are monoclonal antibodies, such as cetuximab and panitumumab 
against the EGFR as well as bevacizumab against the VEGFA, and small molecule 
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kinase inhibitors, such as regorafenib inhibiting VEGFR1 to VEGFR3 (Seow et al. 
2016). In 2006, panitumumab was approved as a single agent therapy, whereas 
cetuximab was approved in 2012 in combination with the chemotherapeutics 5-FU, 
leucovorin and irinotecan (FOLFIRI) for the treatment of metastatic CRC (Haraldsdottir 
and Bekaii-Saab 2013). However, new therapeutic agents and drug combinations that 
target other RTKs and signaling pathways, such as the IGF1R, PDGFR, MET, MEK, 
PI3K, Wnt, Notch and Hedgehog were developed (Seow et al. 2016) and are now 
under clinical investigation. 
One main obstacle of targeted therapies is the development of resistance to the 
treatment. De novo resistance to EGFR inhibitors is often observed (Wheeler et al. 
2008; Lin and Bivona 2012). Bertotti et al. (2015) performed complete exome 
sequence and copy number analyses of 129 patient-derived CRC tumorgrafts and 
targeted genomic analyses of 55 patient CRCs and analyzed the response of the 
tumors to anti-EGFR antibody blockade. The authors detected mutations for example 
in ERBB2, EGFR and FGFR1 and predicted these mutations as potential mechanisms 
of primary resistance to the anti-EGFR therapy (Bertotti et al. 2015). Lurje and Lenz 
(2009) suggested that the activation of alternative RTKs and the downstream signaling 
pathways, by which EGFR inhibition is circumvented, are potential mechanisms of 
resistance to EGFR-targeted therapy (Lurje and Lenz 2009). In lung cancer cells with 
wild type EGFR, Suda et al. (2014) proved that the IGF1R caused acquired resistance 
to erlotinib (small molecule kinase inhibitor of the EGFR) and predicted the IGF1R as 
an important target to circumvent or overcome erlotinib resistance (Suda et al. 2014). 
In CRC, resistance to EGFR inhibitors was also associated with IGF1R signaling (Buck 
et al. 2008; Kaulfuß et al. 2009; Yang et al. 2011). For this reason, Kaulfuß et al. (2009) 
and Seemann (2013) targeted both RTKs and showed that simultaneous silencing of 
IGF1R and EGFR by siRNA or the small molecule kinase inhibitors AEW541 (directed 
against the IGF1R) and erlotinib (directed against the EGFR) with or without combined 
RCT in CRC cells resulted in the reduction of cell proliferation and the induction of 
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4.6.2 Combination of IGF1R- and EGFR-targeted therapy in addition to combined 
5-FU-based RCT as treatment option of CRC 
In the present study, the effect of simultaneous inhibition of IGF1R and EGFR in 
addition to combined RCT on tumor growth was analyzed in vivo. Therefore, the CRC 
cell lines DLD-1 and CaCo-2 and the rectal cancer cell line SW837 were 
subcutaneously implanted in immune-deficient nude mice. After establishment of the 
tumors, mice were treated with AEW541, erlotinib, the combination of 
AEW541 / erlotinib or the solvent as control. In addition to inhibitor treatment, mice 
were administered to combined 5-FU-based RCT similar to the human treatment 
settings of neoadjuvant RCT (Spitzner et al. 2010). 
In the DLD-1 (see Fig. 68, Fig. 69a, b and Fig. 70a, b) and CaCo-2 xenograft mouse 
models (see Fig. 71a, b and Fig. 72a, b), single and even simultaneous inhibition of 
IGF1R and EGFR in addition to combined RCT did not result in a significant reduction 
of tumor progression, tumor volume and weight compared to control treatment. 
Interestingly, in contrast to the DLD-1 and CaCo-2 xenograft mice, SW837 xenograft 
mice simultaneously treated with AEW541 / erlotinib in addition to combined RCT 
revealed a significant decrease in tumor growth, tumor volume and weight compared 
to control mice (see Fig. 73 and Fig. 74a, b). These in vivo data indicate that the       
DLD-1, CaCo-2 and SW837 xenograft mice exhibited a differential sensitivity to the 
inhibitor treatment in addition to the combined RCT. Furthermore, only the results of 
the SW837 xenograft experiment reflected the in vitro data of the colony formation 
experiments of Seemann (2013). Seemann (2013) demonstrated that simultaneous 
inhibition of the IGF1R and EGFR in addition to combined RCT resulted in a significant 
reduction of cell survival in DLD-1 and SW837 cells. The inhibitor treatment in addition 
to combined RCT even led to a complete loss of survival in CaCo-2 cells (Seemann 
2013), which could not be observed in vivo (see chapter 3.26). These findings lead to 
the following questions: 
1. Why did the three cell lines (DLD-1, CaCo-2 and SW837) respond 
differentially to inhibitor treatment in addition to combined RCT in vivo? 
2. Why did the results of the DLD-1 and CaCo-2 xenograft experiments not 
mirror the in vitro data of Seemann (2013)? 
Regarding question 1, the fact that the DLD-1 and CaCo-2 cell lines are CRC cell lines, 
whereas SW837 cells are rectal cancer cells (see chapter 2.9.1) could be of high 
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importance since only the SW837 xenograft mice revealed a significant reduction of 
tumor progression after simultaneous treatment with AEW541 / erlotinib in addition to 
combined RCT (see Fig. 73). As shown in table 3, the current standard treatment for 
metastatic colon cancer consists of surgery in addition to adjuvant CT and targeted 
therapy, whereas in the case of advanced rectal cancer the standard treatment is 
surgery plus neoadjuvant RCT plus targeted therapy (American Cancer Society; 
National Cancer Institute). In the present study, neoadjuvant RCT in addition to 
targeted therapy was applied to the SW837 xenograft mice, but also to the DLD-1 and 
CaCo-2 xenograft mice, although DLD-1 and CaCo-2 cells are colorectal cancer cell 
lines. The effect of neoadjuvant therapy on survival and surgical benefits in colon 
cancer is still controversial (Huang et al. 2014). Jakobsen et al. (2015) studied the 
effect of neoadjuvant chemotherapy (NCT) in 77 patients with resectable colon cancer 
and demonstrated that NCT in colon cancer is feasible. Nevertheless, they also 
discussed the limitations of their study, including that it was a phase II trial not allowing 
any conclusion about the importance of NCT. Furthermore, the authors argued that the 
observation time was too short for allowing any conclusion regarding the long-term 
recurrence rate (Jakobsen et al. 2015). Karoui et al. (2015) showed that approx. 70% 
of colon cancers responded to NCT displayed by using the tumor regression grade 
(Karoui et al. 2015). In the FOxTROT (Fluoropyrimidine Oxaliplatin and Targeted 
Receptor Pre-Operative Therapy) trial 150 high risk stage II and stage III patients were 
treated with preoperative plus postoperative adjuvant CT vs. postoperative CT. 
Significant tumor downstaging and greater regression were shown for the preoperative 
group compared to the postoperative group, indicating that preoperative CT in locally 
advanced resectable primary colon cancer was feasible (Zhou et al. 2013). However, 
analysis of six randomized controlled trials in which the efficacy of NCT was compared 
with that of surgery alone showed that NCT did not contribute to significant survival 
benefits for CRC and that NCT did not outweigh surgery alone regarding survival and 
surgical benefits (Huang et al. 2014). In contrast, preoperative radiotherapy with or 
without chemotherapy followed by total mesorectal excision surgery is currently the 
standard treatment option for locally advanced rectal cancer (Hav et al. 2015). It could 
be shown that neoadjuvant RCT reduced the rates of local recurrence, led to reliable 
tumor downstaging and improved survival (Ferrari and Fichera 2015). In addition, 
neoadjuvant RCT displayed higher reduction rates of local recurrence than 
postoperative treatment (Sauer et al. 2004). 
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Since the efficacy of NCT in colon cancer is still discussed controversially, it could 
possibly explain why the DLD-1 and CaCo-2 xenograft mice showed less or even no 
response to the inhibitor treatment in addition to combined RCT which was applied in 
a neoadjuvant manner. The fact that neoadjuvant RCT is currently applied to rectal 
cancer patients in the clinics might explain that in contrast to the DLD-1 and CaCo-2 
xenograft mice the SW837 xenograft mice displayed a significant response rate to the 
applied treatment in the present study. 
Seemann (2013) proved that the three cell lines DLD-1, CaCo-2 and SW837 revealed 
differential responses to simultaneous inhibition of IGF1R and EGFR in addition to 
combined RCT in vitro. DLD-1 cells showed a decreased survival fraction after 
simultaneous treatment with AEW541 / erlotinib in addition to combined RCT.      
SW837 cells revealed an even stronger reduction of the survival fraction and           
CaCo-2 cells showed a complete loss of survival after inhibitor treatment in addition to 
combined RCT (Seemann 2013). In vivo, single and simultaneous inhibition of IGF1R 
and EGFR in addition to combined RCT did not result in significantly decreased tumor 
progression compared to control treatment in DLD-1 xenograft mice (see Fig. 68 and 
Fig. 69a, b). In the present study, the DLD-1 xenograft experiment was the first 
xenograft experiment performed. Since many DLD-1 xenograft mice did not tolerate 
the treatment and died already before the treatment was completed as a consequence 
of the combined RCT, the treatment settings were adapted in cooperation with             
Dr. Melanie Spitzner (Department of General, Visceral and Pediatric Surgery)             
(see chapter 3.26). Furthermore, DLD-1 cells exhibit a high proliferation rate. In the 
present study, DLD-1 tumors grew rapidly so that treatment was already started 16 to 
18 days after DLD-1 cell implantation, and mice were already sacrificed 31 days after 
CRC cell implantation (see Fig. 68 and Fig. 69a, b). These facts could indicate that the 
tumors were growing rapidly and therefore sufficient treatment to inhibit tumor 
progression was not successful. In addition, DLD-1 cells are known to harbor a point 
mutation in the K-RAS gene, namely G13D (Ahmed et al. 2013), leading to a 
constitutively active protein (Shaib et al. 2013). K-RAS is a proto-oncogene in the 
MAPK pathway downstream of the EGFR promoting cell growth (Ahmed et al. 2013). 
Interestingly, it was shown that the K-RAS mutation status predicts the response rate 
to EGFR-targeted therapy (Haraldsdottir and Bekaii-Saab 2013) and that an activating 
mutation in codon 12 of the K-RAS gene is a predominate mechanism of resistance to 
EGFR inhibitors in CRC patients (Shaib et al. 2013). Regarding the DLD-1 xenograft 
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experiment this would indicate that inhibition of the EGFR with erlotinib upstream of    
K-RAS did not inhibit MAPK signaling, because K-RAS was constitutively active due 
to the G13D mutation. Furthermore, DLD-1 cells additionally harbor an activating 
mutation in the PI3KCA gene (Seemann 2013), leading to the suggestion that inhibition 
of the IGF1R and EGFR by the small molecule kinase inhibitors does also not inhibit 
downstream signaling via the PI3K signaling pathway. These facts might explain why 
the DLD-1 xenograft mice did not benefit from the IGF1R- and EGFR-targeted 
treatment.  
In contrast to DLD-1 cells, CaCo-2 cells are wild type for K-RAS (Ahmed et al. 2013), 
indicating that the K-RAS mutation status is not the reason for the finding that          
CaCo-2 xenograft mice did not respond to the treatment applied. Interestingly,    
Spitzner et al. (2010) demonstrated that CaCo-2 cells exhibit intermediate sensitivity 
to RCT in vitro (Spitzner et al. 2010). This observation leads to the suggestion that the 
CaCo-2 xenograft mice highly responded to the combined RCT and therefore 
additional inhibition of the IGF1R and EGFR did not improve the outcome. This 
hypothesis is supported by the observation that the tumor volume decreased 
immediately after RCT was completed in the mouse model (see Fig. 71).  
SW837 cells were shown to exhibit low sensitivity to RCT (Spitzner et al. 2010), 
indicating that inhibitor treatment against the IGF1R and EGFR contributed to the 
benefits of the combined RCT. Furthermore, as already discussed, SW837 are rectal 
cancer cells and thus SW837 xenograft mice received, by applying inhibitors against 
the IGF1R and EGFR in addition to combined RCT, the treatment setting which is 
currently used in the clinics for advanced rectal cancer. These facts could explain why 
the SW837 xenograft mice showed significant response rates toward the treatment 
setting. Of note, SW837 cells are also known to harbor a K-RAS mutation (Spitzner et 
al. 2010). Again, this fact would point to the suggestion that, as in DLD-1 cells, inhibition 
of the EGFR is useless since the downstream MAPK signaling pathway is constitutively 
activated due to the activating K-RAS mutation. 
In conclusion, inhibition of the IGF1R and EGFR in addition to combined RCT led to a 
significant decrease in tumor progression only in SW837 xenograft mice. In contrast, 
a significant reduction of tumor growth could not be observed in the DLD-1 and      
CaCo-2 xenograft experiments. The underlying causes for the different response rates 
remain unknown. Assumptions to explain the differential responding comprise the         
K-RAS mutation status, the differential sensitivity to combined RCT and the treatment 
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setting. In addition, these facts indicate that xenograft experiments might not be 
suitable models to investigate the effect of IGF1R- and EGFR-targeted inhibition. The 
present study impressively displayed that the IGF1R / Igf1r predominantly plays a role 
during colonic tumor progression rather than colonic tumor formation (see chapter 
4.4.2). In the xenograft mouse model the effect of treatment on tumor cell proliferation 
was analyzed rather than the effect on tumor progression and invasion, demonstrating 
that other models are needed. For example, IGF1R-oe Villin-TRE-IGF1R mice 
administered to AOM / DSS to induce colonic tumor formation could be used in a future 
experiment. These mice overexpress the IGF1R in epithelial cells of the intestine and 
develop colonic tumors, thus mimicking the situation of CRC patients. Using this mouse 
model, the effect of IGF1R- and EGFR-targeted therapy in addition to combined RCT 
could be examined. Furthermore, this mouse model can be used to analyze also other 
novel treatment strategies in CRC (see chapter 4.7). 
 
4.7 Perspectives 
In the present study, the receptor tyrosine kinase IGF1R was proven to play an 
important role during the development of the intestine and during colonic tumor 
progression.  
The IGF1R was overexpressed, under the control of the villin promoter, in epithelial 
cells of the small intestine and colon of IGF1R-overexpressing mice. Strikingly, the 
ectopic, villin-guided expression pattern of IGF1R overexpression did not resemble the 
endogenous Igf1r expression pattern. In addition, staining for ectopic, villin-guided 
IGF1R overexpression indicated that only a particular epithelial cell type 
overexpressed IGF1R in the small intestine and colon. Double stainings proved that 
neither goblet cells, nor Paneth cells, nor enteroendocrine cells overexpressed IGF1R. 
CBCCs and transit-amplifying cells could also be excluded. To date, analyses did not 
include microfold cells (M cells), cup cells and tuft cells, indicating that these epithelial 
cell types are still potential candidates for being the cell type overexpressing the IGF1R 
in the Villin-TRE-IGF1R mouse model. To finally identify the epithelial cell type 
overexpressing the IGF1R, further double staining experiments with markers specific 
for M cells, such as glycoprotein 2 (GP2) (Kobayashi et al. 2013), cup cells, such as 
vimentin (Ramirez and Gebert 2003), and tuft cells, such as the combination of 
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microtubule-linked protein kinase Dclk1 and cytokeratin 18 (CK-18) (Gerbe et al. 
2012), in combination with an antibody against human IGF1R should be performed. 
Nevertheless, the present study proved that IGF1R overexpression led to a significant 
extension of the average crypt depth in the small intestine. Furthermore, IGF1R 
overexpression was shown to promote epithelial cell proliferation and to inhibit 
epithelial cell differentiation in four weeks and three months old and adult                
IGF1R-oe mice. These facts indicated that IGF1R overexpression influences the 
development of the murine intestine. In fact, it is known that in contrast to humans, 
development of the murine intestine is not completed before birth (Montgomery et al. 
1999), but it was also proven that particular stages of intestinal development occur 
during murine embryogenesis (Gregorieff and Clevers 2005). Specification of definitive 
endodermal cells occurs at E6.0 during gastrulation. At E8.5, the endodermal tube is 
initiated to form by folding of the endodermal lining. The primitive gut tube is patterned 
along the anterior-posterior axis at 9.5 to E14.5. At E14.5, villus formation and 
differentiation into either goblet cells, enteroendocrine cell, Paneth cells or enterocytes 
is initiated (Gregorieff and Clevers 2005). These facts indicate that important 
developmental stages of the murine intestine occur already before birth. Since the 
influence of IGF1R overexpression on intestinal development was only investigated 
postnatally, the effect of IGF1R overexpression on intestinal development should be 
further analyzed in embryonic mice. Therefore, IGF1R overexpression should be 
already induced in pregnant mice by doxycycline administration. For the detailed 
analysis if IGF1R overexpression influences a particular stage of intestinal 
development, IGF1R overexpression should be induced at the different development 
stages mentioned above. Similar to this plan, the Igf1r knockout should also be induced 
in small intestinal and colonic epithelial cells of embryonic mice by tamoxifen injection 
to analyze if the Igf1r is sufficient for “normal” intestinal development. Again, the Igf1r 
knockout should also be induced at the different embryonic stages mentioned above 
to examine if Igf1r expression is necessary for a particular stage of “normal” intestinal 
development. 
Against our expectation, the present study revealed that villin-directed IGF1R 
overexpression per se did not induce colonic tumor formation. In chapter 4.5.1 some 
issues were discussed that the villin promoter might not be a suitable promoter to direct 
IGF1R expression to intestinal epithelium, i.e., differences in the expression pattern of 
endogenous Igf1r and villin. Furthermore, a comparison of the studies of Bennecke et 
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al. (2010) and Feng et al. (2011) revealed that the intestinal expression of oncogenic 
K-rasG12D under the control of different promoters in mice lead to different results. 
Bennecke et al. (2010) reported that expression of K-rasG12D under the control of the 
villin promoter resulted in the upregulation of p16ink4a. In contrast, Feng et al. (2011) 
observed that expression of K-rasG12D under the control of the CDX2P9.5 promoter did 
not significantly increase the p16ink4a protein expression. For these reasons, IGF1R 
overexpression should again be induced in the small intestine and colon, but under the 
control of another promoter to verify that IGF1R overexpression is indeed not sufficient 
to induce colonic tumor formation. Possible promoters were already discussed           
(see chapter 4.5.1). The mCA1 promoter appeared to be an excellent promoter 
candidate for the present study (Xue et al. 2010), but to date a mouse model that drives 
rtTA2-M2 expression under the control of the mCA1 promoter is not available. Thus, a 
mouse line driving mCA1-guided rtTA2-M2 expression has to be generated first. 
Interestingly, Dow et al. (2014) generated a mouse line that guided cre-dependent, 
robust expression of rtTA3 and thus provided tissue-restricted and consistent induction 
of TRE-controlled mKate2 and TG-Ren.713 transgenes. Strong and uniform transgene 
expression was detected in the small intestine along the crypt-villus axis (Dow et al. 
2014). Crossing this mouse strain with the Lgr5-EGFP-IRES-creERT2 knock-in mouse 
(Barker et al. 2007) (see 4.5.1) and the TRE-IGF1R mouse line (Jones et al. 2007), 
that was already used in the present study, would result in IGF1R overexpression 
specifically in the crypts of the small intestine and at the bottom of the colonic crypts, 
because Lgr5+ CBCCs are known to be localized at the bottom of the crypts (Medema 
and Vermeulen 2011). IGF1R overexpression induced by doxycycline administration 
in the progeny mice of this crossing (CAGs-rtTA3/Lgr5-EGFP-IRES-creERT2/TRE-
IGF1R mice) would lead to a superior resemblance of the endogenous Igf1r expression 
pattern than the villin-guided IGF1R overexpression. Since the TRE-IGF1R mouse was 
already established for the present study and the other two mouse lines are available 
to purchase, the long term experiment should be repeated using the                            
CAGs-rtTA3/Lgr5-EGFP-IRES-creERT2/TRE-IGF1R mouse to examine if IGF1R 
overexpression per se induces colonic tumor formation when the IGF1R is exclusively 
expressed at the bottom of the crypts of the small intestine and colon. 
Remarkably, the present study proved that IGF1R overexpression promotes colonic 
tumor progression, demonstrated by a higher number of tumors of advanced stage 
derived in IGF1R-oe mice compared to control Villin-TRE-IGF1R mice. In addition, 
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IGF1R-oe even developed invasive carcinomas, whereas control mice did not            
(see chapter 3.10, 3.11 and 3.15). These results are of high interest since the IGF1R 
is known to be frequently overexpressed in CRC patients (Hakam et al. 1999; 
Reinmuth et al. 2002; Wu et al. 2014). These facts lead to the suggestion that tumors 
with IGF1R overexpression of CRC patients reveal enhanced tumor progression.         
De facto, strong IGF1R positivity was shown to correlate with higher-stage tumors, 
predicting a role of IGF1R expression during the transition of colorectal adenoma to 
carcinoma (Hakam et al. 1999). Thus, inhibition of IGF1R and thereby inhibition of the 
downstream signaling pathway would theoretically prevent tumor progression in CRC 
patients. Several biologic agents that inhibit the IGF1R are known, such as the 
monoclonal antibodies dalotuzumab, cixutumumab and AMG479 (Seow et al. 2016) 
and the small molecule kinase inhibitor AEW541 that was already used in the present 
study. To examine the effect of these inhibitors in vivo, also in combination with e.g. 
inhibitors targeting EGFR or in combination with chemotherapeutics, such as 
irinotecan or 5-FU and irradiation, IGF1R-overexpressing Villin-TRE-IGF1R mice 
administered to AOM / DSS to induce colonic tumor formation could be used. In 
addition, inhibition of the IGF1R in IGF1R-overexpressing Villin-TRE-IGF1R mice 
treated with AOM / DSS could finally prove that IGF1R overexpression promotes tumor 
progression since IGF1R inhibition should reduce tumor progression, indicated by a 
lower number of tumors with increasing stage compared to IGF1R-overexpressing 
mice. Furthermore, IGF1R- and EGFR-targeted inhibitor treatment in addition to 
combined RCT that was applied to the xenograft mice in the present study could also 
be administered to IGF1R-overexpressing Villin-TRE-IGF1R mice treated with         
AOM / DSS.  
To date, molecular analyses of the tumors regarding their mutation status, e.g. K-Ras, 
β-catenin, Apc and p53, are lacking in the present study. These analyses would 
possibly explain the advanced progression of tumors derived in IGF1R-overexpressing 
mice compared to control mice. In addition, these molecular analyses would also be of 
high interest when treating IGF1R-overexpressing Villin-TRE-IGF1R mice with colonic 
tumors induced by AOM / DSS with IGF1R- and EGFR-targeted inhibitor treatment in 
addition to combined RCT as previously proposed since an activating K-ras mutation 
would influence the benefit of IGF1R- and EGFR-targeted therapy as described in 
chapter 4.6.2. Furthermore, in the present study the analysis of PI3K and MAPK 
signaling was only performed on a small number of tumors. In addition, tumors were 
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not discriminated regarding their stage. This discrimination of the tumors regarding 
their stage would further contribute to the clarification if IGF1R overexpression 
promotes tumor progression. 
Taken together, IGF1R overexpression was shown to influence intestinal development 
by promoting epithelial cell proliferation and inhibiting epithelial cell differentiation in 
the murine intestine. In addition, IGF1R overexpression was proven to promote colonic 
tumor formation. The Igf1r knockout was shown to moderately influence colonic tumor 
initiation and to inhibit colonic tumor progression. Thus, the IGF1R turned out to 

















5 Summary  187 
5 Summary 
 
It is well known that the IGF1R is overexpressed in several tumor entities, such as 
ovarian-, prostate-, endometrial-, gastric- and colorectal cancer (Hewish et al. 2009). 
Several studies examining the expression of the IGF1R in human colorectal cancer 
biopsies exist, confirming a strong correlation of high IGF1R expression with an 
increased tumor stage (Freier et al. 1999; Hakam et al. 1999; Weber et al. 2002). 
Additionally, IGF1R overexpression was found to induce the formation of mammary 
tumors in transgenic mice (Carboni et al. 2005; Jones et al. 2007). Interestingly, studies 
analyzing if the IGF1R / Igf1r plays a role during epithelial cell differentiation and 
proliferation in the intestine and furthermore analyzing the function of the IGF1R / Igf1r 
during the development and progression of intestinal tumors were not available to date. 
Therefore, one mouse line used as a model for the inducible overexpression of human 
IGF1R in the intestine, called Villin-TRE-IGF1R, and another mouse line used as a 
model for the inducible knockout of Igf1r in the intestine, called Villin-CreERT-Igf1r, 
were established in the present study. Overexpression of IGF1R in the small intestine 
and colon of IGF1R-overexpressing Villin-TRE-IGF1R mice (IGF1R-oe) upon 
doxycycline administration could be confirmed by immunohistochemical staining and 
western blot analysis. Multiple immunofluorescence stainings using an antibody 
specific for human IGF1R in combination with an antibody against one specific 
epithelial cell type of the intestine, i.e., goblet cells (mucin 2), enteroendocrine cells 
(Chromogranin A) and Paneth cells (lysozyme), were performed to identify the cell type 
overexpressing the IGF1R. Interestingly, a concordant staining of IGF1R with one of 
these cell types could not be observed, showing that neither goblet cells nor 
enteroendocrine cells nor Paneth cells overexpress the IGF1R. Although IGF1R is not 
overexpressed by these cells, it influences the differentiation process of these cells in 
the intestine. This observation is the result of the quantification of the number of goblet 
cells, enteroendocrine cells, Paneth cells and proliferating cells in IGF1R-oe mice 
compared to control mice at three different time points. The number of goblet cells and 
Paneth cells decreased in IGF1R-oe mice compared to control mice, whereas the 
number of proliferating cells increased in IGF1R-oe mice, showing that IGF1R 
overexpression in the intestine led to a reduction of differentiation and an elevation of 
proliferation. The number of enteroendocrine cells did not alter after IGF1R 
overexpression. Sustained proliferation is a hallmark of cancer (Hanahan and 
5 Summary  188 
Weinberg 2011). For this reason it was of high interest to analyze if IGF1R 
overexpression in the intestine per se induces intestinal tumor formation in IGF1R-oe 
Villin-TRE-IGF1R mice. Therefore, IGF1R overexpression was induced in IGF1R-oe 
mice by administration of doxycycline. Colonoscopy was regularly performed to screen 
for colonic tumor formation. Since the mice had not developed intestinal tumors after 
1.5 years, mice were sacrificed. Macroscopic and histopathological analyses 
confirmed that IGF1R overexpression per se did not result in intestinal tumor formation. 
This result led to the hypothesis that IGF1R overexpression rather influences intestinal 
tumor progression. To test this hypothesis, colonic tumor formation was induced in 
IGF1R-oe and control Villin-TRE-IGF1R mice by the mutagenic agent azoxymethane 
(AOM) or the combination of AOM and the inflammatory agent dextran sulfate sodium 
(DSS). Interestingly, after AOM treatment, IGF1R-oe mice revealed an increased 
number of intraepithelial neoplasias compared to control mice and even developed an 
intramucosal as well as an invasive carcinoma. The average tumor sizes showed an 
increase of 22.5% in IGF1R-oe mice compared to control mice. Even more remarkable 
results could be observed after AOM / DSS administration in IGF1R-oe mice. Here, 
histopathological analyses revealed an elevated number of intraepithelial neoplasias 
of increased stage in IGF1R-oe mice compared to control mice. In contrast to control 
mice, IGF1R-oe mice developed a high number of intramucosal carcinomas and even 
invasive carcinomas. The average tumor sizes showed an increase of 66.2% in     
IGF1R-oe mice compared to control mice. Western blot analysis of the downstream 
PI3K and MAPK signaling pathways revealed elevated activation levels in the tumors 
of IGF1R-oe mice. Taken together, these results support the hypothesis that the IGF1R 
promotes intestinal tumor progression.  
Additionally, the influence of the endogenous Igf1r during the development of the 
intestine and during colonic tumor formation and progression was also analyzed using 
the Igf1r knockout mouse line Villin-CreERT-Igf1r. The knockout of Igf1r in the murine 
intestine was confirmed by PCR on genomic DNA extracted from small intestinal and 
colonic tissue samples and by western blot analysis. Morphological examination of the 
villi and crypts in the small intestine and colon using hematoxylin and eosin stainings 
indicated that the Igf1r knockout had no influence on intestinal morphology. Although 
the Igf1r knockout did not alter the morphology of the villi and crypts, the Igf1r may play 
a role during epithelial cell proliferation and differentiation in the intestine. To verify this 
hypothesis, the different epithelial cell types in Villin-CreERT-Igf1r mice were quantified 
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as described above. The number of goblet cells showed indeed an increase, whereas 
the number of Paneth cells decreased in Cre+/Igf1rfl/fl mice compared to control mice. 
Interestingly, the number of proliferating cells was reduced in Cre+/Igf1rfl/fl mice, 
supporting the hypothesis that Igf1r influences the differentiation and proliferation 
processes in the intestine. Furthermore, experiments in which colonic tumor formation 
and inflammation was induced by AOM / DSS indicated that the Igf1r knockout 
moderately influenced colonic tumor formation. Regarding tumor progression, 
Cre+/Igf1rfl/fl mice showed a decreased number of tumors with advanced stage 
compared to control mice, indicating that the Igf1r knockout influenced colonic tumor 
progression. Western blot analysis of the downstream PI3K and MAPK signaling 
pathways in the colonic tumors revealed a reduced activation level of AKT (pAKT) in 
Cre+/Igf1rfl/fl mice compared to control mice, but phosphorylation of ERK (pERK) was 
increased in Cre+/Igf1rfl/fl mice compared to control mice. These data showed that the 
downstream MAPK signaling pathway was activated in colonic tumors.  
In summary, the IGF1R overexpression experiments and the Igf1r knockout 
experiments of the present study display an important role of the IGF1R / Igf1r in 
colonic tumor progression. These results lead to the suggestion, that the IGF1R could 
be an important molecular target to treat patients with CRC. It is well known that the 
overexpression of the IGF1R is associated with an aggressive phenotype, tumor 
progression and poor prognosis in ovarian-, prostate-, endometrial- and colorectal 
cancer (Hewish et al. 2009). In addition, in non-small lung cancer patients, IGF1R 
overexpression has been implicated with resistance to erlotinib, a small molecule 
kinase inhibitor of the epidermal growth factor receptor (EGFR) (Lin and Bivona 2012). 
Interestingly, the EGFR was also found to be overexpressed in up to 80% of colorectal 
cancer patients (Spano 2005b). For this reason, a potential strategy to improve the 
patient’s outcome could be the inhibition of the IGF1R combined with the inhibition of 
the EGFR. Kaulfuß et al. (2009) proved that simultaneous inhibition of the IGF1R by 
the small molecule kinase inhibitor AEW541, and EGFR by erlotinib leads to a 
reduction of proliferation and an increase in apoptosis induction in colorectal cancer 
cells. To confirm these in vitro results of Kaulfuß et al. (2009) in vivo, immune-deficient 
nude mice that were subcutaneously implanted with the colorectal cancer cells DLD-1 
and CaCo-2 and the rectal cancer cell line SW837 were treated with the inhibitors in 
addition to combined 5-FU-based RCT. Single as well as simultaneous treatment of 
DLD-1 and CaCo-2 xenograft mice with AEW541 / erlotinib in addition to combined 
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RCT did not result in a significant decrease in tumor progression as well as tumor 
volume and weight compared to control mice. In contrast, SW837 xenograft mice 
showed a significant reduction of tumor growth, tumor volume and weight after 
simultaneous treatment with the inhibitors compared to control mice. Additionally, 
western blot analysis of the downstream PI3K and MAPK signaling pathways revealed 
diminished activation after simultaneous inhibition of the IGF1R and EGFR in the 
SW837 tumors. These in vivo results thus supported the hypothesis that the 
simultaneous inhibition of the IGF1R and EGFR is a potential strategy in CRC 
treatment. 
In conclusion, the results of the present study display a pivotal role of the IGF1R in 
CRC. The data indicate that IGF1R overexpression reduces epithelial cell 
differentiation and promotes proliferation. In fact, the results show that IGF1R 
overexpression is not sufficient to induce colonic tumor formation, but indicate that 
IGF1R overexpression promotes intestinal tumor progression. These findings can be 
used to investigate new therapeutic strategies, in which tumor progression is prevented 
by the inhibition of the IGF1R. In this context, the Villin-TRE-IGF1R mouse line can be 
used to examine the effect of IGF1R inhibiting agents after colonic tumor induction by 
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